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ABSTRACT 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
The aim of this thesis was to identify selected potential probiotic characteristics of 
Bifidobacterium longum strains isolated from human sources, and to examine these 
characteristics in detail using genomic and phenotypic techniques. One strain in 
particular Bifidobacterium longum DPC 6315 was the main focus of the thesis and 
this strain was used in both the manufacture of yoghurt and an animal study. In total, 
38 B. longum strains, obtained from infants and adults, were assessed in vitro for the 
selected probiotic traits using a combined phenotypic and molecular approach. 
Differentiation of the 38 strains using amplified ribosomal DNA restriction analysis 
(ARDRA) into subspecies indicated that of the 38 bifidobacterial strains tested, 34 
were designated B. longum subsp. longum and four B. longum subsp. infantis.  
The results of the screening analysis revealed that of the 38 B. longum strains 
tested, 15 B. longum subsp. longum and one B. longum subsp. infantis strain displayed 
an exopolysaccharide (EPS) phenotype in mMRS with 7% (w/v) lactose agar and 
broth, and 24 B. longum subsp. longum and two B. longum subsp. infantis strains 
displayed a positive PCR product using specific primers for a previously identified 
priming glycosyltransferase (pGTF) of a bifidobacterial EPS operon. Nine B. longum 
subsp. longum and one B. longum subsp. infantis strain converted free linoleic acid to 
cis-9, trans-11 (c9, t11) conjugated linoleic acid (CLA), and although lantibiotic 
production was not confirmed by the methods employed in this study, PCR analysis 
using primers specific to a previously identified lantibiotic structural gene lanA 
indicated the presence of the lanA gene in five B. longum subsp. longum and one B. 
longum subsp. infantis strain. B. longum DPC 6315 exhibited an EPS phenotype and 
converted free linoleic acid to c9, t11 CLA in vitro and whilst it did not produce a 
detectable bacteriocin by the methods employed in this study, it contained the EPS 
priming glycosyltranferase gene wblE and lanA gene. 
 xi 
 The sequencing of the draft genome of B. longum DPC 6315 revealed it is 2.4 
Mb in size with a 59% G + C content, encoding 10 scaffolds, comprised of 90 large 
contigs. Four predicted rRNA operons were found to be encoded within the genome. 
In addition, two plasmids of approximately 10.2 kb and 8.2 kb respectively were 
identified which were found to be almost identical (~99.5%) to previously isolated B. 
longum plasmids pNAC3 and pNAL8L. These plasmids were found to contain genes 
encoding replication, mobilization and transposase functions along with a host of 
hypothetical proteins. The draft genome of B. longum DPC 6315 also contains the 
genes necessary for EPS, lantibiotic production and myosin cross-reactive antigen 
(mcra) genes believed to be involved in CLA production in Lactobacillus reuteri 
PYR8. B. longum DPC 6315 was found to produce an EPS consisting of 12:6:3:1 of 
mannose: glucose: galactose: rhamnose and to display a ropy phenotype in mMRS 
with 7% (w/v) lactose, sucrose and glucose broth. A putative EPS operon (~16 kb) 
was identified in the genome of B. longum DPC 6315 – this potentially contained all 
the genes necessary for EPS biosynthesis i.e. chain length determination and export. 
These included genes coding for glycosyltransferases including a pGTF gene (wblE) 
and genes wblB and wblC involved in the synthesis of the EPS repeating subunit, and 
the genes wblA involved in EPS repeat unit polymerization and wblD involved in 
chain length determination.  
The influence of the EPS-producing adjunct strain, Bifidobacterium longum 
DPC 6315 on the functional properties of yoghurt was examined. In situ production of 
EPS by B. longum DPC 6315 during product manufacture and up to 14 days of cold 
storage at 4°C was found to significantly (P<0.05) increase (from 36.9 (± 2.9) mg/l on 
day 0 to an average of 51.4 (± 9.4) mg/l EPS on day 7). In contrast, the concentration 
of EPS in the EPS containing yoghurt slightly declined on day 14, 21 (P<0.01) and 28 
 xii 
(P<0.01) of cold storage, to an average of 19.3 (± 4.4) mg/l EPS on day 28. The 
performance and viability of the yoghurt cultures were not affected by addition of B. 
longum DPC 6315, with Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus 
thermophilus detected at 1.7 × 10
7
 CFU/g and 2.8 × 10
5
 CFU/g, respectively, 
following 28 days of storage at 4°C. The viability of the EPS-producing B. longum 
DPC 6315 was 4.7 × 10
6
 CFU/g after 28 days of storage at 4°C, which is above the 
minimum of 10
6
 CFU/g recommended by the FAO/WHO guidelines (FAO/WHO, 
2002) for a probiotic bacterium in a fermented food. During yoghurt manufacture and 
at 14 days of storage at 4°C, a significant decrease (P<0.05) in syneresis was obtained 
in yoghurt containing the EPS producing strain compared with the control. No 
significant difference was found in viscosity after fermentation and during 28 days of 
storage at 4°C between the yoghurt manufactured with the EPS-producing B. longum 
DPC 6315 and the control yoghurt. Confocal laser scanning microscopy (CLSM) of 
unstirred yoghurt samples demonstrated that the EPS was present around the edges of 
the pores of the yoghurt network but not in the control yoghurt. This study 
demonstrates that the use of B. longum DPC 6315 as an adjunct culture during 
yoghurt manufacture resulted in lower levels of syneresis and higher levels of EPS, 
and as such use of the adjunct offers some technological improvements to the product 
over and above its probiotic characteristics.  
Finally, B. longum DPC 6315 was fed along with a high fat diet enriched with 
α-linolenic acid (test group) to BALB/c mice. In the control or unsupplemented 
group, BALB/c mice were fed with the high fat diet enriched with α-linolenic acid but 
without the strain. B. longum DPC 6315 was found to survive passage through the 
mouse GIT. Following 6 weeks of feeding B. longum DPC 6315, it was recovered at 
~4.4 × 10
4
 CFU/g faeces in the test group. Fatty acid composition analysis revealed 
 xiii 
that mice that received B. longum DPC 6315 had significantly lower (P<0.01) levels 
of linoleic acid and γ-linolenic acid (P<0.001) acid in the liver, and stearic acid 
(P<0.05) levels in the brain compared with unsupplemented mice. In contrast, mice 
that received B. longum DPC 6315 had significantly higher concentrations of stearic 
acid (P<0.05), EPA, (P<0.05) and DPA, (P<0.05) in the liver. The microbial diversity 
of the caecal samples from the two mouse groups was determined using 16S rRNA 
amplicon pyrosequencing technology. In total 425,285 sequences were obtained from 
19 caecal samples collected from the two mouse groups. The mouse microbiota 
samples taken from both groups fed B. longum DPC 6315 and α-linolenic acid and the 
unsupplemented group were dominated by Firmicutes (72% and 61% respectively), 
followed by Bacteriodetes (17% and 29% respectively). Firmicutes were found at a 
significantly (P=0.0076) higher (0.2 fold increase) relative abundance in the group 
that received B. longum DPC 6315, while Bacteriodetes were found at a significantly 
(P=0.0057) higher (0.7 fold increase) proportions in the unsupplemented group. At 
the genus level, Alistipes was detected at a significantly (P=0.04) higher (0.8 fold 
increase) relative abundance in the unsupplemented group, while Roseburia was 
detected at a significantly (P=0.04) higher (0.5 fold increase) relative abundance in 
the group that received B. longum DPC 6315. In conclusion, supplementation with B. 
longum DPC 6315 led to significant differences in fatty acid composition in both the 
murine liver and brain tissues compared to supplementation with α-linolenic acid 
alone. B. longum DPC 6315 supplementation also led to significant differences in 
caecal microbiota composition at both the phylum and genus level.     
Overall, the results presented in this thesis outlined some of the potentially 
probiotic traits present in B. longum strains, the presence of these genes in the genome 
of B. longum DPC 6315, and the capacity of B. longum DPC 6315 to influence the 
 xiv 
functional properties of yoghurt and the fatty acid composition and overall caecal 
microbiota in a murine model in vivo.    
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CHAPTER 1 
 
Metabolic activities and probiotic potential of bifidobacteria. 
 
 
 
 
 
 
 
 
 
This chapter has been published as a review article; 
Russell, D.A., Ross, R.P., Fitzgerald, G.F. & Stanton, C. (2011). Metabolic activities and 
probiotic potential of bifidobacteria. Int. J. Food Microbiol. 149, 88-105. 
 2 
1.1 ABSTRACT 
It has been shown that the gut microbiota regulates fat storage in the body and 
that disturbances in its composition can lead to the development of certain metabolic 
disease states. Bifidobacteria are found among the resident microbiota in the 
gastrointestinal tract (GIT) and their metabolic activities have been shown to beneficially 
influence the human host. It has been reported that they inhibit intestinal colonisation by 
pathogenic microorganisms and have anti-carcinogenic, immunostimulatory, and anti-
diarrhoeal properties, as well as aiding in the alleviation of lactose intolerance and ability 
to lower serum cholesterol levels in humans. One particular health promoting property of 
bifidobacteria is bioactive fatty acid production, which when ingested, may confer health 
benefits on the host. The major bioactive fatty acid produced by bifidobacteria is 
conjugated linoleic acid (CLA), of which cis-9, trans-11 (c9, t11) and trans-10, cis-12 
(t10, c12) CLA are the main biologically active CLA isomers. The production of CLA by 
Bifidobacterium can also have a positive effect on the immune system of the human host 
leading to numerous health benefits. This is an example, where the metabolic activities of 
an ingested bacterium are beneficial to the host, rather than the direct interaction of the 
bacterium with the host. 
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1.2  INTRODUCTION 
Since bifidobacteria were first isolated from the faeces of breastfed infants by 
Henry Tissier from the Pasteur Institute in 1899 (Scardovi & Trovatelli, 1969; Tissier, 
1900; Yaeshima et al., 1992), they have come to be regarded as one of the most 
important bacterial groups associated with human health. Bifidobacteria are commonly 
used as probiotics for human consumption, as they are normal inhabitants of the GIT of 
humans (Simon & Gorbach, 1984). They have a long history of safe use in fermented 
milks (Ishibashi & Yamazaki, 2001) and are added to the human diet as food 
supplements. Bifidobacteria exert numerous positive effects on human health such as 
prevention of infection by pathogenic bacteria (Wang et al., 2004), immunostimulatory 
(Furrie et al., 2005) and anti-carcinogenic capabilities (Le Leu et al., 2010), protection 
against infectious diarrhoea, (Saavedra et al., 1994), lowering of serum cholesterol and 
alleviation of lactose maldigestion, all of which will be discussed below.  
 The expansion in bifidobacterial genomics has helped develop our understanding 
of their interactions within the human GIT and will lead to more interesting aspects of 
bifidobacterial physiology and their roles in the normal GIT being discovered in the 
future. This review will focus on a number of aspects of Bifidobacterium such as their 
classification, where they are found in nature, bifidobacteria’s composition among the 
normal gut microbiota, their metabolic activities and how these activities impact on the 
human host. Also discussed, will be the role bifidobacteria can play in the regulation of 
host fat tissue composition, through the production of bioactive fatty acids. In addition, 
the use of bifidobacteria as a probiotic, and the future implications of bifidobacteria as a 
probiotic will be addressed in this review. 
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1.3   CLASSIFICATION 
Bifidobacteria are Gram-positive polymorphic rods that can occur singly, in chains 
or in clumps. These bacteria are non-spore-forming, non-motile, and non-filamentous 
(Felis & Dellaglio, 2007). Their morphology ranges from uniform to branched bifurcated 
Y and V forms which are spatula or club shaped (Leahy et al., 2005). The branching 
nature of bifidobacteria is strain- and media-dependent (Tannock, 1999). They are 
obligate anaerobes (some strains can tolerate oxygen in the presence of carbon dioxide), 
(Simpson et al., 2004) and chemoorganotrophic (organisms that use organic compounds 
as their energy source). Bifidobacterium are saccharolytic and produce acid but not gas 
from a variety of carbohydrates.  
Bifidobacteria were first found in faeces of breastfed infants (Tissier, 1900) and 
have also been isolated from breast milk (mainly Bifidobacterium longum followed by 
Bifidobacterium animalis, Bifidobacterium bifidum, and Bifidobacterium catenlatum), 
(Fanaro et al., 2003; Gueimonde et al., 2007). The original name, Bacillus bifidus 
communis (Tissier, 1900) signifies the branching morphology of the bacteria; bifidus in 
Latin meaning cleft in two parts (Ishibashi, 1997). Bifidobacteria are often difficult to 
isolate and grow in the laboratory, as they have special nutritional requirements 
(Arunachalam, 1999). Orla-Jensen (Jensen, 1924) first proposed that Bacillus bifidus be 
classified as a separate species under the genus name Bifidobacterium. The explanation 
for this was that species of bifidobacteria should constitute a separate genus, which would 
possibly form a link between lactic acid bacteria (LAB) and the propionic acid bacteria 
(Jensen, 1924). However, for much of the 20
th
 Century there was still no taxonomic 
consensus for this new genus, and they were classified as members of the genera 
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Bacillus, Bacteroides, Nocardia, Lactobacillus and Corynebacterium among others, 
before the 8
th
 edition of Bergey’s Manual reclassified them as a general taxon and 
designated the genus Bifidobacterium, consisting of 11 species (Bergey et al., 1974). 
Bifidobacteria are phylogenetically distinct from LAB with a G + C content 
ranging from 42% to 67% (Biavati and Mattarelli, 2001), but are often included in this 
group because of their metabolic capacities. Bifidobacteria belong to the phylum 
Actinobacteria, whereas other LAB such as Lactobacillus, Lactococcus, Leuconostoc, 
Pediococcus, or Weisella are Firmicutes (Ishibashi, 1997). In the phylum Actinobacteria, 
the order Bifidobacteriales consists of two families, Bifidobacteriaceae and Incertae 
(Garrity et al., 2007). In the most recent Taxonomic Outline of Bacteria and Archaea, 
release 7.7 (TOBA 7.7), it is suggested that the Bifidobacteriaceae family be divided into 
five genera: Bifidobacterium, Aeriscardovia, Gardnerella, Parascardovia, and Scardovia 
(Garrity et al., 2007). The inclusion of the genera Aeriscardovia, Parascardovia, and 
Scardovia was suggested because of the different G + C contents and partial heat shock 
protein 60 gene sequences of three Bifidobacterium species, which are, Bifidobacterium 
aerophilum, Bifidobacterium denticolens, and Bifidobacterium inopinatum, respectively 
(Jian & Dong, 2002; Simpson et al., 2004). These three species are therefore not 
presently included in the Bifidobacterium genus. Bifidobacteria catabolise hexoses 
through a peculiar metabolic pathway involving the key enzyme fructose-6-
phosphoketolase (EC 4.1.2.2), the fructose-6-phosphate pathway or the so-called bifid 
shunt. Before the reclassification of Bifidobacterium species into a new genus, this 
enzyme was considered a taxonomic character for the identification at the genus level 
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(Biavati & Mattarelli, 2001), but now it can be considered a taxonomic marker for the 
family Bifidobacteriaceae.  
In the genus Bifidobacterium, several species are associated in groups that have 
been named according to the oldest name included in the group; these groups are 
Bifidobacterium adolescentis group (which includes B. adolescentis, Bifidobacterium 
angulatum, B. catenulatum, Bifidobacterium dentium, Bifidobacterium merycicum, 
Bifidobacterium pseudocatenulatum, and Bifidobacterium ruminantium), 
Bifidobacterium pullorum group (Bifidobacterium gallinarum, B. pullorum, and 
Bifidobacterium saeculare), Bifidobacterium asteroides group (B. asteroides, 
Bifidobacterium coryneforme, B. indicum), Bifidobacterium boum group (B. boum, 
Bifidobacterium thermacidophilum, Bifidobacterium thermophilum), Bifidobacterium 
pseudolongum group (Bifidobacterium animalis, Bifidobacterium choerinum, 
Bifidobacterium cuniculi, Bifidobacterium gallicum, B. pseudolongum). The species 
Bifidobacterium breve and B. longum form a couple, as well as Bifidobacterium minimum 
and Bifidobacterium psychroaerophilum (less supported). B. bifidum, Bifidobacterium 
magnum, Bifidobacterium scardovii and Bifidobacterium subtile form distinct branches 
(Felis & Dellaglio, 2007).  
Probiotic properties which appear to be strain specific, have been found in some 
bifidobacterial strains that are not phylogenetically related, these strains belong to the 
species B. adolescentis, B. animalis, B. bifidum, B. breve, and B. longum. In the genus 
Bifidobacterium there are some taxonomic issues regarding the species B. longum and 
Bifidobacterium infantis, this has led to their union under B. longum and the 
reclassification in 2008 (Mattarelli et al., 2008) of three biotypes by molecular methods, 
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the infantis type, the longum type, and the suis type (Sakata et al., 2002). Also the 
interaction of B. infantis and B. longum with dentritic cells has led to some interesting 
results. The study performed by Young et al. (2004) found that ATCC/DSMZ cultures of 
these two species have different interactions with dendritic cells and should be kept 
distinct. The relationship between B. animalis and B. lactis is also debatable, with the 
latter being reclassified as B. animalis subsp. lactis (Masco et al., 2004). The 
differentiation between B. indicum and B. asteroides could be clearly established, but not 
so with B. indicum and B. coryneforme (Felis & Dellaglio, 2007).  
 
1.3.1  Where Bifidobacterium species are found in the GIT 
In general Bifidobacterium species inhabit the GIT of humans and animals where 
they coexist with a large variety of obligate anaerobes (Vaughan et al., 2000). The GIT is 
composed of different sections or subdivisions, beginning with the oral cavity, the 
stomach, the small intestine (duodenum, jejunum and ileum) and the large intestine 
(caecum, colon and rectum). A distinct bacterial community can be found in each section 
and bifidobacteria can be found all along the GIT (Crociani et al., 1996; Marteau et al., 
2001; Nielsen et al., 2003; Rasic & Kurmann, 1983). Ten species have been isolated from 
human sources, B. adolescentis, B. angulatum, B. bifidum, B. breve, B. catenulatum, B. 
dentium, B. gallicum, B. longum subsp. longum and infantis, B. pseudocatenulatum and 
B. scardovii (Biavati et al., 1984; Biavati et al., 1986; Gavini et al., 2001; Hoyles et al., 
2002; Mangin et al., 1999; Matsuki et al., 1999; McCartney et al., 1996; Requena et al., 
2002; Sakata et al., 2002).  In total, species of bifidobacteria inhabit seven different 
ecological niches: the human intestine (Reuter, 1963), the human vagina (Verhelst et al., 
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2005), the oral cavity (Okamoto et al., 2008; Scardovi & Crociani, 1974), food 
(Delcenserie et al., 2007), the animal GIT (Scardovi et al., 1979), sewage (Biavati et al., 
1982), and the intestine of honeybees (Scardovi & Trovatelli, 1969), as shown in (Table 
1.1). Two Bifidobacterium species, B. asteroides and B. coryneforme have been detected 
in the intestine of the honeybee, whereas B. indicum has been detected in the intestine of 
two other honeybee species, Apis cerana and Apis dorsata from the Philippines and 
Malaysia (Goulson, 2003; Killer et al., 2009b). Killer and colleagues (Killer et al., 
2009b) were the first to isolate bifidobacteria from the digestive tract of bumblebees. In 
this study, it was predicted that bifidobacteria form an essential part of the bumblebee gut 
microbiota, and that because all of the species isolated in this study were different from 
the three species of the genus Bifidobacterium (asteroides, coryneforme and indicum) 
found in the intestine of honeybees, that they might belong to new species within the 
family Bifidobacteriaceae.  In total, four bifidobacterial groups were isolated from the 
bumblebee intestine. The first of these groups to be proposed as a new species of 
Bifidobacterium was Bifidobacterium bombi sp. nov. (Killer et al., 2009a). Two new 
species of Bifidobacterium were also proposed, which were Bifidobacterium 
actinocoloniiforme sp. nov., and Bifidobacterium bohemicum sp. nov. (Killer et al., 
2010a). Killer et al. (2010b) also proposed another new species of Bifidobacterium 
isolated from the bumblebee intestine which was Bombiscardovia coagulans gen. nov., 
sp. nov. Watanabe and colleagues, (2009) isolated a new species of Bifidobacterium from 
airag, which is a traditional fermented mare’s milk product from Mongolia. This species 
was named Bifidobacterium mongoliense (Watanabe et al., 2009). Another new species 
of Bifidobacterium was isolated by Kim et al. (2010) from human faeces, from a healthy 
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27 year Korean male. This species was called Bifidobacterium stercoris sp. nov. (Kim et 
al., 2010).   
The Bifidobacterium species which inhabit the human intestinal tract are distinct 
from those that inhabit animal intestines (Mitsuoka, 1984). Species that are representative 
of human origin include B. longum, B. breve, B. bifidum, B. adolescentis and B. 
pseudocatenulatum. Animal derived species include B. pseudolongum, B. thermophilus 
and B. animalis. Some animal species are host specific such as B. magnum and B. 
cuniculi which have only been found in rabbit faecal samples, B. pullorum and B. 
gallinarum in the chicken intestine and B. suis only in piglet faeces (Matteuzzi et al., 
1971). B. minimum and B. subtile have only been identified in sewage. 
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1.4  BIFIDOBACTERIAL GENOMICS 
The public genomic databases at present contain 18 complete bifidobacterial 
genomes, in addition to a large number of ongoing sequence projects 
(http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi). The first bifidobacterial genome to 
be sequenced and made public was Bifidobacterium longum NCC2705 (Schell et al., 
2002). The genome was 2.26 Mb comparable to LAB genomes ranging from 1.8 to 2.6 
Mb (Siezen et al., 2004). The sequencing of the B. longum NCC2705 genome was a 
considerable step forward, as previously there were less than 50 bifidobacterial protein 
sequences deposited in GenBank. The complete sequences of other B. longum genomes 
(Bifidobacterium longum DJO10A, (Lee et al., 2008), Bifidobacterium longum subsp. 
infantis ATCC 15697 (Sela et al., 2008) and Bifidobacterium longum subsp. longum 
JDM301 (Wei et al., 2005) have become publicly available for genetic comparison with 
the NCC2705 genome. This has led to an understanding of the evolution within 
Bifidobacterium species, and has helped determine genes that form the bifidobacterial 
backbone or in other words are conserved in all strains. Variable regions of DNA 
sequence that determine strain specificity, and enable adaptation to a particular niche or 
lifestyle can be identified using comparative analysis on these recently published 
genomes.  
The genome of B. longum NCC2705 (Schell et al., 2002) (GenBank accession 
number AE014295) is a 60% GC circular chromosome, which contains 4 ribosomal RNA 
operons, 57 transfer RNAs, 16 intact insertion sequence (IS) elements, integrated plasmid 
sequences (Schell et al., 2002), and a prophage-like element (Ventura et al., 2005). There 
are 1,727 proteins encoded within the genome. B. longum is a strict anaerobe it has no 
 11 
aerobic respiratory components (Schell et al., 2002). It is a bacterium that has 
successfully adapted to living in the colon, and physiological traits relating to this can be 
seen in its genome (Schell et al., 2002). A large amount of the coding capacity of the 
genomes of B. longum NCC 2705 and Bifidobacterium breve UCC2003 (>8% of the 
genome) seems to be committed to the transport (mainly ABC-type transporters) and 
catabolism (glycosyl hydrolases) of mono-, oligo-, and poly- saccharides (Coutinho & 
Henrissat, 1999), traits that are present in other colonic inhabitants, such as Enterococcus 
faecium and Bacteroides fragilis (Flint, 2008). Genome evaluation has revealed some 
interesting bifidobacterial interactions with their hosts such as, many polypeptides which 
were discovered with homology to proteins involved in the production of glycoprotein-
binding fimbriae, which may be valuable for adhesion and persistence in the GIT (Schell 
et al., 2002).  
Many enzymes involved in carbohydrate metabolism were identified from the 
genome of B. breve UCC2003, which are similar to B. longum NCC 2705, including up 
to 40 glycosyl hydrolases whose possible substrates are a broad selection of oligo- and 
polysaccharides (Mayo et al., 2008). Many of these identified glycosyl hydrolases are 
believed to be active outside the cytoplasm; one of which is amylopullulanase, which 
gives UCC2003 the capacity to grow on starch and other related polymers (Ryan et al., 
2005). Genome analysis has revealed that the biosynthetic capabilities of Bifidobacterium 
species have adapted to an environment where there is not a reliable extraneous source of 
amino acids, nucleotides and certain vitamins. 
Bifidobacteria display minimal phylogenetic diversity and are characterised by a 
high degree of conservation and synteny across the entire genomes (Ventura et al., 2007). 
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The genome comparison of species with distinct eco-phenotypes such as the oral B. 
dentium and the intestinal B. adolescentis has identified breakpoint regions of genomic 
plasticity (Ventura et al., 2009a). A relative expansive autotrophy for amino acids, 
nucleotides, vitamins and cofactors and an extended capacity for degradation and 
utilisation of complex carbohydrates have been revealed from bifidobacterial genomics 
(Ventura et al., 2007). The carbohydrate sequestering capacity of bifidobacteria in the 
intestine is likely to establish a large competitive advantage over other bacterial species 
present. 
 Many mostly intracellular glycosylhydrolases involved in the initial degradation 
of complex carbohydrates such as arabinogalactans, arabinoxylans, starch, and similar 
polysaccharides are present in the bifidobacterial genome (Kim et al., 2008; Ryan et al., 
2005; Scheffers & Pinho, 2005; Sela et al., 2008). Transport systems for the 
internalisation of structurally diverse carbohydrates are combined with these 
glycosylhydrolases, these were identified and found to contain docking sites for 
carbohydrate binding to the bacterial cell wall, which possibly prevents loss to nearby 
competitors (van den Broek et al., 2008). Different Bifidobacterium species have distinct 
capacities for the utilisation of complex carbohydrates; which would indicate an 
ecological specificity. This has been revealed by the discovery of an operon 
independently present in the genomes of B. breve strains commited to the breakdown of 
starch, amylopectin, and pullulan (Maze et al., 2007), which might clarify the 
corresponding abundance of B. breve in the infant microbiota (Ventura et al., 2004).  
With the determination of the complete genome of the oral B. dentium (2.7Mb), an 
interesting capacity to metabolise a wide range of simple sugars as well as complex 
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carbohydrates has been revealed, which would be related to the nutrient availability in the 
oral habitat (Ventura et al., 2009b).  
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1.5  GUT MICROBIOTA – COMPOSITION 
The resident microbiota in the GIT is a heterogeneous microbial ecosystem 
harbouring up to 1 × 10
14
 colony-forming units (CFU) of bacteria (Berg, 1996; Morelli et 
al., 1998; Vaughan et al., 2000; Zboril, 2002) i.e. 10- to 100-fold more genes than the 
human genome and providing regulatory signals for immune and gastrointestinal 
maturation (O'Hara & Shanahan, 2006; Round & Mazmanian, 2009; Shanahan, 2009). It 
is estimated that the GIT of healthy adults accommodates around 300-400 various 
cultivable species belonging to more than 190 genera (Holzapfel et al., 1998). Overall, 
there are between 1,000 to 1,150 prevalent bacterial species, and each individual person 
harbours at least 160 such species, which are predicted to be largely shared (Qin et al., 
2010).  The phylogenetic core of a healthy adult faecal microbiota consists of a set of five 
phyla: Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia 
(Tap et al., 2009). The predominant genera in the gut microbiota, identified by molecular 
methods, include Faecalibacterium, Ruminococcus, Eubacterium, Dorea, Bacteroides, 
Alistipes and Bifidobacterium (Tap et al., 2009). Within the known GIT microbiota, only 
a few major groups dominate at levels around 10
11
/g faeces, these are all strict anaerobes 
such as Bacteroides, Eubacterium, Bifidobacterium and Peptostreptococcus (Holzapfel et 
al., 1998). The GIT microbiota has many important functions in the human gut such as 
nutrient synthesis, digestion and absorption, immune stimulation and the control of 
pathogens. In both humans and mice, it has been reported that the onset of obesity is 
associated with changes in the relative abundance of the two dominant bacterial phyla in 
the gut, the Bacteriodetes and Firmicutes (Ley et al., 2005; Ley et al., 2006; Turnbaugh 
et al., 2009). Gut microbiota have been reported to promote obesity by increasing the 
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capacity of the host organism to extract energy in the form of calories from ingested food, 
this was displayed by transferring the gut microbiota from obese (ob/ob) mice to germ-
free wild-type (WT) recipients, which led to an increase in fat mass in the recipients 
(Turnbaugh et al., 2006).  
Toll-like receptor (TLR) 5 is a transmembrane protein that recognises bacterial 
flagellin and is highly expressed in the intestinal mucosa. In previous studies with mice 
genetically deficient in TLR5 (T5KO mice), it has been demonstrated that 10% of the 
mutant mice exhibited severe colitis and an extra 30% exhibited gross and/or 
histopathological evidence of colitis (Vijay-Kumar et al., 2007). The remaining 60% of 
the T5KO mice exhibited widely elevated proinflammatory gene expression but did not 
display the histopathologic features that define colitis, however, it was recorded that, by 4 
weeks of age, these mice had body masses that were on average 15% higher than those of 
their WT littermates.  
T5KO mice were reported to possess body masses that were 20% greater than 
those of WT mice, with an increased fat mass throughout their body, particularly in 
visceral fat as revealed by magnetic resonance imaging (MRI). The epididymal fat pads 
of T5KO mice were about twice as large as those in WT littermates at 20 weeks of age.  
This increase in fat mass was found to be associated with a substantial increase in serum 
levels of triglycerides and cholesterol, and also with an increase in blood pressure, 
features often observed with metabolic syndrome. Also it was reported in T5KO mice, a 
higher production of proinflammatory cytokines interferon-γ (IFN- γ) and interleukin-1β 
(IL-1 β) in T5KO adipose tissue versus WT adipose tissue, this would suggest that 
 16 
increased adiposity may play a part in the attenuation of the low-grade chronic 
inflammation exhibited by the mutant mice.  
After an overnight (15-hour) fast, T5KO mice displayed mild but statistically 
significant elevations in blood glucose compared to WT littermates. Furthermore, when 
T5KO mice were administered a bolus of glucose, they displayed impaired ability to 
restore blood glucose to baseline levels. Basal insulin levels on the other hand, were 
found to be significantly elevated in T5KO mice, as was the amount of insulin produced 
in response to glucose challenge. T5KO mice also exhibited a reduced response to 
exogenous insulin compared to WT mice, all these features are indicative of insulin 
resistance.  
In this study undertaken by Vijay-Kumar et al. (2010), it was investigated if 
alterations in the gut microbiota as a loss of TLR5 promote the onset of metabolic 
syndrome in these mice. T5KO mice were administered broad-spectrum antibiotics upon 
weaning for 12 weeks. This treatment lowered gut bacterial load by 90% and led to the 
enlargement of the ceca. The decimation of the gut microbiota corrected T5KO metabolic 
syndrome relative to similarly treated WT mice. To determine whether the changes in the 
gut microbiota were a cause or consequence of the metabolic syndrome in T5KO mice, 
the T5KO microbiota was transplanted into WT germ-free mice, which, like newborn 
mice can be colonised by a diverse microbiota in a manner that preserves the complex 
composition of the transferred organisms (Turnbaugh et al., 2009). In principle, any gut 
dysbiosis present in the host would be transferred to the recipient (Garrett et al., 2007; 
Turnbaugh et al., 2006). It was reported that the transplanted T5KO microbiota conferred 
various aspects of the T5KO phenotype to the WT germ-free hosts, such as hyperphagia, 
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obesity, hyperglycemia, insulin resistance, colomegaly, and elevated levels of 
proinflammatory cytokines. These effects suggest that the changes in the gut microbiota 
seen in the T5KO mice are likely to be a predetermining aspect in the onset of metabolic 
syndrome in mice. From this study, it was concluded that the specific composition of 
microbiota to which individuals are first exposed may be an important means by which 
early environment exerts a lasting influence on metabolic phenotype (Vijay-Kumar et al., 
2010). Also the excess caloric consumption promoting the currect epidemic of metabolic 
syndrome may be caused partly, by changes in host-microbiota interactions.   
In newborns, high bifidobacterial counts are especially important in early infancy 
(Chierici et al., 2003). A stable microbiota, rich in Bifidobacterium species is usually 
established after the first weeks of life. However, in some infants the appearance of 
bifidobacteria is significantly delayed (Mitsuoka, 1992). In general, Bifidobacterium 
constitute 40-60% of the total faecal microbiota of a 2-week-old infant; however, in some 
formula-fed infants, bifidobacteria can be non-detectable, and can constitute 90% of total 
microbiota in some exclusively breast-fed infants (Harmsen et al., 2000a; Harmsen et al., 
2000b). Breastfeeding and environmental factors influence gut colonisation (Marques et 
al., 2010). One of the main components of human milk are oligosaccharides (Thurl et al., 
1996), which have been identified as a “bifidogenic” factor of human milk (Kunz and 
Rudloff, 1993; Newburg et al., 2000). Moro et al. (2002) reported that supplementation 
of a formula for term infants with a mixture of galacto- and fructooligosaccharides 
promoted the growth of Bifidobacterium and Lactobacillus species in the GIT and led to 
softer stools in a dose-dependent manner (Moro et al., 2002). In industralised countries 
there is often a low colonisation rate of bifidobacteria, even in breast-fed infants, this is 
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probably related to routine hygienic procedures (Hall et al., 1990; Lundequist et al., 
1985).  
       Bifidobacteria predominate in newborns, and in breast-fed infants constitute up to 
95% of the intestinal microbiota (Yoshioka et al., 1991), and 75% in formula-fed infants 
(Hadadji et al., 2005). Breast-fed infants generally harbour higher levels and a more 
diverse Bifidobacterium population compared to formula-fed infants (Roger et al., 2010; 
Roger & McCartney, 2010). In the adult GIT bifidobacteria form a mere 3% of the 
overall gut microbiota (Vaughan et al., 2005). During weaning, bifidobacterial numbers 
gradually decrease and Bacteroides and Eubacterium become predominant, but 
nevertheless Bifidobacterium are still a main and vital part of the adult intestinal 
microbiota. In Northern Europe, bifidobacterial content accounts for 4.4 ± 4.3% of the 
total faecal microbiota of adults (Lay, 2005), and Bifidobacterium longum subsp. longum 
is one of the ten most prevalent species found (Tap et al., 2009). In old age, 
bifidobacteria become reduced in number while Clostridium and other species increase 
(Mitsuoka, 1978). The overall faecal composition of an individual changes with 
advancing age, and in elderly subjects a decrease in the total number of bifidobacteria 
and a decline in species diversity has been detected. This may play a role in the 
susceptibility of these individuals to disease (Hopkins et al., 2001; Hopkins et al., 2002; 
Woodmansey et al., 2004).  
  In specific age groups, and in geographically distinct population groups, the 
dominant bifidobacterial species differ (Matsuki et al., 1999; Reuter, 2001). In an 
individual, the bifidobacterial community is often diverse and several bifidobacterial 
species and several strains of the same bifidobacterial species may colonise the GIT 
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simultaneously (Kimura et al., 1997; Mangin et al., 1999; McCartney et al., 1996; 
Satokari et al., 2001).  In a study carried out by Silvi et al. (2003), LAB strains were 
isolated, using selective media from the faecal samples of elderly Italian subjects. In this 
study, it was reported that with regards to the bifidobacterial microbiota, the mean counts 
were more stable and on average higher than those of lactobacilli. These results were also 
reported by Hartemink, (1999) and Rowland, (1998). Furthermore, Silvi and co-workers, 
(2003) demonstrated with the identification of Bifidobacterium in each of the faecal 
samples, that there is a typical set of species for each person, with B. longum (7 people 
out of 12) being the most represented species (Silvi et al., 2003).  
It was reported that only a limited number of bifidobacterial species such as B. 
longum, B. adolescentis, B. breve, B. pseudocatenulatum appeared to be dominant in the 
human intestinal and faecal samples investigated (Turroni et al., 2009), and may 
therefore be considered widespread Bifidobacterium species, on the other hand it was 
also discovered that certain other Bifidobacterium species seemed to be restricted to a 
particular ecological niche such as B. bifidum and B. pseudolongum (Turroni et al., 
2009). 
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1.6  METABOLIC ACTIVITIES OF BIFIDOBACTERIA 
1.6.1  Characteristics and effects of Conjugated linoleic acid isomers 
  Conjugated linoleic acid (CLA) is a natural component of ruminant milk and 
tissue fat, and is a mixture of positional and geometric conjugated isomers of the essential 
fatty acid linoleic acid. The major biologically active CLA isomers are cis-9, trans-11 
CLA (c9, t11-CLA) and trans-10, cis-12 CLA (t10, c12-CLA), (Ip et al., 1994; Park et 
al., 1999). About 80% of CLA found in dairy products is c9, t11-CLA. Its existence in 
ruminant fat is a consequence of the microbial biohydrogenation of dietary linoleic and 
linolenic acids to stearic acid in the rumen via the action of the enzyme linoleic acid 
isomerase (Kepler et al., 1966) or by the endogenous conversion of vaccenic acid to CLA 
via the action of the enzyme ∆9-desaturase (Corl et al., 2001; Griinari et al., 2000). 
Linoleic acid (LA) (C18:2n-6, precursor of n-6 series of fatty acids) and α-linolenic acid 
(C18:3n-3, precursor of n-3 series of fatty acids) are the only two fatty acids that cannot 
be synthesised by humans and thus are considered nutritionally essential (Nettleton, 
1995).  Mammalian cells can metabolise these fatty acids through a series of elongation 
and desaturation reactions, whereby LA is converted to arachidonic acid (C20:4n-6) and 
α-linolenic acid is metabolised to eicosapentaenoic acid (EPA) (C20:5n-3) by the 
enzymes D6 desaturase, D5 desaturase and elongase (Simopoulos, 2002). These highly 
unsaturated fatty acid metabolites have vital roles in cell membrane function and in the 
development and function of the brain and nervous system. 
CLA has been linked with many physiological activities such as anti-adipogenic, 
anti-diabetogenic, anti-carcinogenic, and anti-atherosclerotic properties (reviewed in 
(Belury, 2002). CLA was originally described as an anti-carcinogenic agent in grilled 
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ground beef (Hayek et al., 1999). During both the initiation and promotion stages of 
carcinogenesis CLA has been shown to be anti-carcinogenic, and in inhibiting the 
development of mammary tumours, CLA has been reported to be more anti-carcinogenic 
than any other fatty acid tested (Ip et al., 1991). Activators of PPARγ have been shown to 
suppress colon cancer growth (Sarraf et al., 1998), and CLA is a ligand for the 
peroxisome PPARγ, and growth of colon cancer cells has been reported to be repressed in 
a dose-dependent fashion by CLA exposure (Kim & Park, 2003).  Animal studies have 
shown that the anti-carcinogenic effects of CLA are observable at dosages of 0.5-1% 
(w:w) of the total diet (Park et al., 2004; Petrik et al., 2000). Pomegranate seed oil (PGO) 
from pomegranate seeds contains punicic acid, which is a form of conjugated linolenic 
acid (CLN). It was reported by Kohno et al. (2004), that PGO, rich in c9, t11, c13-CLN, 
significantly inhibited the development of azoxymethane (AOM)-induced colonic 
adenocarcinomas in male F344 rats, without any adverse effects. In this trial, different 
groups of rats were administered AOM+0.01% PGO, AOM+0.1% PGO, AOM+1% PGO 
or AOM alone as the control group. At all the dose levels of PGO tested, it was observed 
that there was a significant reduction of multiplicity of carcinomas in the colon of the rats 
compared with the control group (Kohno et al., 2004). 
CLA has been shown to normalize impaired glucose tolerance and prevent or 
slow the development of hyperglycemia in the pre-diabetic Zucker fatty rat (Houseknecht 
et al., 1998). CLA has also been reported to reduce leptin in Zucker diabetic fatty rats 
(Belury & Vanden Heuvel, 1997), nondiabetic mice (Tsuboyama-Kasaoka et al., 2000), 
and humans with type 2 diabetes (Belury et al., 2003). Leptin is a hormone secreted by 
adipose tissue that regulates food intake so it may be significant to note that dietary CLA 
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reduces food intake in mice and rats (Belury & Kempa-Steczko, 1997; Park et al., 1997). 
The study performed by Belury et al. (2003), reported that lower body weights and serum 
leptin values in human subjects with type 2 diabetes were associated with t10, c12-CLA 
isomer accumulation in the plasma more so than the c9, t11-CLA isomer.  
Previous studies have found that CLA positively influenced calcium and bone 
metabolism (Brownbill et al., 2005; Kelly & Cashman, 2004; Watkins & Seifert, 2000; 
Watkins et al., 1997), and Rahman et al. (2006) reported that CLA is a strong inhibitor of 
osteoclastogenesis, which increases during inflammatory-induced bone loss such as 
rheumatoid arthritis, periodontal disease, and postmenopausal osteoporosis (Rahman et 
al., 2003). CLA may have possible uses as a dietary therapeutic agent to treat bone 
diseases caused by chronic inflammatory conditions.  
 
1.6.2  Bifidobacterial CLA production   
CLA production by Bifidobacterium species was first reported by Coakley et al. 
(2003). It was observed that B. breve NCIMB 702258 was the most efficient strain for the 
conversion of LA to CLA. It converted 66% of LA to c9, t11-CLA and 6.21% of LA to 
t9, t11-CLA. Another strain Bifidobacterium breve NCIMB 8815 was also found to 
efficiently convert LA with 40% conversion to c9, t11-CLA and 2.87% conversion to t9, 
t11-CLA. It was reported by Coakley et al. (2003), that the maximum conversion of LA 
to c9, t11-CLA was associated with logarithmic and early stationary phase growth of the 
culture. The CLA isomer was primarily found in the cell supernatant fluid, while very 
small amounts were recovered in the cell pellet. Also it was recorded that the 
concentration of the c9, t11-CLA isomer decreased following 27 h of growth when c9, 
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t11-CLA was further converted to t9, t11-CLA. CLA production in bifidobacterial strains 
appears to vary from strain to strain as reported by Barrett et al. (2007). In this study, nine 
CLA-producing strains belonging to B. longum species were isolated, six strains 
belonging to B. breve, and a single strain each belonging to B. infantis, B. dentium, and B. 
catenulatum. The ability of these CLA producing strains to convert free LA to CLA 
varied from 76.65% conversion to 2.60% conversion. In the diverse population that was 
screened for CLA production in the study, it was recorded that one in four subjects 
harboured a CLA-producing Bifidobacterium strain. In this study the best source of CLA-
producing bifidobacteria within a group, in terms of both conversion of linoleic acid to 
CLA and prevalence of CLA-producing, was the faecal material of elderly patients 
infected with the bacterium Clostridium difficile. Others have reported the isolation of 
CLA-producing bifidobacteria from the faecal material of neonates (Oh et al., 2003; 
Rosberg-Cody et al., 2004).  
It was demonstrated by Hennessy et al. (2009), that some antioxidants, sugars and 
certain prebiotic compounds had a negative impact on c9, t11-CLA production by B. 
breve NCIMB 702258. The sodium salts of acetate, propionate and butyrate were some 
of the most effective compounds tested for increasing the production of c9, t11-CLA by 
the strain tested. This study revealed that yeast extract was one of the most effective 
prebiotic components for increasing B. breve c9, t11-CLA production. This would be 
expected as yeast extract is a plentiful source of amino acids, short peptides, B-vitamin 
complexes, carbon, nitrogen, minerals and trace ingredients all of which benefit the 
growth of bifidobacteria (Dave & Shah, 1998; Gomes et al., 1998; Klaver et al., 1993; 
Poch & Bezkorovainy, 1988; Poch & Bezkorovainy, 1991). It was reported by Oh et al. 
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(2003) that CLA production by two Bifidobacterium strains examined in their study, 
which were a B. breve strain and a B. pseudocatenulatum strain, with maximal production 
being in the early stationary phase of growth at 30 h. The B. breve and B. 
pseudocatenulatum cultures produced the c9, t11-CLA isomer, which accounted for 96% 
and 93% of their total CLA isomer products, respectively. The CLA production of the 
two cultures varied according to the growth stage of the two strains. CLA was found to 
be mainly present in the extracellular phase, i.e. in the growth medium; much less CLA 
was found to be intracellular when the cultures were tested for CLA production after 
fermentation. The cell pellets of each Bifidobacterium culture used in this study were 
washed with 50 mM Tris/HCL buffer (pH 7.5). It was reported that the washed cells 
when tested also produced CLA, which accumulated mainly as intracellular or cell-
associated lipids (Blaut & Clavel, 2003).  
 It was reported by Coakley et al. (2006), that the c9, t11-CLA and t9, t11-CLA 
isomers produced by the isomerase activity of B. breve NCIMB 702258 exhibited 
antiproliferative activity against two different colon cancer cell lines (SW480 and HT-29 
cancer cells). The t9, t11 isomer was shown to have a more potent effect than the c9, t11 
isomer in both cell lines, with 10 µg/ml significantly reducing growth of SW480 cells 
after 48 h incubation, and after 4 days incubation the same concentration reduced growth 
by 43%. An incubation for 48 h with 20 µg/ml c9, t11-CLA, significantly reduced 
SW480 cell growth by 35%, whereas after 4 days incubation 10-20 µg/ml c9, t11-CLA 
significantly reduced growth by up to 65%. Also maximum inhibition of HT-29 cell 
growth was achieved with 56 µg/ml c9, t11-CLA and with 17 µg/ml t9, t11-CLA. The 
study by Coakley et al. (2009) reported that five strains of bifidobacteria, all of human 
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intestinal origin were capable of converting alpha-linolenic acid to conjugated linolenic 
acid (CLNA). This microbially produced CLNA exhibited inhibitory effects on the 
growth of SW480 colon cancer cells, in vitro. One of these products was identified as c9, 
t11, c15 C18:3-CLNA produced by B. breve NCIMB 702258. A concentration of 
50µg/ml (180 µM) c9, t11, c15 C18:3-CLNA led to an 85% reduction in SW480 colon 
cancer cell numbers (Coakley et al., 2009).   
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1.6.3  Immunostimulation 
Bifidobacteria are known to have immunodulatory effects on host mucosal cells, as 
seen in the human and animal studies in Table 1.2, except for one large human study 
which showed no statistically significant differences. The interaction of various 
Bifidobacterium species can have different effects on the host immune system as seen in 
Table 1.2; also different strains of the same species can interact with host mucosal cells 
producing varying immune responses. It is reported in some of the studies carried out, 
that bifidobacteria in combination with other bacterial species can have important 
immunodulatory effects on the host organism.  From the studies listed in Table 1.2, 
bifidobacteria are generally reported to have a positive effect on the host immune system. 
The exact mechanisms of the immunodulatory activity of bifidobacteria and other 
intestinal bacteria are not fully known and presently are undergoing extensive scientific 
research. 
 
1.6.4  Short Chain Fatty Acid production 
Short chain fatty acids (SCFAs) are organic fatty acids of one to six carbon atoms 
long in the acyl chain, and are water soluble and readily absorbed in the body (McNeil et 
al., 1978). They are found naturally in foods such as fruits, vegetables and particularly, in 
milk fat (Newmark and Young, 1995). SCFAs are the main products of anaerobic 
breakdown of polysaccharide, oligosaccharide, and protein in the rumen and large 
intestine of plant-eating animals, where they can be found at millimolar concentrations 
(Cummings et al., 1987).  Acetate (C2), propionate (C3) and butyrate (C4) are the major 
anions of SCFAs found in the lumen of the human large intestine (von Engelhardt et al., 
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1989). Bifidobacteria metabolise non-digestible carbohydrates such as cellulose and 
starch, which are hexoses, through the “bifid shunt” catabolic pathway that uses fructose-
6-phosphate phosphoketolase, producing phosphoenolpyruvate (PEP) which is degraded 
to pyruvate, the primary metabolite for SCFA production. Pyruvate is further metabolised 
by bifidobacteria to form acetyl-CoA, this then leads to the formation of acetate, lactate 
and ATP. This pathway produces 1.5 moles acetate for every mole of hexose that enters 
(Sela et al., 2008).      
  SCFA concentrations are highest in the proximal colon and are estimated to range 
from 70 to 140 mM (Cook, 1998), and decrease progressively towards the distal colon 
where they range from 20 to 70 mM (Roberfroid, 2005; Topping & Clifton, 2001). 
SCFAs are metabolised at three main locations in the body: colonocytes which utilise 
butyrate through β-oxidation as the main energy source; liver cells which metabolise 
butyrate and propionate for glucogenesis, also approximately 50 to 70% of acetate is 
absorbed by the liver; the third site are muscle cells that generate energy from the 
oxidation of residual acetate (Roberfroid, 2005).  
Butyrate has been shown to be a major source of energy for colonic epithelial 
cells (Cummings, 1981; Cummings et al., 1987; Roediger et al., 1982). It has been 
reported to provide isolated colonocytes with around 60-70% of their energy 
requirements (Roediger & Millard, 1996) whilst also providing the body with 7-10% of 
its energy needs (Roy et al., 2006). Butyrate has also been found to cause differentiation 
of mammalian and carcinoma cells at low concentrations (Kruh, 1981; Tanaka et al., 
1989). It is believed to prevent carcinogenic effects by mutagens at their active site, i.e. 
DNA (Smith, 1995). It has been observed in rats, that the supplementation of butyric acid 
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to a diet containing 20% margarine inhibited mammary tumour formation by 7, 12-
dimethylbenz[a]anthracene. A study by Roediger, (1980), reported that butyrate uptake in 
colonic mucosal cells of patients with ulcerative colitis was reduced compared with 
normal controls, and postulated that a reduced utilisation of butyrate could be a 
predetermining factor in ulcerative colitis.   
Propionate is largely absorbed by the liver, whereas acetate is metabolised by 
peripheral tissues during peripheral circulation (Wong et al., 2006). The study performed 
by Lankaputhra and Shah, (1998) detailed that all the strains of Bifidobacterium tested 
produced acetate. It was also reported that acetic and lactic acid accounted for > 90% of 
the organic acids produced. Acetate is the major SCFA produced in the colon, but departs 
the colon to be utilised by the liver, muscle and other peripheral tissues (Kien et al., 
1992; Puchowicz et al., 1999). Acetate has been reported to provide the body with around 
1.5-2 kcal/g (Topping & Clifton, 2001). It has also been reported to prevent DNA and 
cell damage to freshly isolated colon cells activated by hydrogen peroxide (Abrahamse et 
al., 1999).  Acetate has been found to stimulate sodium absorption in the rat colon. The 
study undertaken by Argenzio and Whipp, (1979), reported that acetate transport into the 
cell in the perfused pig colon drives Na
+
-H
+
 exchange, as the secreted H
+
 ion facilitates 
absorption of the unionised acid which is acetate. This leads to water being absorbed by 
the body, which could possibly have a benefit to patients suffering from various 
diarrhoeal conditions, as often these patients have lost a lot of water from their bodies.  
Production of SCFAs in the colon might also directly influence ammonia 
absorption. A study undertaken by Visek, (1978), revealed that ammonia can induce 
changes in intestinal cells which can lead to tumour growth. In this study it was detailed 
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that the production of SCFAs in the colon directs nitrogen metabolism towards bacterial 
protein synthesis, this lowers luminal ammonia concentrations, and diminishes ammonia 
absorption, thereby reducing the risk of tumour growth.  
  The fermentation of different polysaccharides gives rise to different SCFA 
profiles. Acetate was found to be the main product of pectin and xylan breakdown, while 
large amounts of acetate and propionate were produced from arabinogalactan. In one 
study, butyrate was the only SCFA found to be produced in large amounts from starch 
(Englyst et al., 1987). The study performed by Jiang and Savaiano, (1997), showed that 
supplementation with B. longum B6 decreased lactose concentration during a three-day 
continuous culture at pH 6.7. This reduction in lactose concentration may be due to the 
increased production of acetate. This suggests that bifidobacteria may have the potential 
to help manage colitis by changing bacterial metabolism from lactate to SCFA formation.  
 
1.6.5  Prebiotic utilisation 
  A prebiotic is defined as, “a non-digestible food ingredient that beneficially affects 
the host by selectively stimulating the growth and/or activity of one or a limited number 
of bacteria in the colon that have the potential to improve host health” (Gibson & 
Roberfroid, 1995). It has been observed that the growth and metabolic activity of 
bifidobacteria can be selectively promoted by prebiotics (Gibson & Roberfroid, 1995). 
Prebiotics have been shown to reduce the populations of non-beneficial bacteria by 
promoting microbial competition (Chow, 2002). Lactulose and galactooligosaccharides 
(GOS) are widely used in Europe, Japan and the United States as prebiotic carbohydrates 
(Tuohy et al., 2005). The first carbohydrate commercialised with recognised beneficial 
 30 
effects on gut bifidobacteria was lactulose, a synthetic disaccharide created by the 
isomerisation of lactose in basic media (Aider & De Halleux, 2007; Mendez & Olano, 
1979; Rycroft et al., 2001). GOS on the other hand, generally originates from enzymatic 
transgalactosylation of lactose (Mahoney, 1998; Panesar et al., 2006). Any fermentable 
dietary ingredient that passes undigested to the colon has the capability to act as a 
prebiotic. If anaerobic bacteria such as bifidobacteria, which have the metabolic capacity 
to degrade various oligo- and polysaccharides, did not colonise the distal region of the 
mammalian intestine, these dietary compounds would be lost (Vaughan et al., 2005). 
Bifidobacteria possibly acquired their specific ecological success from the ability to 
metabolise complex carbohydrates. As a consequence of this activity the host gains 
carbon and energy through the absorption of SCFAs, whereas bifidobacteria are afforded 
a vast amount of glycans and a safe anoxic environment. Bifidobacteria degrade oligo- 
and polysaccharides to monosaccharides and these are then metabolised to intermediates 
of the hexose fermentation pathway, which are then converted to SCFAs and other 
organic compounds (De Vries, 1969; Scardovi & Trovatelli, 1965). 
Presently almost all prebiotics and all those manufactured commercially have 
been carbohydrates. These range from small sugar alcohols and disaccharides, to 
oligosaccharides and large polysaccharides (all with a number of sugar combinations and 
glycosidic linkages). Fructo-oligosaccharide (FOS) is the most commonly used 
commercial prebiotic, it is a mixture of oligosaccharides containing a varying number of 
fructose moieties connected by β (2-1) glycosidic bonds. B. breve UCC2003 genome 
analysis revealed a fos operon, encoding a putative permease, a conserved hypothetical 
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protein, and a β-fructofuranosidase all involved in the breakdown of short-chain FOS 
(Ryan et al., 2006).  
In a study carried out by Cardelle-Cobas et al., (2009), it was observed that the 
four purified fractions derived from lactose and lactulose tested in their study acted as 
fermentable substrates for intestinal bacteria in vitro, leading to an increase in 
bifidobacterial numbers in human faecal cultures. A corresponding increase mainly in 
acetic acid and a moderate increase of propionic and butyric acid was also observed. It 
has been observed that carbohydrates with the degree of polymerisation (DP) = 3 showed 
the highest selectivity towards bifidobacteria (Kaneko et al., 1994; Kaplan & Hutkins, 
2000).  
It was also reported in the study undertaken by Carbelle-Cobas et al. (2009), that 
the GOS mixtures used, which were derived from lactose and lactulose contained 
trisaccharides with a high percentage of Gal β (1-6) and/or β (1-1) linkages, led to a 
similar or stronger bifidogenic effect than their precursor disaccharides and the 
commercial oligosaccharide Vivinal®-GOS (Cardelle-Cobas et al., 2009). 
  
1.6.6  Health benefits of prebiotics involving Bifidobacterium species 
  It has been reported that a diet high in non-digestible fibres decreases body 
weight, fat mass and the severity of diabetes (Cani et al., 2005b; Cani et al., 2004; Cani et 
al., 2006a; Cani et al., 2006b; Cani et al., 2005c) . These dietary fibres increase the 
numbers of bacteria able to digest these fibres and thus supply extra energy to the host. 
The study performed by Cani et al. (2008) investigated whether high-fat diet-
induced diabetes could be improved in mice by selectively increasing bifidobacteria in 
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the gut microbiota. Mice fed a high-fat diet for two to four weeks were found to display a 
significant increase in plasma lipopolysaccharide (LPS). This endotoxemia was 
characterised as a “metabolic endotoxemia”, since the LPS plasma concentrations were 
10 to 50 times lower than those recorded during a septic shock (Mitaka, 2005). LPS is 
known to be a strong inducer of inflammatory response and is involved in the release of 
certain cytokines that are key factors triggering insulin resistance (Cani et al., 2008). It 
has been reported that high-fat diet feeding changes gut microbiota leading to an increase 
in the Gram negative to Gram positive bacterial ratio. The numbers of Bifidobacterium 
species were reported to be reduced, and these Gram positive bacteria have been found to 
reduce endotoxin levels in rodents and improve mucosal barrier function (Griffiths et al., 
2004; Wang, 2004; Wang et al., 2006) 
The prebiotic dietary fibre oligofructose [OFS] (Tuohy et al., 2005), was fed to 
specifically increase the number of bifidobacteria in the gut of high-fat diet treated mice. 
It was reported that among the different gut bacteria analysed, plasma LPS concentrations 
correlated negatively with Bifidobacterium species (Cani et al., 2007). OFS stimulates the 
release of a satiety-inducing gut hormone, GLP-1 (7-36) amide, and its precursor 
proglucagon mRNA in the proximal colon of rats (Cani et al., 2005a; Cani et al., 2004; 
Cani et al., 2005d). In mice fed a high-fat diet exhibiting a higher endotoxemia, this 
endotoxemia was completed abolished by feeding the prebiotic oligofructose. In the 
prebiotic treated mice, Bifidobacterium species significantly and positively correlated 
with improved glucose-tolerance, glucose-induced insulin-secretion, and normalised 
inflammatory tone (decreased endotoxemia, plasma and adipose tissue pro-inflammatory 
cytokines), (Cani et al., 2007). This study suggests that gut microbiota contributes to the 
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pathophysiological regulation of endotoxemia, and sets the tone of inflammation for the 
occurrence of diabetes/obesity. It would be therefore beneficial to develop specific 
methods to favour bifidobacteria growth and prevent the deleterious effect of high-fat 
diet-induced metabolic disease. 
OFS promotes satiety following breakfast and dinner, and suppresses hunger and 
possible food consumption in subjects after dinner compared to placebo which was 
maltodextrin (DM) (Cani et al., 2006a). During OFS feeding it was reported that 
breakfast, lunch and total energy intake were moderately (5-10%), but significantly lower 
than those observed during the DM treatment. It was also reported that in rats, OFS 
supplementation decreased food intake – with effects on fat mass development, steatosis 
and hyperglycemia – through the promotion of intestinal synthesis and portal release of 
GLP-1 (7-36) amide (Cani et al., 2005b; Cani et al., 2004; Cani et al., 2005c) . GLP-1 (7-
36) amide has been found to be a satiety hormone which causes weight loss in humans 
when delivered exogenously at levels in the range of physio to supraphysiologic doses 
(Flint et al., 1998; Flint et al., 2001; Verdich et al., 2001). 
Prebiotic supplementation for 2 weeks is correlated with lowered subjective 
hunger (Cani et al., 2009), as was previously described by Cani et al. (2006a)  Other 
studies involving animals have reported that changes in gut microflora after fermentable 
dietary carbohydrate ingestion decrease food intake, body weight, and fat mass 
development by activities correlated with the upregulation of endogenous GLP-1 and 
peptide YY production (Cani et al., 2005b; Cani et al., 2004; Cani et al., 2005c; 
Delzenne, 2005; Maurer et al., 2009; Zhou, 2006). The study by Cani et al. (2009) 
associated for the first time, the appetite regulation effects of prebiotics with increased 
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concentration responses of postprandial plasma gut peptide after a standardised meal in 
healthy subjects; this would support the role of the modulation of microbial activity or 
fermentation by prebiotics in the control of appetite sensations. 
   
1.6.7  Exopolysaccharide production 
The production of EPS has been reported for numerous strains of bifidobacteria 
including B. pseudocatenulatum, B. longum, B. animalis and B. adolescentis (Ruas-
Madiedo et al., 2007). The physiological roles of these carbohydrate polymers have not 
yet been precisely established. Genetic studies and preliminary analyses carried out by 
Ruas-Madiedo et al. (2007) on the composition of EPS from human intestinal 
bifidobacteria revealed that they are heteropolysaccharides possessing glucose, galactose, 
and in many cases, rhamnose. Heteropolysaccharides are produced in much lower 
amounts than homopolysaccharides which would explain their low level of production in 
most intestinal bifidobacteria (Cerning et al., 1995; van Geel-Schutten et al., 1998). The 
study by Roberts et al. (1995) found that B. longum BB-79 produced the highest amount 
of EPS when lactose was used as the primary carbon source in liquid media. This 
represented a comparative increase of 200-300% of EPS yield over media containing 
sucrose, fructose or glucose. EPS was found to be produced in the log growth phase as 
after day 1 there was no significant increase in EPS production. EPS in bifidobacteria 
possibly play a role in cell recognition, adhesion to surfaces, and formation of biofilms to 
promote the colonisation of different ecosystems. They might also protect against 
phagocytosis, phage, and osmotic stress as seen in other bacteria (Looijesteijn et al., 
2001; Whitfield et al., 1993). 
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In the study performed by Ruas-Madiedo et al. (2009), the production of EPS by 
B. animalis subsp. lactis in the presence of bile was detected. Two strains of B. animalis 
subsp. lactis were used in this study. One was the parental strain and the other a bile-
adapted strain. Both strains appeared to have enhanced production of EPS in the presence 
of bile. These observations confirmed that bile promoted the synthesis of EPS in B. 
animalis subsp. lactis, possibly as a mechanism of protection against this toxic compound 
(Ruas-Madiedo et al., 2009).  The study undertaken by Salazar et al. (2008) tested the 
abilities of some EPS produced by human intestinal bifidobacteria to act as fermentable 
substrates or prebiotics, and it was found that SCFA levels obtained in faecal cultures 
with the bifidobacterial EPS tested were similar to those obtained with the prebiotic 
inulin. Incubation of the intestinal microbiota with EPS led to an altered SCFA profile in 
faecal cultures, with an observed decrease in acetic acid and an increase in propionic acid 
levels, decreases or moderate increases in butyric acid levels, and a reduction in the acetic 
acid-to-propionic acid ratio through time. The highest decrease in the acetic acid-to-
propionic acid ratio was found in four B. longum strains with EPS and with EPS C52 
from B. pseudocatenulatum.  
The EPS tested by Salazar et al. (2008), showed a bifidogenic effect with 
moderate increases in the levels of bifidobacteria during the faecal slurry culture 
incubation. The level of the effect depended on the EPS and the donor and was lower 
than that observed with glucose, being similar to that found with inulin. In the study 
performed by Salazar et al. (2009), it was observed that the EPS-producing strains of 
human origin had higher rhamnose content than strains of food origin examined 
previously by other authors. It was also found that in the EPS tested, the monosaccharides 
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galactose and glucose were universally present, and rhamnose in half of those tested. 
Also there were three major sugar components in EPS isolated from food environments, 
which were mannose, fucose, and N-acetyl-glucosamine. The high rhamnose content of 
EPS from Bifidobacterium has been linked to the protection against gastric ulcers induced 
in rats (Nagaoka et al., 1994).  
 
1.6.8  Implications of Bifidobacterium species metabolism in the host 
As bifidobacteria are naturally found in the human GIT, their presence and 
metabolic activities are considered integral to the maintenance of human health and well 
being, as bifidobacteria are found in the human GIT throughout life, present just days 
after birth (van der Werf & Venema, 2001). Bifidobacteria are found in the GIT in a 
reverse correlation to undesirable bacteria such as clostridia and E. coli, as observed from 
clinical feeding studies (Alvaro et al., 2007; Chen et al., 1999), which would suggest that 
bifidobacteria’s metabolic activities have a role in preventing the growth in the GIT of 
these undesirable microorganisms. The utilization of non-digestible substrates by 
Bifidobacterium, such as complex carbohydrates like cellulose and starch provides the 
human host with a valuable energy source which would otherwise be lost from the body, 
unused as waste to the outside environment (Vaughan et al., 2005).  
Bifidobacteria as an indigenous bacterium in many human hosts have developed a 
symbiotic relationship with their host as both the bacterium and the carrier benefit from 
the association. Bifidobacteria are provided with substrates and anaerobic conditions to 
support their growth, and the host benefits from the beneficial metabolic activities of the 
Bifidobacterium species that inhabit its GIT.  
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1.7  BIFIDOBACTERIA AS PROBIOTICS 
Probiotics are described as such as ‘live microorganisms, which when  
administered in adequate amounts confer a health benefit on the host’ (FAO/WHO, 
2002). Bifidobacteria are used globally as probiotics in many food products such as 
yoghurt, milk, infant formula, cheese, and dietary supplements (Champagne et al., 2005; 
Charalampopoulos et al., 2002; Mattila-Sandholm et al., 2002; Phillips et al., 2006; 
Vinderola et al., 2000). As discussed above, Bifidobacterium can have positive influences 
on host immunostimulation; this ability has made bifidobacteria very attractive as 
probiotics. 
  
1.7.1  Safety of Bifidobacterium species as probiotics 
Bifidobacteria have a long history of safety as probiotics in fermented foods and 
dairy products, and the risk of infection from ingested bifidobacteria is very low (Gasser, 
1994; Ouwehand et al., 2002). In a study undertaken by Abe et al. (2009) , it was 
discovered that the three bifidobacterial strains namely Bifidobacterium longum BB536, 
Bifidobacterium breve M-16V and Bifidobacterium infantis M-63, have no mucin 
degrading activity, and that B. longum BB536 has no translocation ability in the normal 
host. B. longum BB536 and B. breve M-16V are used as probiotics in many different 
foods and their continued use as such is safe. In Japan, B. longum BB536 is used as a 
functional ingredient in products designated as Food for Specified Health Uses (FOSHU) 
(Shortt, 1999).    
Administration of B. animalis subsp. lactis and B. bifidum to mothers during the 
final month of pregnancy and infants during the first 6 months of life, most of whom 
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were at an advanced risk of atopic disease, was not associated with an increase in adverse 
events, which were defined as any untoward medical occurrence in a subject in the trial 
(Allen et al., 2010)  
 
1.7.2  Survival of Bifidobacterium species in the GIT  
An important property of any probiotic is the ability to survive passage through 
the GIT, as this affects the probiotic’s ability to positively influence the host’s indigenous 
microbiota. It can only be expected that the beneficial effects of probiotics can be seen 
when viable cells of these organisms are able to survive passage through the human 
stomach and digestive system and colonise the GIT (Kailasapathy & Chin, 2000).  
Colonisation of the GIT may be unnecessary but it has been suggested that colonisation is 
a highly desirable trait for an ingested probiotic organism (Klaenhammer, 1982; 
O'Sullivan et al., 1992). This would allow the ingested probiotic microorganism to 
maintain a sufficient level to influence its environment without regular replenishment 
(Kullen et al., 1997). Probiotic bifidobacteria are capable of conferring health benefits 
even though they might be briefly exposed to very acidic conditions after ingestion, and 
may experience a log-scale reduction of viability, there may still be a sufficient 
concentration of bifidobacteria in the GIT, depending on the dose (Jia et al., 2010). The 
study performed by Kullen et al. (1997), demonstrated that the Bifidobacterium strain 
tested in this study survived passage through the GIT; it became the predominant strain 
detected after 8 d of feeding. B. animalis subsp. lactis HN019 was shown to survive GI 
transit in a study carried out by Gopal et al. (2001). Live B. animalis subsp. lactis HN019 
were recovered in the faeces of subjects consuming this strain. In certain subjects, 
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numbers as high as 12.5 × 10
8
 CFU/g wet faeces were recovered, this revealed that the 
strain was able to reach the colon alive and proliferate.  
In general, Bifidobacterium species isolated from the human GIT have been 
shown to be more sensitive to acid conditions than those from animal sources (Sanz, 
2007). This is why strains of the species B. animalis are predominantly used in fermented 
probiotic products in Europe (Gueimonde et al., 2004). It is preferable to use human 
isolated Bifidobacterium species as probiotics for human consumption, as these species 
are found there naturally, and have adapted to the human GIT, and would therefore have 
a stronger possibility of colonising here. This is why the use of acid-stress treatments 
could further enable the use of human derived Bifidobacterium species as probiotics for 
human consumption, overcoming the technological obstacles posed by their low-intrinsic 
stress tolerance (Sanz, 2007). In the study carried out by Jia et al. (2010) , it was observed 
that strains of B. bifidum, B. longum and B. longum subsp. infantis  were able to survive 
gastric conditions (pH 3) after 5 h, with counts greater than 2 log CFU/ml, which 
indicates that these strains are quite resistant to acidic conditions. These strains survived 
well in 0.45% (w/v) bile salt, with more than 4.5 log CFU/ml present after 10 h. The 
physiological bile salt concentration in the GIT of humans is estimated to be 0.3% to 
0.4% w/v. There was an overall increase of bifidobacteria in the gut from 0.8% of total 
anaerobes to 16% of total bacterial counts, following feeding probiotic bifidobacterial 
strains to human subjects (Grmanova et al., 2010).  The number of bifidobacteria 
decreased 7 days after administration and after 14 days were not detected, this showed 
that the bifidobacterial strains in this study didn’t colonise the GIT. 
    
 40 
1.7.3  Stability of Bifidobacterium species in probiotic supplements  
An important property of a probiotic is its ability to survive in the carrier material, 
as this ensures that the probiotic bacteria remains viable and retains its metabolic activity 
so that it can function at its target site when consumed by the host (Holzapfel et al., 
1998). In the study performed by Abe et al. (2009), it was observed that the probiotic B. 
longum and B. breve strains they tested were stable in Indonesian powdered formulas, as 
they detected counts of 1 × 10
7
 CFU/g of bifidobacteria after 24 months storage at 30˚C 
which is presumed to be the ambient temperature in Indonesia. It has been observed that 
higher water activity leads to a lower survival rate (Higl et al., 2007; Schoug et al., 
2006). The commercial formula had a significantly lower water activity than the 
powdered formula used in the strain comparison tests.  
When B. longum was introduced to skimmed milk, the bacterium displayed a log-
linear reduction over time when the pH value was low (pH 4.0, 4.25) but displayed 
shouldering and/or tailing as the pH value increased (Jayamanne & Adams, 2009). On the 
other hand, B. animalis subsp. lactis survived significantly longer, with survival 
measured in weeks rather than hours. The optimum survival temperature for B. lactis was 
over a range of temperatures from 4 to 8˚C. It survived longer at a low oxidation-
reduction potential (Eh) and high pH values. These results indicate that B. animalis has a 
greater ability to withstand environmental stress conditions, such as high oxygen and 
acidity environments. This is why it has been widely used as a probiotic bacterium in 
many different foods. 
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1.7.4 Use of Bifidobacterium species to establish a healthy microbiota in preterm  
             infants. 
Before birth the infant GIT is sterile (Claud & Walker, 2001), and the rapid 
establishment of a healthy GIT microbiota in preterm infants is considered to be 
important for mucosal host defenses and in the prevention of some intestinal infections 
(Dai & Walker, 1999). Some studies listed in (Table 1.2) have been carried out to 
determine the effect of early oral supplementation with bifidobacterial probiotics on 
preterm infants. These studies have shown that early supplementation reduces the time 
for a bifidobacterial population to be established in the immature gut (Marques et al., 
2010). This would be expected when large numbers of bacteria are ingested orally, which 
possibly offers some protective effects against GIT infection. 
 
1.7.5  Use of Bifidobacterium species to treat infectious diarrhoea. 
Infectious diarrhoea is a worldwide health problem. Among infants and children it 
remains a leading cause of illness and death in many developing countries (Thapar & 
Sanderson, 2004).  Even in more developed countries, nosocomially-contracted 
diarrhoeal disease can significantly lengthen hospital stays and increase overall medical 
costs. The supplementation of probiotic bacteria such as bifidobacteria to infants can help 
to address this problem. Table 1.2 lists some human and animal studies undertaken 
involving bifidobacteria and their ability to treat infectious diarrhoea. 
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1.7.6  Improvement of lactose maldigestion using Bifidobacterium species 
It has been reported that about two-thirds of the world’s adult population suffers 
from lactose maldigestion (Vesa et al., 2000). Lactose maldigestion is caused by a 
reduction in lactase β-galactosidase (β-gal) activity in the small intestine after weaning. 
In lactose intolerant individuals, unhydrolysed lactose passes into the large intestine, 
where it is fermented by the native microbiota into gases such as hydrogen, methane, and 
carbon dioxide and SCFAs. The excessive gas production and the osmotic effects of 
excessive undigested lactose can lead to GI disturbances such as flatulence, abdominal 
pain, and diarrhoea (Jiang et al., 1996). This leads to the avoidance of milk and other 
dairy products by lactose intolerant people.  
Bifidobacteria as a lactose-digesting culture has been used in studies using 
lactose-intolerant people to determine if it can alleviate the symptoms of lactose 
intolerance (Table 1.2). The effects reported in these studies are significant and generally 
regarded as scientifically sound, because the mechanism of action (digestion of lactose) is 
clear. 
 
1.7.7  Use of Bifidobacterium species to reduce serum cholesterol levels 
A high level of serum total cholesterol has been linked to an increased risk of 
cardiovascular disease (Taranto et al., 2004). Some studies involving the supplementation 
of bifidobacteria to reduce serum cholesterol have been undertaken (Table 1.2). One 
difficulty these studies have is obtaining an accurate baseline cholesterol measurement, as 
these levels can alternate. This is one reason why these studies generally do not show a 
significant effect of bifidobacteria supplementation in reducing serum cholesterol levels. 
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The exact mechanism by which bifidobacteria could reduce serum cholesterol levels 
remains unclear. The production of the enzyme bile salt hydrolase has been suggested as 
one possible mechanism (De Smet et al., 1998; St-Onge et al., 2000). 
 
1.7.8  Bifidobacterium species and protection against infection 
An important property of bifidobacteria as a probiotic bacterium is the ability to 
help prevent infection by pathogenic bacteria such as E. coli, Salmonella and H. pylori. 
These pathogenic bacteria if allowed to infect and colonise the GIT would cause 
detrimental effects for the host so the presence of bifidobacteria in the GIT is very 
important to prevent this occurring. Several mechanisms of protection have been 
proposed for bifidobacteria such as SCFA production, hydrogen peroxide or bacteriocins, 
competition for adhesion receptors or nutrients, anti-toxin action and stimulation of the 
immune system (Fooks & Gibson, 2002; Rakoff-Nahoum et al., 2004; Steer et al., 2000). 
Table 1.2 lists some studies carried out involving bifidobacteria and their potential 
protection against infection. 
 
1.7.9  Bifidobacterium species and prevention of cancer 
Cancers of the gut such as colorectal cancer which is the second most common 
cancer after lung cancer in men and breast cancer in women in Europe (Boyle & 
Langman, 2000), could be prevented by the administration of a probiotic such as 
bifidobacteria. The studies listed in Table 1.2 involving bifidobacterial anti-carcinogenic 
effects are mainly animal studies, which provide some evidence of the anti-carcinogenic 
effects of bifidobacterial supplementation. Most of these studies used bifidobacterial 
 44 
supplementation in combination with a prebiotic to reduce the risk of cancer-inducing 
cells in the model tested. At present, there are no human studies with conclusive evidence 
displaying a protective effect of this type of supplementation. 
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1.8      CONCLUSIONS AND FUTURE IMPLICATIONS 
As bifidobacterial genomics expands, our understanding of this probiotic bacterium 
increases. One important aspect of bifidobacteria that needs further investigation is their 
interactions as an indigenous bacterium within a host organism. Furthermore, the 
interactions of bifidobacteria introduced as new probiotic species with the resident 
bifidobacteria in the GIT also needs further research. This would determine if more 
symbiotic associations can be influenced by the introduction of probiotic bifidobacteria, 
with a view to maintaining an overall balance of healthy bacteria in the human host. As 
more Bifidobacterium species are being sequenced, it is possible that new insights into 
bifidobacterial interactions within the human host will be revealed. The identification of 
the genes involved in the production of bioactive fatty acids by bifidobacteria is 
important, as these are currently unknown.  The identification of these genes would make 
it possible for their manipulation in order to produce increased concentrations of these 
bioactive fatty acids. Bifidobacterial strains producing large quantities of these fatty acids 
could be given as a probiotic supplement, to improve gut health or prevent certain 
metabolic disorders. The increased understanding of bifidobacteria as a probiotic 
bacterium would be useful in developing new bifidobacterial probiotics, with specific 
benefits to the recipient. The probiotic carrier would need to provide the most suitable 
conditions like optimum pH, water activity, and redox potential to allow the 
Bifidobacterium strain contained within to survive and colonise more efficiently within 
the host’s GIT. This would optimise the benefit of the probiotic’s interactions and 
metabolic activities within the host. The colonisation of probiotic Bifidobacterium 
species within the human GIT would negate the need for continual supplementation of 
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that probiotic species. As the ‘Functional Foods’ market expands, bifidobacteria can have 
a major role to play in the development of new probiotic foods specifically for human 
health.  
With the increasing need to prove the health conferring benefits of probiotics, it is 
vital that the beneficial capacities of bifidobacteria are proven in the laboratory. 
Bifidobacterial genomics provides us with the opportunity to achieve these aims. There is 
also a need for the proper selection and characterisation of bifidobacterial strains intended 
for probiotic use. As the incidence of metabolic diseases such as cancer and obesity 
increasing worldwide, it is possible that new probiotic species of Bifidobacterium can 
help alleviate some of these conditions within the human host.  
 As the understanding of bifidobacterial substrate utilization capabilities expands, 
developing more suitable substrates such as new prebiotics to help establish and/or 
maintain the colonization of bifidobacteria in the human host will be possible.  New 
substrates could be added to the human diet to help maintain and promote the growth of 
resident and new probiotic Bifidobacterium species within the human GIT. It is likely that 
future research into bifidobacteria will focus on the development of appropriate 
conditions within a probiotic to maintain the bifidobacterial strain or strains contained 
within, so that they will arrive in the GIT in an optimum state to influence the human 
host. It is also likely that new metabolic activities of bifidobacteria will be revealed from 
bifidobacterial genomics, which will help in the design of new probiotics to specifically 
treat certain diseases in humans. 
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Table 1.1 – Habitats and references of the species of the genus Bifidobacterium 
Species                 Habitat first identified from Reference  
B. actinocoloniiforme Bumblebee intestine Killer et al. (2010a) 
B. adolescentis  Faeces of human adult, bovine 
rumen, sewage and human vagina 
Reuter (1963) 
B. angulatum  Sewage, faeces of human adult Scardovi & Crociani (1974) 
B. animalis subsp. 
animalis 
Animal faeces Scardovi & Trovatelli (1974) 
subsp. lactis Yoghurt Meile et al. (1997) 
B. asteroides  Honeybee intestine  Scardovi & Trovatelli (1969) 
B. bifidum  Faeces of human adult, infant, 
suckling calf and human vagina 
Orla-Jensen (1924) 
B. bohemicum Bumblebee intestine Killer et al. (2010a) 
B. boum  Bovine rumen, faeces of piglet  Scardovi et al. (1979) 
B. bombi Bumblebee intestine Killer et al. (2009b) 
Bombiscardovia 
coagulans 
Bumblebee intestine Killer et al. (2010b) 
B. breve  Faeces of infant and suckling calf, 
human vagina and sewage 
Reuter (1963) 
B. catenulatum  Faeces of infant and human adult 
and sewage 
Scardovi & Crociani (1974) 
B. choerinum  Faeces of piglet and sewage  Scardovi et al. (1979) 
B. coryneforme  Honeybee intestine  Biavati et al. (1982) 
B. crudilactis Raw milk and raw milk cheeses Delcenserie et al. 2007 
B. cuniculi  Faeces of rabbit  Scardovi et al. (1979) 
B. dentium  Human dental caries and oral 
cavity; faeces of  human adult, 
abscess and appendix 
Scardovi & Crociani (1974) 
B. gallicum  Human faeces  Lauer (1990) 
B. gallinarum Chicken caecum  Watabe et al. (1983) 
B. indicum  Honeybee intestine Scardovi & Trovatelli (1969) 
B. infantis  Faeces of infant and suckling calf Reuter (1963) 
B. longum subsp. 
longum 
Faeces of human adult Reuter (1963) 
subsp. infantis Faeces of infant Reuter (1963) 
subsp. suis Faeces of piglet Matteuzzi et al. (1971) 
B. magnum  Faeces of rabbit Scardovi & Zani (1974) 
B. merycicum  Bovine rumen Biavati & Mattarelli (1991) 
B. minimum  Sewage Biavati et al. (1982) 
B. mongoliense Fermented mare's milk product 
from Mongolia 
Watanabe et al. (2009) 
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Adapted from Biavati et al. (2000). 
 
 
 
 
 
B. pseudocatenulatum  Faeces of infant and suckling 
calf and sewage 
Scardovi et al. (1979) 
B. pseudolongum  
subsp. pseudolongum 
Faeces of pig, chicken, bull, 
calf, rat and guinea  pig 
Yaeshima et al. (1992) 
ex Mitsuoka (1969) 
subsp. globosum Faeces of piglet, suckling calf, 
rat, rabbit and lamb; sewage; 
bovine rumen 
ex Biavati et al. (1982) 
B. psychraerophilum Pig faeces Simpson et al. (2003) 
B. pullorum  Faeces of chicken Trovatelli et al. (1974) 
B. ruminantium  Bovine rumen  Biavati & Mattarelli (1991) 
B. saeculare  Faeces of rabbit Biavati et al. (1991) 
B. scardovii Human blood Hoyles et al. (2002) 
B. stercoris Human faeces Kim et al. (2010) 
B. subtile  Sewage Biavati et al. (1982) 
B. thermacidophilum 
subsp. 
theracidophilum   
Waste water from anaerobic 
digester 
Dong et al. (2000) 
B. thermophilum 
subsp. porcinum   
Faeces of piglet Mitsuoka (1969) 
B. tsurumiense Hamster dental plaque Okamoto et al. (2008) 
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Table 1.2 Summary of some clinical studies identifying bifidobacterial potential health  
                  
Health benefit Study Summary Reference 
Establishment of a 
healthy microbiota  
in preterm infants 
Large human study (69 preterm infants) showing that 
supplementation with B. animalis subsp. lactis Bb-12 
increased the number of bifidobacteria, while reducing 
the numbers of enterobacteria and clostridia. 
Mohan et al. 
(2006) 
 Medium-sized human study (33 preterm infants per 
group) which observed that supplementation with B. 
breve reduced (P<0.05) faecal butyric levels. This was 
only observed in the subgroup of infants weighing 
>2,500 g. 
Wang et al. 
(2007) 
 Large human study (66 preterm infants) which reported 
that supplementation with B. breve decreased (P<0.05) 
aspirated air volume from the stomach and improved 
weight gain.  
Kitajima et 
al. (1997) 
 Large human study (145 preterm infants) which were 
fed a probiotic mixture (B. longum subsp. infantis, 
Streptococcus thermophilus, and B. bifidus) reduced 
both the severity and incidence of necrotising 
enterocolitis in those fed the probiotic (P=0.005). 
Bin-Nun et 
al. (2005) 
Immunostimulation Small human study (7 healthy children) showing that 
feeding a powdered cow milk-based follow-up formula 
for children containing B. animalis subsp. lactis Bb-12 
significantly increased total faecal IgA and anti-
poliovirus IgA. 
Fukushima 
et al. (1998) 
 Small human study (8 patients with ulcerative colitis per 
group) supplemented with B. longum, inulin, and 
fructooligosaccharides showed no significant change in 
symptom scores but showed some decrease (P<0.05) in 
the expression of genes encoding human 
proinflammatory cytokines. 
Furrie et al. 
(2005) 
 Small mouse study (10 per group) showing that 
supplementation with B. animalis subsp. lactis Bb-12 
led to significantly higher levels of total IgA and anti-β-
lactoglobulin IgA in faecal extracts and milk of 
lactating dams compared to lactating dams not fed B. 
lactis Bb-12. 
Fukushima 
et al. (1999) 
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 Large mouse study (30 per group) showing that 
supplementation with B. longum promoted dendritic cell 
maturation in Peyer's Patches, up-regulated IL-10, IL-
12, interferon-γ (IFN-γ) mRNA and the interferon-γ/IL-
4 ratio in intestinal mucosa, increased IFN-γ gene 
expression and raised immunoglobulin secretion in 
cultured peripheral blood mononuclear cells. 
Dong et al. 
(2010) 
 Small mouse study (6 per group) which reported that 
supplementation with Bifidobacterium significantly 
suppressed the skewed Th2 response and increased the 
number of regulatory T cells in allergic mice. 
Zhang et al. 
(2010) 
 Large rat study (156 rats) showing that supplementation 
with B. longum significantly inhibited colon, small 
intestine, and liver tumour incidences in male rats 
(P>0.05). In female rats supplementation of B. longum 
also decreased mammary carcinogenesis to 50% and 
liver carcinogenesis to 27% of those observed in rats fed 
the control diet, but these differences were not 
statistically significant (P>0.05).  
Reddy & 
Rivenson, 
(1993) 
 Two small mice studies (8 or 9 per group using BALB/c 
and SCID mice) and a small pig study (16 weanling 
pigs) showing that supplementation with 
Bifidobacterium breve NCIMB 702258 and linoleic acid 
significantly increased liver c9, t11 CLA in both mice 
(P<0.001) and pigs (P<0.05). This led to the reduced 
(P<0.05) production of the inflammatory metabolites 
interferon (IFN)-γ, tumour necrosis factor (TNF)-α, 
interleukin (IL)-8, and IL-12, combined with an 
increase in the regulatory cytokine, IL-10. Also 
significantly (P<0.001) higher concentrations of 
eicosapentaenoic acid (EPA) and docosahexanoic acid 
(DHA) were found in adipose tissue of B. breve 
supplemented mice compared to the control fed mice. 
Wall et al. 
(2009) 
 Large mouse study (18 or 20 per group) showing that 
supplementation with B. animalis subsp. lactis 
(P<0.01), Lactobacillus rhamnosus (P<0.005), or 
Lactobacillus acidophilus (P<0.005) enhanced 
phagocytic cell function, and production of IFN-γ and 
increased immune mediated resistance to challenge to 
Salmonella typhimurium. 
Gill et al. 
(2000) 
 Large human study (5 groups of 13 to 15 subjects 
supplemented with different amounts of Lactobacillus 
paracasei and B. animalis subsp. lactis) which showed 
no statistically significant differences in cytokine levels. 
Christensen 
et al. (2006) 
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 Medium-sized human study (12 or 13 elderly subjects 
per group) which showed some increase (P<0.05) in the 
anti-inflammatory cytokine IFN-α and in phagocytic 
activity after 6 weeks of supplementation with B. 
animalis subsp. lactis.   
Arunachalam 
et al. (2000) 
Cholesterol 
reduction 
Small human study (18 or 11 women per group) 
showing an increase in high-density lipoprotein (HDL) 
levels but no reduction in total cholesterol (P=0.001) in 
subjects fed yoghurt with Lactobacillus acidophilus and 
B. longum. 
Kiessling et 
al. (2002) 
 Small rat study (5 per group) showing that 
supplementation with B. breve protected (P<0.05) 
against the increase of serum total cholesterol and lower 
density lipoprotein (LDL) cholesterol compared to that 
of a high cholesterol diet alone. 
Rhee et al. 
(2002) 
 Small rat study (7 per group) and medium-sized human 
study (32 adult males) showing that supplementation 
with milk containing B. longum and starter cultures led 
to lowering (P>0.05) of serum levels of total 
cholesterol, LDL cholesterol, and triglycerides, with no 
change in HDL cholesterol levels compared to the 
control. 
Xiao et al. 
(2003) 
Lactose intolerance Small human study (15 lactose intolerant people) 
showing some reduction (P<0.05) in breath hydrogen 
after supplementation with B. longum. 
He et al. 
(2007) 
 Small human study (11 Chinese lactose intolerant 
individuals) supplemented with B. animalis subsp. lactis 
and yoghurt cultures showing some reduction (P<0.05) 
in symptom scores.  
 
Prevention of 
infectious 
diarrhoea 
Large human study (55 infants) showing a small 
(P=0.035) protective effect of B. bifidum and 
Streptococcus thermophilus supplementation, seen as 
reduced shedding of rotavirus (P=0.025). 
Saavedra et 
al. (1994) 
 Small human study (10 infants per group) showing that 
diarrhoea caused by rotavirus infection does not affect 
B. animalis subsp. lactis Bb12 adherence (P=0.84). 
Also B. animalis subsp. lactis Bb12 adherence was 
increased (P=0.018) during diarrhoea when used in 
combination with Lactobacillus rhamnosus GG. 
Juntunen et 
al. (2000) 
 Large human study (46 or 44 infants per group) 
showing a non-statistically protective effect of B. 
animalis subsp. lactis. 
Choraqui et 
al. (2004) 
 Large human study (69 elderly patients per group) 
which showed a non-statistically protective of L. 
acidophilus and B. bifidum supplementation against 
Clostridium difficile associated diarrhoea. 
Plummer et 
al. (2004) 
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 Small piglet study (8 or 9 per group) which showed a 
moderate, statistically significant (P<0.01) protective 
effect of B. animalis subsp. lactis against rotaviral and 
Escherichia coli associated diarrhoea and a higher titre 
of anti-rotaviral antibodies in the faeces.  
Shu et al. 
(2001) 
 Large mouse study (29 to 41 per group) showing a 
statitically significant (P<0.001) protective effect 
against rotaviral diarrhoea of B. bifidum and B. longum 
subsp. infantis supplementation. 
Qiao et al. 
(2002) 
 Large mouse study (52 to 111 per group) which showed 
a small, statistically significant (P<0.05) protective 
effect of B. bifidum supplementation, with reduced 
rotaviral shedding (P=0.025).  
Duffy et al. 
(1994) 
Prevention of 
cancer 
Large rat study (30 per group) which showed a 
significant reduction (P<0.001) in carcinogen-induced 
colonic neoplasms after supplementation with both B. 
animalis subsp. lactis in combination with resistant 
starch. No reduction was observed with B. animalis 
subsp. lactis alone. 
Le Leu et al. 
(2010) 
 Large rat study (4 groups of 15) which showed some 
reduction (P<0.05) in carcinogen-induced aberrant crypt 
foci following supplementation with B. longum and a 
significant decrease (P<0.001) after supplementation of 
B. longum in combination with inulin.  
Rowland et 
al. (1998) 
 Large human study (4 groups of 18 to 22 
polypectomised or colon cancer patients) which showed 
that there was some improvement (P<0.05) only in 
polypectomised patients in epithelial barrier function 
and cell toxicity after supplementation with B. animalis 
subsp. lactis, L. rhamnosus, and inulin.  
Rafter et al. 
(2007) 
 Medium-size mouse study (12 per group) which showed 
some reduction (P<0.01) in occurrence of tumours 
when heat-killed B. longum subsp. infantis cells were 
injected into mice along with tumour cells, along with a 
significant increase (P<0.001) in the number of mice 
which were cured of tumours. 
Sekine et al. 
(1985) 
Prevention of 
infection 
Small mouse study (7 or 8 per group) which showed 
that supplementation with milk containing a B. breve or 
a Bifdobacterium catenulatum strain significantly 
inhibited (P<0.01) the production of Shiga toxin by 
Shiga toxin producing Escherichia coli 0157:H7 in the 
intestine of infected mice.   
Asahara et 
al. (2004) 
 Large mouse study (30 per group) showing that 
supplementation with B. longum one month after E. coli 
infection led to disappearance of E. coli from the lung, 
kineys, spleen, and liver of germfree mice. 
Romond et 
al. (1997) 
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 Small mouse study (9 per group) showing that 
supplementation with Bifidobacterium 
thermacidophilum attenuated intestinal injuries due to 
E. coli 0157:H7 infection, and significantly increased 
(P<0.01) anti-E. coli O157:H7 IgA titers and IgG+IgM 
response (P<0.01) 2 weeks after E. coli 0157:H7 
infection. 
Gagnon et al. 
(2006) 
 Mouse study showing that supplementation with B. 
longum led to significantly (P=0.05) higher survival of 
mice infected with Salmonella Typhimurium compared 
to the control group. 
Silva et al. 
(2004) 
  Large human study (11 or 59 subjetcs infected with 
Helicobacter pylori per group) showing that 6 week 
supplementation with a yoghurt containing a L. 
acidophilus strain and B. animalis subsp. lactis Bb12 
significantly (P<0.0001) decreased the urease activity of 
H. pylori. Also B. animalis subsp. lactis had an 
inhibitory effect on H. pylori growth in some patient 
samples in vitro.   
Wang et al. 
(2004) 
Adapted from Lee and O'Sullivan, (2010). 
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CHAPTER 2 
 
Intraspecies diversity in Bifidobacterium longum with respect to 
genomic relatedness and microbial metabolite production. 
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2.1 ABSTRACT 
Many potentially probiotic traits have been identified in Bifidobacterium species 
of which EPS production, CLA production and lantibiotic production were examined in 
this study. The differentiation of the bifidobacterial strains into subspecies using 
amplified ribosomal DNA restriction analysis was also performed. 38 bifidobacterial 
strains, obtained from infants and adults, were assessed in vitro for the selected probiotic 
traits using a combined phenotypic and molecular approach. Of the 38 strains tested, 27 
strains were obtained from breast fed infants and one strain from a formula plus prebiotic 
fed infant. In addition, 10 CLA producing strains from a previous study (Barrett et al., 
2007) obtained from healthy infants, healthy adults and a C. difficile positive patient were 
used. Differentiation of the 38 strains into subspecies indicated that 34 were designated 
B. longum subsp. longum and four B. longum subsp. infantis.  
The results of the screening analysis revealed that of the 38 B. longum strains 
tested, 15 B. longum subsp. longum and one B. longum subsp. infantis strain displayed an 
EPS phenotype in mMRS with 7% (w/v) lactose agar and broth. Of these, 24 B. longum 
subsp. longum and two B. longum subsp. infantis strains displayed a positive PCR 
product using specific primers for a previously identified pGTF of a bifidobacterial EPS 
operon (Audy et al., 2010). Nine B. longum subsp. longum and one B. longum subsp. 
infantis strain converted free linoleic acid to cis-9, trans-11 (c9, t11) CLA as reported by 
Barrett et al. (2007). With regard to bacteriocin production, lantibiotic production was not 
confirmed by the methods employed in this study, however, PCR analysis using primers 
specific to a previously identified lantibiotic structural gene lanA (Lee et al., 2011) 
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indicated the presence of the lanA gene in five B. longum subsp. longum and one B. 
longum subsp. infantis strain.  
B. longum DPC 6315 exhibited an EPS phenotype and converted free linoleic acid 
to c9, t11 CLA in vitro and whilst it did not produce a detectable bacteriocin by the 
methods employed in this study, it contained the EPS priming glycosyltranferase gene 
wblE and lantibiotic prepeptide lanA gene. 
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2.2 INTRODUCTION 
Since bifidobacteria were first isolated from the faeces of breast fed infants 
(Tissier, 1900), they have come to be regarded as one of the most important bacterial 
groups associated with human health. Bifidobacteria are widely used probiotics, defined 
as ‘live microorganisms, which when administered in adequate amounts confer a health 
benefit on the host’ (FAO/WHO, 2002). Bifidobacteria have a long history of safe use in 
fermented milks and dairy products, and the risk of infection from ingested bifidobacteria 
is minimal (Gasser, 1994; Ouwehand et al., 2002).  
Strains of Bifidobacterium longum have been reported in many human, animal 
and in vitro studies to possess probiotic effects such as immune stimulation (Wu et al., 
2010), lowering of serum cholesterol (Xiao et al., 2003), alleviation of lactose 
maldigestion (Jiang et al., 1996), prevention of infectious diarrhoea (Qiao et al., 2002) 
and anti-carcinogenic properties (Coakley et al., 2003). Potential probiotic traits that have 
been reported for different strains of B. longum include the production of an EPS (Salazar 
et al., 2008), production of CLA (Barrett et al., 2007) and lantibiotic production (Lee et 
al., 2011). 
The production of EPS has been reported for numerous strains of bifidobacteria 
including B. longum, B. adolescentis, B. animalis and B. pseudocatenulatum (Ruas-
Madiedo et al., 2007). It is generally accepted that EPS produced by bifidobacteria are 
heteropolysaccharides consisting of repeating units of polysaccharides and non-
carbohydrate units, such as phosphate, acetyl and glycerol. An EPS operon was found in 
Bifidobacterium longum subsp. longum CRC 002 (Audy et al., 2010) containing all the 
genes necessary for EPS assembly and biosynthesis, such as the wblE gene which plays 
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an important role in the initial stages of EPS biosynthesis. The wblE gene codes for the 
predicted pGTF and the C-terminal domain of this glycosyltransferase catalyses the 
transfer of a sugar-1-phosphate to a lipophilic carrier molecule anchored in the cellular 
membrane, this being the first step for the assembly of the repeating unit that builds many 
heteropolysaccharides (Audy et al., 2010). EPS isolated from bifidobacteria have been 
demonstrated to exert prebiotic effects on other bifidobacteria and other bacterial groups 
(Salazar et al., 2008), positive immunological effects (Wu et al., 2010) and antimicrobial 
activity against pathogenic organisms (Wu et al., 2010).  
In the study performed by Fanning et al. (2012), it was demonstrated that naïve 
splenocytes isolated from mice and stimulated with B. breve UCC2003 EPS producing 
cells had significantly (P<0.01) lower levels of proinflammatory cytokines IFN-γ, TNF-α 
and IL-2 compared to naïve splenocytes stimulated with B. breve UCC2003 deficient 
EPS producing cells (Fanning et al., 2012). It was also shown in the study of Fanning et 
al. (2012) that the presence of B. breve UCC2003 EPS producing cells significantly 
(P<0.05) reduced the colonisation levels of the gut pathogen Citrobacter rodentium in 
BALB/c mice compared to mice fed B. breve UCC2003 deficient EPS producing cells as 
early as 24 h and up to day 14 post infection. 
CLA is a natural component of ruminant milk and tissue fat, and is a mixture of 
positional and geometric conjugated isomers of the essential fatty acid linoleic acid. The 
major biologically active CLA isomers are cis-9, trans-11 CLA (c9, t11-CLA) and trans-
10, cis-12-CLA (t10, c12-CLA) (Ip, 1994; Park, 1999), which have been linked with 
many physiological activities such as anti-adipogenic, anti-diabetogenic, anti-
carcinogenic, and anti-atherosclerotic activities (reviewed in (Belury, 2002)). CLA 
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production by bifidobacteria was first reported by Coakley et al. (2003), and in this study 
c9, t11-CLA was the most common isomer produced. CLA production by bifidobacteria 
has been reported to differ from strain to strain (Barrett et al., 2007), and in a study 
performed by Hennessy et al. (2009) some antioxidants, sugars and certain prebiotic 
compounds present in the growth medium were reported to enhance the production of c9, 
t11-CLA by B. breve NCIMB 702258. 
Lantibiotics (lanthionine-containing antibiotics) are class I bacteriocins which are 
ribosomally synthesized small peptides, characterized by post-translational modification 
of primary residues into modified residues such as lanthionine (Ala-S-Ala) and β-
methylanthionine Abu-S-Ala) (Chatterjee et al., 2005). They have generally been 
reported to possess a broad inhibition spectrum of activity against other gram positive 
bacteria. Nisin produced by some strains of Lactococcus lactis was the first lantibiotic to 
be characterised and was first recognised as a non-acid inhibitor by Rogers in 1928 
(Rogers, 1928). Nisin is now approved for use as a food preservative in approximately 50 
countries due to its wide range of applications (Delves-Broughton, 1990). Lantibiotics are 
divided into type A or type B, depending on the topology of their ring structure and their 
biological activities (Jung, 1991). It is widely understood that type A lantibiotics disrupt 
the integrity of the cell membrane leading to pore formation, loss of ions and solutes and 
eventually cell death. A common mechanism is the dissipation of the proton motive force 
of sensitive cells (See review Guinane et al., 2005 thesis). Unlike the pore-forming type 
A lantibiotics, type B peptides have no net charge, are hydrophobic in nature and do not 
form pores in the cell membrane. Mersacidin (Brötz et al., 1997) and actagardine (Brötz 
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et al., 1997), both type B lantibiotics have been shown to inhibit cell wall synthesis, at the 
level of transglycosylation in target organisms (Brötz et al., 1997).  
The first bifidobacterial lantibiotic was isolated from B. longum subsp. longum 
DJO10A (Lee et al., 2008). The lantibiotic produced by this B. longum strain was 
encoded by a characteristic lantibiotic operon, including the lantibiotic prepeptide or 
lantibiotic encoding gene lanA, and other genes encoding production, modification and 
regulatory functions (Lee et al., 2008). The lanA structural gene encodes a ribosomally 
synthesised precursor prepeptide which contains a leader sequence at the N-terminus, 
which is ultimately cleaved, and a propeptide at the C-terminus (Lee et al., 2011). This 
lantibiotic displayed a broad spectrum of inhibition against some closely related bacterial 
strains and also some potentially pathogenic strains (Lee et al., 2011). Lantibiotics can 
confer a selective advantage on the producer organism by inhibiting the growth of other 
organisms found in the same habitat. Lantibiotics have the potential to be used as natural 
food preservatives due to their high stability and broad inhibition spectrum (Chen & 
Hoover, 2003; Deegan et al., 2006).  
The aim of this study was to assess a range of B. longum strains, primarily of 
infant intestinal origin, for their ability to exhibit potentially probiotic traits in vitro: 
namely EPS, CLA and lantibiotic production. The differentiation of these 38 
bifidobacterial strains into subspecies longum and infantis was also performed. 
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2.3 MATERIALS AND METHODS 
2.3.1 Bacterial strains and culture conditions. 
38 B. longum strains, all of human intestinal origin, were used in this study, 
(Table 2.1). The strains abbreviated with DPC were isolated in the study of Barrett et al. 
(2007). Strains numbered 1 to 61 were obtained from the stool of breast fed infants and 
strain numbered 74 was obtained from a prebiotic formula fed infant (Barrett et al., 
unpublished results). Strains were cultured on modified deMan Rogosa Sharpe (mMRS) 
(Difco Laboratories, Detroit, MI) medium supplemented with 0.05% (w/v) cysteine 
hydrochloride (98% pure; Sigma, St. Louis, MO) and 1.5% (w/v) agar (Oxoid, 
Hampshire, UK). Strains were cultured on mMRS medium supplemented with 0.05% 
(w/v) cysteine hydrochloride, 1.5% (w/v) agar (Oxoid) with 7% (w/v) lactose, and in 
mMRS with 7% (w/v) lactose broths to detect the EPS phenotype. Agar plates and broths 
were incubated anaerobically (anaerobic jars with Anaerocult® A gas packs [Merck, 
Darmstadt, Germany]) at 37°C for 72 h.  
 
2.3.2 Nucleic acid extraction and manipulation.  
Chromosomal DNA preparations were isolated from stationary phase cultures 
(~48 h) of the B. longum strains as outlined by Vincent et al. 1998 (Vincent et al., 1998).   
DNA was quantified using a Thermo Scientific nanodrop 1000 (Mason Technology, 
Ireland). DNA was quantified using a Thermo Scientific nanodrop 1000 (Mason 
Technology, Ireland). 
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2.3.3 Species and subspecies-specific identification by amplified ribosomal DNA 
restriction analysis (ARDRA). 
The differentiation of the B. longum strains into subspecies longum and 
subspecies infantis was performed by ARDRA analysis using the restriction enzyme 
Sau3AI and visualised by UV spectrophotometry following a previously described 
method (Šrůtková et al., 2011).  
 
2.3.4 PFGE analysis. 
High-molecular-weight chromosomal DNA was isolated from stationary-phase 
cultures as previously described (Hoffman & Winston, 1987). PFGE of all B. longum 
strains was undertaken as previously described (Simpson et al., 2003) with the following 
modifications: Restriction enzyme XbaI (New England Biolabs) was used to cleave 
chromosomal DNA, and the fragments were separated using contour-clamped 
homogeneous electric field CHEF-DR III pulsed-field system (Bio-Rad Laboratories). 
Fragments were resolved with a linear ramp pulse time of 1 to 15 sec for 18 h at 6V/cm 
in a running buffer containing 0.5 × Tris base-borate-EDTA maintained at 12°C. DNA 
fragment sizes were estimated by comparison with low range PFG marker ranging in size 
from 2.03 kb to 194.0 kb (New England Biolabs) and DNA-macro-restriction profiles 
were visualised using the Alpha Imaging system.  
The DNA macro-restriction profiles were stored as tagged image file format files 
and imported into Bionumerics software (Version 6.5, Applied Maths, Kortrijk, 
Belgium). The Dice coefficient of similarity was calculated and the unweighted pair 
group method with arithmetic averages (UPGMA) was used for cluster analysis with 
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optimisation and position tolerance set at 1.5%. A cut-off at 90% similarity of the Dice 
co-efficient was used to indicate identical PFGE patterns. 
  
2.3.5  EPS Screening. 
The loop touch test (Ruas-Madiedo & de los Reyes-Gavilan, 2005) was used to 
detect strains with an EPS phenotype on agar plates. For the detection of the EPS 
phenotype in mMRS with 7% (w/v) lactose broth, strains were incubated for 72 h in 30 
ml mMRS with 7% (w/v) lactose broth. The mMRS with 7% (w/v) lactose broth was 
centrifuged at 3,500 × g for 10 min before analysis. 
 
2.3.6 EPS isolation and quantification. 
EPS was isolated from the 16 EPS positive phenotypic strains grown in mMRS 
with 7% (w/v) lactose broth for 72 h at 37°C following the isolation method of 
Mårtensson et al. (2002) with the following modifications. The pH of the samples were 
adjusted to pH 6.2 with 4M NaOH followed by overnight hydrolysis using 0.2 mg/ml 
proteinase K (Sigma-Aldrich, Wicklow, Ireland) at 37°C. To terminate the reaction, the 
mixture was heated at 90°C for 10 min and centrifuged at 4,000 × g for 30 min 
(Sorvall
®
LegendRT, Thermo Scientific, Loughborough, UK). The supernatant was 
collected and precipitated with 4 volumes of chilled ethanol and agitated (100 rpm) 
overnight at 4°C. To recover the precipitate, the mixture was centrifuged at 4,500 × g for 
30 min. The pellet was dissolved in 10 ml of sterile deionised water and dialysed 
(molecular mass cut-off of 12, 000 Da) against deionised water for 3 d at 4°C (with two 
daily washing steps).  
 102 
The colorimetric phenol-sulphuric method was performed to estimate the EPS 
content with glucose as standard (Dubois, 1956). The concentrations of EPS were 
determined by subtracting the total amount of glucose detected in unfermented culture 
medium (which was used as a blank) from total amount of glucose detected in the 
inoculated fermentation medium.  
 
2.3.7 CLA screening.  
Microbial conversion of linoleic acid to CLA was assessed using a previously 
described rapid CLA screening method (Barrett et al., 2007). 
 
2.3.8 Screening of wblE and lanA genes by PCR analysis. 
Primers specific to the wblE gene from B. longum subsp. longum CRC 002 (Audy 
et al., 2010) EPS operon were designed and PCR was used to detect its presence in the 
strains used in this study. These primers were wblE F (5’-
GGGTGTGGTCGCTCTATGTT-3’) and wblE R (5’-GTCAGCCACCATAACGGTCT-
3’). A second set of hybrid primers G-Bact-a-F-36 and G-Bact-a-R-27 which were 
previously developed by Provencher et al. (2003) were also used to detect the presence of 
the pGTF gene in the 38 B. longum strains. 
To detect the presence of a previously described lantibiotic encoding lanA gene, 
primers F-lanA forward primer  (5’-GTCCATTGTCGGTGAATCCT-3’) and R-lanA 
reverse primer (5’-AGTTCCCACAGGATGCAAGT-3’) were used for PCR 
amplification of the lanA structural gene (Lee et al., 2011). 
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2.3.9 Screening for lantibiotic presence and production. 
The bacteriocin-producing capabilities of strain was determined using cell-free 
supernatants in a modified agar well diffusion assay described previously (McAuliffe et 
al., 1998)  and using an overlay agar bioassay for lantibiotic production previously 
described in Lee et al. (2008).  Indicator strains used included B. breve DPC 702258, 
Bifidobacterium breve DPC 6330 and each of the 38 B. longum strains were used as 
indicator strains to examine any zones of inhibition from the supernatants of the other 38  
strains. 
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2.4 RESULTS 
 38 bifidobacterial strains were obtained from a number of different human 
sources which included both infants and adults as mentioned above. It was then necessary 
to classify these bifidobacterial isolates into subspecies. These B. longum strains were 
then tested for a number of potentially probiotic traits which included EPS, CLA and 
lantibiotic production. 
   
2.4.1 Phylogenetic analysis. 
ARDRA analysis was used to distinguish between the subsp. longum and subsp. 
infantis as previously described (Šrůtková et al., 2011). 38 strains were analysed and it 
was revealed that 34 belonged to B. longum subsp. longum and four to B. longum subsp. 
infantis (Table 2.1). 
PFGE was also used to distinguish the strains using a method previously 
described by Simpson et al. (2003) and this analysis revealed that each of the 38 strains 
were distinct from each other, as each strain possessed a distinct PFGE profile (Fig. 2.1) 
and (Fig. 2.2). Certain distinct PFGE macro-restriction patterns appear to be highly 
conserved among the B. longum strains examined in this study, such as those at ~110 kb 
which was observed in 26 (68.4%) strains (Fig. 2.1) and (Fig. 2.2), at ~120 kb and at 
~194 kb in 25 (65.8%) strains, at ~23.1 kb present in 21 (55.3%) and at ~9.42 kb in 19 
(50%) strains of the 38 B. longum strains (Fig. 2.1) and (Fig. 2.2). PFGE macro-
restriction patterns present in less than half of the B. longum strains were those at ~145.5 
kb which was present in 18 (47.4%) strains, at ~97 kb and at ~48.5 kb present in 17 
(44.7%) of strains and (Fig. 2.1) and (Fig. 2.2).  
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A dendogram generated based on computer comparisons of the DNA macro-
restriction profiles of the 38 B. longum strains examined in this study revealed that all 
strains shared 40% or more genetic similarity. Indeed, some of the B. longum subsp. 
longum strains shared a very high percentage of similarity. Two such strains were 47 and 
49, which shared approximately 80% genomic similarity (Fig. 2.3), these strains shared 
12 macro-restriction patterns between their PFGE profiles (Fig. 2.2). Strain 56 shared 
approximately 70% genetic similarity with the two strains 47 and 49 (Fig. 2.3), sharing 9 
macro-restriction patterns between their PFGE profiles (Fig. 2.2). Strains 17 and 19 
shared approximately 75% genetic similarity (Fig. 2.3), sharing 9 macro-restriction 
patterns. Strains 1 and 9 shared approximately 68% genetic similarity with one another 
(Fig. 2.3), sharing 9 macro-restriction patterns. There was approximately 65% genetic 
similarity between the pairs of strains DPC 6315 and DPC 6322 (Fig. 2.3) (sharing 9 
macro-restriction patterns) (Fig. 2.1), strains 28 and 58 (Fig. 2.3) (sharing 8 macro-
restriction patterns) (Fig. 2.2) and the strains DPC 6321 and 13 (Fig. 2.3) (sharing 8 
macro-restriction patterns) (Fig. 2.2).     
 
2.4.2 Screening for probiotic traits: EPS production. 
The loop touch test (Ruas-Madiedo & de los Reyes-Gavilán, 2005) and 
centrifugation (3,500 g × 10 min) of strains grown for 72 h in mMRS with 7% (w/v) 
lactose were used to detect strains with an EPS phenotype on agar plates and in broth 
respectively. 
Of the 38 strains tested, 15 B. longum subsp. longum and one B. longum subsp. 
infantis strain possessed the EPS phenotype (Table 2.2). B. longum subsp. longum DPC 
- 
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6315 and the B. longum subsp. infantis strain numbered 1, produced the highest amount 
of EPS of the B. longum strains tested when grown for 72 hours in mMRS with 7% (w/v) 
lactose broth in this study, with B. longum DPC 6315 producing 234.8 (± 5.4) mg/l and 
strain 1 producing 188 (± 4.2) mg/l (Table 2.2). EPS levels produced by the B. longum 
strains possessing the EPS positive phenotype in this study displayed a wide range from 
23.8 (± 2.7) mg/l to 234.8 (± 5.4) mg/l (Table 2.2). 
 
2.4.3 CLA production. 
Using a rapid CLA screening method previously described in the study (Barrett et 
al., 2007), nine B. longum subsp. longum and one B. longum subsp. infantis strain 
converted free linoleic acid to cis-9, trans-11 (c9, t11) CLA as reported previously in the 
study Barrett et al. (2007). B. longum DPC 6315 was found to be the strain with the 
highest percentage conversion of linoleic acid to CLA of 60.1 ± 5.1% (Table 2.3). None 
of the remaining 28 B. longum strains were found to convert free linoleic acid to CLA 
(Table 2.3). 
 
2.4.4 PCR analysis – wblE and lanA genes. 
Two sets of primers specific to the wblE (pGTF) gene designed in previous 
studies were used to detect the presence of this EPS coding gene in the strains using PCR 
analysis. The wblE gene was found to be present in 24 B. longum subsp. longum and two 
B. longum subsp. infantis strains (Table 2.2). Interestingly two of the B. longum subsp. 
longum strains tested, numbered 52 and 53 displayed an EPS positive phenotype but did 
not possess the wblE gene (Table 2.2). Overall, 14 of the B. longum strains possessed the 
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EPS phenotype and gave a positive PCR result for the wblE gene, while 11 of the strains 
possessed only the wblE gene but did not display the EPS positive phenotype by the 
method used in this study (Table 2.2). 
PCR analysis using previously described primers designed to amplify the lanA 
structural gene (Lee et al., 2011) revealed that 6 of the 38 B. longum strains were found 
to give a positive PCR result for the lanA gene (Table 2.4) using this specific primer set. 
These strains were B. longum DPC 6315, and B. longum subsp. longum strains numbered 
3, 9, 28 and 36 and the B. longum subsp. infantis strain numbered 6 (Table 2.4). 
 
2.4.5 Lantibiotic production.  
The bacteriocin-producing capabilities of the strains was determined using cell-
free supernatants in a modified agar well diffusion assay described previously (McAuliffe 
et al., 1998) and using an overlay agar bioassay for lantibiotic production previously 
described in Lee et al. (2008).  
The modified agar well diffusion assays and overlay agar bioassays did not reveal 
any inhibitory action of the supernatants taken from the 38 B. longum strains on the 
indicator strains used, B. breve DPC 702258, B. breve DPC 6330 and the B. longum 
strains examined in this study (Table 2.4).  
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2.5 DISCUSSION 
This study identified the subspecies’ differentiation and certain probiotic traits of 
38 B. longum strains obtained from human infant and adult intestines. Of the 38 strains, 
34 were found to be B. longum subsp. longum and just four were typed as B. longum 
subsp. infantis.  
PFGE analysis demonstrated that all the 38 B. longum strains were distinct from each 
other.  However, the 38 B. longum strains did appear to share a high level of genetic 
similarity as found from dendogram analysis with all the strains sharing 40% or higher 
genetic similarity, and some strains such as 47 and 49 sharing approximately 80% genetic 
similarity. Certain DNA macro-restriction fragments appear to be found in a high 
proportion of the 38 B. longum strains such as those at ~110 kb, ~120 kb, ~194kb, ~23.1 
and at ~9.42 kb. These patterns would appear to be highly conserved parts of the 
genomes of the B. longum strains examined in this study. 
There were no noticeable differences reported in the probiotic traits identified in 
the B. longum subsp. longum and the four B. longum subsp. infantis strains. Of the 38 B. 
longum strains tested, B. longum DPC 6315 was found to possess an EPS phenotype, and 
produce the highest amount of EPS (234.8 ± 5.4 mg/l) in mMRS with 7% (w/v) lactose 
broth. The study performed by Barrett et al. (2007) revealed that it produced the highest 
percentage conversion of linoleic acid to CLA (60.1 ± 5.1%) of the B. longum strains 
tested. PCR analysis revealed that it also possessed the wblE gene of the EPS operon 
(Audy et al., 2010) and lanA gene of the lantibiotic operon (Lee et al., 2011).  
The presence of the lanA gene would suggest that B. longum DPC 6315 has the 
capability of producing a lantibiotic which has already been identified in B. longum 
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DJO10A (Lee et al., 2008). This lantibiotic was purified and characterised in the study of 
Lee et al. (2011) and was found to inhibit both gram positive and gram negative bacterial 
strains including several bifidobacteria strains such as those from the species longum, 
adolescentis, breve, bifidus and animalis, two Lactococcal lactis strains, one 
Streptococcus thermophilus strain, one Micrococcus luteus strain, several potentially 
pathogenic strains such as Enterococcus faecalis LG110, a Clostridium perfringens 
strain, a C. difficile strain, a Staphylococcus epidermidis strain, a Staphylococcus aureus 
strain, a Bacillus subtilis strain, an Escherichia coli DH5a strain, a Serratia marcescens 
strain and a Proteus vulgaris strain. In their study, no production of the lantibiotic could 
be detected on agar, unless an inducer such as the purified lantibiotic itself was added to 
the broth (Lee et al., 2011). This effect was also seen in the streptin lantibiotic produced 
by Streptococcus pyogenes (Wescombe & Tagg, 2003).  
 No activity of the potential purified lantibiotic produced by B. longum DPC 6315 
was observed in this study using well diffusion assays against indicator strains. This 
could be due to one or all of the genes essential for lantibiotic production being switched 
off in B. longum DPC 6315 or that the level of the lantibiotic produced by the strain was 
too low to detect under the conditions used in this study. It is possible that this lantibiotic 
could still have an effect in vivo as there is more competition for nutrients and binding 
sites from other gut bacteria in close proximity to the producer.  
Overall, the results of this study reveal that a high percentage of the B. longum 
strains displayed a ropy phenotype after growth in mMRS with 7% (w/v) lactose broth 
and agar. The amount of EPS produced by the B. longum strains examined in this study 
varied widely with the lowest amount (23.8 ± 2.7 mg/l) being produced by B. longum 
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DPC 6321 and the highest amount (234.8 ± 5.4 mg/l) being produced by B. longum DPC 
6315. EPS production appears to be a feature of B. longum growth; it possibly helps the 
bacterial cells to adhere to the mucosal cell walls and to resist environmental stresses in 
the GIT, conferring a select advantage over non-EPS producing organisms present in the 
gastrointestinal tract. In the strain Bifidobacterium breve UCC2003, the production of 
cell surface EPS provided stress tolerance to both acid (pH 5.0) and bile stress (0.3%) and 
promoted in vivo persistence but not initial colonisation in BALB/c mice compared to 
EPS-deficient variants of B. breve UCC2003 (Fanning et al., 2012). The study performed 
by Fanning et al. (2012) demonstrated that mice fed bacterial cells of B. breve UCC2003 
strains deficient in EPS production had significantly (P<0.05-0.001) lower bacterial 
numbers compared to mice fed B. breve UCC2003 EPS producing cells. The bacteria 
were fed initially for 3 days and this result was seen from day 9 up to day 31 of the trial. 
On day 31, the viable counts of the B. breve UCC2003 strains deficient in EPS 
production were significantly (P<0.05) reduced within the murine caeca and colons 
compared to those of mice fed B. breve UCC2003 EPS-producing strains (Fanning et al., 
2012). This would suggest that the production of EPS in B. breve UCC2003 is enhancing 
the strain’s ability to persist in the murine intestine.  
Interestingly, two of the B. longum subsp. longum strains tested, (numbered 52 and 
53) displayed an EPS phenotype, but not a gtf phenotype but there are potentially many 
other genes from other bacteria and possibly bifidobacteria that code for polysaccharides, 
producing different EPSs. CLA production appears to be less common than EPS 
production in B. longum strains, as only ten of the 38 tested strains converted linoleic 
acid to CLA.  With regard to bacteriocin production, the presence of the lanA gene was 
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detected in 6 of the 38 tested strains which would suggest this is a less common feature of 
B. longum strains. 
As B. longum DPC 6315 was originally isolated from adult faeces, and has been 
found to survive passage through the murine intestine (Wall et al., unpublished results), it 
has the ability to survive passage through the gastrointestinal tract which is a prerequisite 
for any probiotic bacterial strain. The production of EPS, CLA and the potential 
production of a lantibiotic by B. longum DPC 6315 make it an exciting multifacitated 
bacterial strain for future possible applications in a range of probiotic studies. 
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Table 2.1 Strain, source, subspecies differentiation and origin of 38 B. longum strains  
                 used in this study. 
Strain Source Subspecies Origin 
DPC 6315 G
1
 longum Barrett et al. (2007) 
DPC 6316 G
1
 longum Barrett et al. (2007) 
DPC 6317 A longum Barrett et al. (2007) 
DPC 6318 C longum Barrett et al. (2007) 
DPC 6319 I infantis Barrett et al. (2007) 
DPC 6320 J longum Barrett et al. (2007) 
DPC 6321 A longum Barrett et al. (2007) 
DPC 6322 H longum Barrett et al. (2007) 
DPC 6323 B
2
 longum Barrett et al. (2007) 
DPC 6324 B
2
 longum Barrett et al. (2007) 
1 D
3
 longum Barrett et al. (2014) 
3 D
3
 longum Barrett et al. (2014) 
6 F infantis Barrett et al. (2014) 
9 D
4
 longum Barrett et al. (2014) 
10 D
4
 infantis Barrett et al. (2014) 
13 D
4
 longum Barrett et al. (2014) 
17 E longum Barrett et al. (2014) 
18 F
5
 longum Barrett et al. (2014) 
19 F
5
 longum Barrett et al. (2014) 
21 F
5
 longum Barrett et al. (2014) 
22 F longum Barrett et al. (2014) 
26 F longum Barrett et al. (2014) 
28 D longum Barrett et al. (2014) 
31 F infantis Barrett et al. (2014) 
36 F longum Barrett et al. (2014) 
38 D longum Barrett et al. (2014) 
40 F longum Barrett et al. (2014) 
43 F longum Barrett et al. (2014) 
45 F longum Barrett et al. (2014) 
47 E longum Barrett et al. (2014) 
49 F longum Barrett et al. (2014) 
52 D longum Barrett et al. (2014) 
53 E longum Barrett et al. (2014) 
56 D longum Barrett et al. (2014) 
58 D longum Barrett et al. (2014) 
59 E longum Barrett et al. (2014) 
61 F longum Barrett et al. (2014) 
74 D longum Barrett et al. (2014) 
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Legend 
A=Healthy 3 day old baby. B=Healthy 4 day old baby. C=Healthy 5 day old baby. 
D=Healthy 1 week old baby. E=Healthy 4 week old baby. F=Healthy 27 week old baby. 
G=Healthy 25 year old adult. H=Healthy 31 year old adult. I=Healthy 37 year old adult. 
J=64 year old C. difficile positive patient. 
1
Strains with matching superscript numbers 
indicate they originate from the same baby.  
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Figure 2.1 B. longum PFGE macro-restriction patterns following genomic DNA   
                  digestion with restriction enzyme XbaI.  
 
Lanes A, B = Low range PFG marker. Lane 1 – DPC 6315, Lane 2 – DPC 6316, Lane 3 – 
DPC 6317 – Lane 4 – DPC 6318, Lane 5 – DPC 6319, Lane 6 – DPC 6320, Lane 7 – 
DPC 6321, Lane 8 – DPC 6322, Lane 9 – DPC 6323, Lane 10 – DPC 6324, Lane 11 – 
Strain 1, Lane 12 – Strain 3, Lane 13 – Strain 6, Lane 14 – Strain 9, Lane 15 – Strain 10, 
Lane 16 - Strain 13, Lane 17 – Strain 17, Lane 18 – Strain 18, Lane 19 – Strain 19.     
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Figure 2.2 B. longum PFGE macro-restriction patterns following genomic DNA  
                   digestion with restriction enzyme XbaI. 
 
Lanes A, B = Low range PFG marker. Lane 20 – Strain 21, Lane 21 – Strain 22, Lane 22 
– Strain 26, Lane 23 – Strain 28, Lane 24 – Strain 31, Lane 25 – Strain 36, Lane 26 – 
Strain 38, Lane 27 – Strain 40, Lane 28 – Strain 43, Lane 29 – Strain 45, Lane 30 – Strain 
47, Lane 31 – Strain 49, Lane 32 – Strain 52, Lane 33 – Strain 53, Lane 34 – Strain 56, 
Lane 35 – Strain 58, Lane 36 – Strain 59, Lane 37 – Strain 61, Lane 38 – Strain 74.  
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Table 2.2 Strain, presence of EPS phenotype, presence of wblE gene and amount of EPS 
(mg/l) produced by B. longum strains possessing either positive EPS phenotype or 
presence of wblE gene examined in this study.  
 
 
 
 
Strain 
 
Presence of 
EPS 
phenotype.  
 
Presence of wblE gene. 
wblE
gene 500 bp
 
Amount of 
EPS 
produced 
(in mMRS 
with 7% 
lactose 
(mg/l). 
B. longum subsp. longum DPC 6315 + + 234.8 ± 5.4 
B. longum subsp. longum DPC 6316 - + N.D. 
B. longum subsp. longum DPC 6317 - + N.D. 
B. longum subsp. longum DPC 6318 + + 70 ± 4.9 
B. longum subsp. longum DPC 6320 - + N.D. 
B. longum subsp. longum DPC 6321 + + 23.8 ± 2.7 
B. longum subsp. longum DPC 6324 - + N.D. 
B. longum subsp. longum 1 + + 188 ± 4.2 
B. longum subsp. longum 9 + + 123.5 ± 3.8 
B. longum subsp. infantis 10 + + 71.7 ± 1.6 
B. longum subsp. longum 13 - + N.D. 
B. longum subsp. longum 18 - + N.D. 
B. longum subsp. longum 19 - + N.D. 
B. longum subsp. longum 21 + + 66.8 ± 3.1 
B. longum subsp. longum 22 - + N.D. 
B. longum subsp. longum 26 + + 113.8 ± 2.5 
B. longum subsp. longum 28 + + 90.8 ± 3.6 
B. longum subsp. infantis 31 - + N.D. 
B. longum subsp. longum 36 - + N.D. 
B. longum subsp. longum 38 + + 64.1 ± 1.3 
B. longum subsp. longum 40 - + N.D. 
B. longum subsp. longum 52 + - 109.1 ± 3.2 
B. longum subsp. longum 53 + - 68 ± 4. 1 
B. longum subsp. longum 56 + + 55.4 ± 2.3 
B. longum subsp. longum 58 + + 70.1 ± 1.9 
B. longum subsp. longum 59 + + 32.7 ± 2.4 
B. longum subsp. longum 61 + + 102.5 ± 3.7 
B. longum subsp. longum 74 - + N.D. 
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Legend: Presence of EPS phenotype: + depicts ropy phenotype in mMRS with 7%  
               lactose. – depicts ropy phenotype not present in mMRS with 7% lactose. 
               Presence of wblE gene: + depicts presence of wblE gene (DNA band present at  
               ~500 bp). - depicts wblE gene not present (no DNA band present at ~500 bp). 
                N.D. = Not detected 
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Table 2.3 Amount of c9, t11 CLA conversion (%) for each of the 38 B. longum strains 
examined in this study using a rapid CLA screening method previously described by 
Barrett et al. (2007). 
Strain Amount of c9, t11 CLA conversion (%) 
B. longum subsp. longum DPC 6315 60.1 ± 5.1 
B. longum subsp. longum DPC 6316 4 ± 2.6 
B. longum subsp. longum DPC 6317 20.2 ± 3.8 
B. longum subsp. longum DPC 6318 18.7 ± 0.3 
B. longum subsp. infantis DPC 6319 3.7 ± 0.4 
B. longum subsp. longum DPC 6320 53.1 ± 2.5 
B. longum subsp. longum DPC 6321 38.5 ± 1.0 
B. longum subsp. longum DPC 6322 18.1 ± 1.4 
B. longum subsp. longum DPC 6323 5.2 ± 4.8 
B. longum subsp. longum DPC 6324 6.3 ± 0.9 
B. longum subsp. longum 1 N.D. 
B. longum subsp. longum 3 N.D. 
B. longum subsp. infantis 6 N.D. 
B. longum subsp. longum 9 N.D. 
B. longum subsp. infantis 10 N.D. 
B. longum subsp. longum 13 N.D. 
B. longum subsp. longum 17 N.D. 
B. longum subsp. longum 18 N.D. 
B. longum subsp. longum 19 N.D. 
B. longum subsp. longum 21 N.D. 
B. longum subsp. longum 26 N.D. 
B. longum subsp. longum 28 N.D. 
B. longum subsp. infantis 31 N.D. 
B. longum subsp. longum 36 N.D. 
B. longum subsp. longum 40 N.D. 
B. longum subsp. longum 43 N.D. 
B. longum subsp. longum 45 N.D. 
B. longum subsp. longum 47 N.D. 
B. longum subsp. longum 49 N.D. 
B. longum subsp. longum 52 N.D. 
B. longum subsp. longum 53 N.D. 
B. longum subsp. longum 56 N.D. 
B. longum subsp. longum 58 N.D. 
B. longum subsp. longum 59 N.D. 
B. longum subsp. longum 61 N.D. 
B. longum subsp. longum 74 N.D. 
 
Legend: N.D. = Not detected. 
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Table 2.4 Strain, presence of lanA gene and presence of lantibiotic phenotype of the 38  
                 B. longum strains used in this study. 
 
 
Strain 
Presence of lanA gene. 
 
lanA gene
200 bp
 
Presence of 
lantibiotic 
phenotype. 
B. longum subsp. longum DPC 6315 + - 
B. longum subsp. longum DPC 6316 - - 
B. longum subsp. longum DPC 6317 - - 
B. longum subsp. longum DPC 6318 - - 
B. longum subsp. infantis DPC 6319 - - 
B. longum subsp. longum DPC 6320 - - 
B. longum subsp. longum DPC 6321 - - 
B. longum subsp. longum DPC 6322 - - 
B. longum subsp. longum DPC 6323 - - 
B. longum subsp. longum DPC 6324 - - 
B. longum subsp. longum 1 - - 
B. longum subsp. longum 3 + - 
B. longum subsp. infantis 6 + - 
B. longum subsp. longum 9 + - 
B. longum subsp. infantis 10 - - 
B. longum subsp. longum 13 - - 
B. longum subsp. longum 17 - - 
B. longum subsp. longum 18 - - 
B. longum subsp. longum 19 - - 
B. longum subsp. longum 21 - - 
B. longum subsp. longum 22 - - 
B. longum subsp. longum 26 - - 
B. longum subsp. longum 28 + - 
B. longum subsp. infantis 31 - - 
B. longum subsp. longum 36 + - 
B. longum subsp. longum 38 - - 
B. longum subsp. longum 40 - - 
B. longum subsp. longum 43 - - 
B. longum subsp. longum 45 - - 
B. longum subsp. longum 47 - - 
B. longum subsp. longum 49 - - 
B. longum subsp. longum 52 - - 
B. longum subsp. longum 53 - - 
B. longum subsp. longum 56 - - 
B. longum subsp. longum 58 - - 
B. longum subsp. longum 59 - - 
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B. longum subsp. longum 61 - - 
B. longum subsp. longum 74 - - 
 
Legend: Presence of lanA gene: + depicts lanA gene presence (DNA band present at    
               ~200 bp). - depicts lanA gene not present (no DNA band present at ~200 bp). 
               Presence of lantibiotic phenotype: - depicts lantibiotic phenotype not present  
               (no inhibitory action of B. longum supernatants against various indicator strains     
               tested). 
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Figure 2.3 Dendogram based on computer comparisons (UPGMA clustering based on 
Dice correlation coefficient) of B. longum XbaI PFGE patterns for 38 B. longum strains. 
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CHAPTER 3 
 
 
Genomic analysis of the human isolate Bifidobacterium longum DPC 
6315. 
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3.1 ABSTRACT 
B. longum DPC 6315 was previously found to produce an exopolysaccharide 
(Chapter  2), produce CLA (Barrett et al., 2007) and contain a lantibiotic prepeptide lanA 
gene (Chapter  2). Based on these findings the strain was considered to have potential as 
a probiotic strain and as a result its genome was sequenced. The sequencing of the draft 
genome of B. longum DPC 6315 revealed it is 2.4 Mb in size with a 59% G + C content, 
encoding 10 scaffolds, comprised of 90 large contigs. Four predicted rRNA operons were 
found to be encoded within the genome. In addition, two plasmids of approximately 10.2 
kb and 8.2 kb respectively were identified which were found to be almost identical 
(~99.5%) to previously isolated B. longum plasmids pNAC3 (Corneau et al., 2004) and 
pNAL8L (Guglielmetti et al., 2007). These plasmids were found to contain genes 
encoding replication, mobilisation and transposase functions along with a host of 
hypothetical proteins. The draft genome of B. longum DPC 6315 also contains the genes 
necessary for EPS, lantibiotic production and the myosin cross-reactive antigen (mcra) 
gene believed to be involved in CLA production in Lactobacillus reuteri PYR8 (Rosson 
et al., 2004). B. longum DPC 6315 was found to produce an EPS consisting of 12:6:3:1 of 
mannose: glucose: galactose: rhamnose, and to display a ropy phenotype in mMRS with 
7% (w/v) lactose, sucrose and glucose broth. A putative EPS operon (~16 kb) was 
identified in the genome of B. longum DPC 6315 – this potentially contained all the genes 
necessary for EPS biosynthesis i.e. chain length determination and export (Audy et al., 
2010). These included genes coding for glycosyltransferases including a pGTF gene 
(wblE) and genes wblB and wblC involved in the synthesis of the EPS repeating subunit, 
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and the genes wblA involved in EPS repeat unit polymerization and wblD involved in 
chain length determination.  
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3.2 INTRODUCTION 
B. longum DPC 6315 was previously isolated from the faecal sample of a healthy 
25 year old human (Barrett et al., 2007), and was found in the study Barrett et al. (2007) 
and in Chapter 2 of this thesis to convert 60% of free linoleic acid to CLA in vitro. It has 
also been found to survive passage through the murine intestine (Wall et al., unpublished 
results) having faecal excretion rates of ~4 × 10
4
 CFU/g. It has also been reported to 
possess an EPS phenotype in mMRS with 5 and with 7% (w/v) lactose broth and on agar 
plates (Chapter 2), and contain the pGTF wblE gene. It was also previously found to 
contain the lantibiotic prepeptide gene lanA (Chapter 2). For these reasons the probiotic 
traits of the strain were investigated in more detail using genomic analysis and 
characterization. 
As previously described in Chapter 1, the first B. longum genome to be sequenced 
and become publicly available was the genome of Bifidobacterium longum NCC2705 
(Schell et al., 2002). At present, there are 10 published complete B. longum genomes 
(http://www.ncbi.nlm.nih.gov.library.ucc.ie/genome/genomes/183) ranging in size from 
2.26 to 2.83 Mb with a G + C content spanning 59.8% to 60.3%. Of the 10 complete B. 
longum genomes, three contain two plasmids while the B. longum NCC2705 genome 
contains only a single plasmid. The draft genome of B. longum DPC 6315 appears to be 
the first B. longum genome described to contain genes encoding EPS, lantibiotic 
production and genes believed to be involved in CLA production.  
EPS produced by Bifidobacterium species are generally heteropolysaccharides of 
which glucose, galactose and rhamnose are commonly present (Abbad Andaloussi et al., 
1995; Audy et al., 2010; Salazar et al., 2009). They are generally synthesized by an 
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intracellular pathway linked to the central carbon metabolism of the producing cell (de 
Vos, 1996; De Vuyst & Degeest, 1999; Ramos et al., 2001). One process that is central to 
generating the activated sugars is the conversion of glucose-6-phosphate to glucose-1-
phosphate by phosphoglucomutase (Degeest & De Vuyst, 2000). Glucose-1-phosphate 
reacts with UTP to generate UDP-glucose, which can be incorporated into the nascent 
EPS repeating unit (Sjöberg & Hahn-Hägerdal, 1989). The oligosaccharide repeating unit 
is first assembled by the sequential transfer of sugar residues onto a lipophilic carrier by 
specific glycosyltransferases. The C-terminal domain of the pGTF catalyses the addition 
of the first sugar 1-phosphate to a lipophilic carrier molecule for initiation of EPS 
repeating unit assembly - then subsequent glycosyltransferases catalyse glycosidic 
linkages between the oligosaccharide units.  
Some genes and their predicted protein products involved in the biosynthesis of 
galactose 1-phosphate and glucose 1-phosphate and their conversion to EPS precursors 
such as UDP-glucose, UDP-galactose and dTDP-rhamnose have been located in the fully 
sequenced B. longum subsp. longum NCC2705 and DJO10A genomes (Audy et al., 
2010). All functions necessary for EPS biosynthesis were found flanking the pGTF in B. 
longum subsp. longum CRC 002. Overall, seven predicted gene products could be 
involved in heteropolysaccharide production, with putative biological functions spanning 
biosynthesis of the repeating unit (WblB, WblC and WblE), transport (Wzx), 
polymerisation (WblA) and chain length determination (WblD, Wzb) (Audy et al., 2010).     
In B. longum subsp. longum CRC 002, the wblA gene is believed to be involved in 
EPS repeat unit polymerization, whereas genes wblB, wblC and wblE are believed to be 
glycosyltransferases that could be involved in biosynthesis of the repeating unit (Audy et 
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al., 2010). The gene wblD is predicted to encode a protein involved in chain length 
determination, whereas gene wzx, which was located 3 kb from wblA in B. longum subsp. 
longum CRC 002 encodes a product with the topology of a ‘flippase’ type transporter 
(Audy et al., 2010). This is believed to translocate the EPS-repeating sugar subunits 
across the membrane so that the carbohydrate moiety is on the outside of the cell. Gene 
wzb is predicted to encode the protein tyrosine phosphatase, completing all the activities 
essential for chain length determination (Audy et al., 2010).  
As previously mentioned in Chapter 2, the first bifidobacterial lantibiotic was 
isolated from B. longum DJO10A (Lee et al., 2008). This lantibiotic operon was 
identified as a 10.2 kb gene cluster. It was also reported in that study, that this unique 
region was not identified in the B. longum NCC2705 genome. It has been suggested that 
selective pressure leads to the lantibiotic gene cluster being lost from the genome, as 
lantibiotic production would be of benefit for microbial competition in the intestine but of 
no value to a microbe in pure culture grown in the laboratory, as the pure culture is not 
competing with other cultures under these growth conditions (Lee et al., 2008). 
Furthermore, that study revealed that a pure culture growth of B. longum DJO10A 
isolates (~1000 generations in a typical laboratory medium without pH control) that lost 
the regions involved in lantibiotic production format a frequency of 40%. This also 
rendered it sensitive to the lantibiotic produced by the original strain B. longum DJO10A, 
as the cluster that was lost also contains the immunity gene to protect the cells from the 
lantibiotic activity. The location of the lantibiotic region was between two IS30 elements, 
suggests a role for the IS elements in deletion events (Lee et al., 2008).  
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In the study Lee et al. (2011), it was reported that lantibiotic production by B. 
longum DJO10A only occurs on agar and not in broth media which was consistent with 
the observation that the lantibiotic production and immunity genes, lanADMIT, were 
highly up-regulated on agar but down-regulated in broth. Quantitative real-time PCR 
analysis of total RNA samples from broth and agar revealed that the lanA gene was up-
regulated more than 9 times higher on agar. This observation was also confirmed by 
Northern hybridization analysis substantiating that lanA is induced during growth on agar 
media.   
The lantibiotic produced by B. longum DJO10A was collected from agar cultures 
and purified and it was found to have a broad spectrum of inhibition against various gram 
positive and some gram negative bacteria (Lee et al., 2011). B. longum DJO10A did not 
show any inhibition to its own lantibiotic, which would suggest that the self-immunity 
function encoded by lanI was functional. Using this purified lantibiotic it was possible to 
induce B. longum DJO10A lantibiotic production in broth culture. Indeed, lanA gene 
expression was greatly increased in a dose-dependent fashion, confirming that increasing 
the external signal in broth cultures induces transcription of lanA. 
As discussed in Chapter 1, CLA can have many beneficial effects on human health. 
Many different species of Bifidobacterium have been reported to produce CLA from 
linoleic acid (Barrett et al., 2007; Coakley et al., 2003; Rosberg-Cody et al., 2004). The 
mcra gene has been suggested to be a cis-9, trans-11 CLA forming isomerase in 
Lactobacillus reuteri PYR8 (Rosson et al., 2004). In Streptococcus pyogenes M49 the 
MCRA protein was reported to be an FAD-containing enzyme, which acts as a hydratase 
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on cis-9 and trans-11 double bonds of C-16, C-18 unsaturated fatty acids producing 
corresponding 10-hydroxy and 10, 13-dihydroxy fatty acids (Volkov et al., 2010).  
In this Chapter, the potential probiotic characteristics of B. longum DPC 6315 were 
examined using both genomic and phenotypic techniques to identify the genes 
responsible.    
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3.3 MATERIALS AND METHODS 
3.3.1 Bacterial strains, growth conditions, and media.  
The bacterial strains used in this study B. longum DPC 6315 and B. longum DPC 
6316, were previously isolated in the study of Barrett et al. (2007). The strains were 
grown on mMRS (Difco) medium supplemented with 0.05% (w/v) cysteine 
hydrochloride (Sigma Aldrich), 1.5% (w/v) agar (Oxoid) with 7% (w/v) lactose, sucrose, 
glucose, and in mMRS with 7% (w/v) lactose, sucrose and glucose broths to detect for 
the EPS phenotype. B. longum DPC 6315 was also grown in Brain heart infusion (BHI) 
media (Merck, Darmstadt, Germany) and the EPS produced by the strain was extracted 
for EPS characterisation. The agar plates and broths were incubated anaerobically 
(anaerobic jars with Anaerocult A gas packs (Merck) at 37°C for 72 h.   
 
3.3.2 Nucleic acid extraction and manipulation.  
Chromosomal DNA preparations were isolated from stationary phase cultures 
(~48 h) of B. longum DPC 6315 as outlined by Vincent et al. 1998 (Vincent et al., 1998).  
DNA extraction from agarose gels and PCR purification were performed with the Qiagen 
gel extraction kit (Qiagen), the QIAprep spin miniprep kit (Qiagen), and the PCR 
purification kit (Qiagen), respectively. DNA was quantified using a Thermo Scientific 
nanodrop 1000 (Mason Technology, Ireland). 
 
3.3.3 DNA sequencing. 
A draft genome sequence of B. longum DPC 6315 was obtained by ROCHE 454 
pyrosequencing using GS-FLX titanium chemistry technology. Primers were designed to 
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close any sequence gaps that were present in the B. longum DPC 6315 chromosomal and 
plasmid genome. The assembled draft genomes were subjected to automatic gene calling 
using GAMOLA (Altermann & Klaenhammer, 2003)  and GLIMMER (Delcher et al., 
1999). Briefly, potential protein-, rRNA-, and tRNA-coding genes were predicted by 
GLIMMER3, RNAmmer (Lagesen et al., 2007), and tRNAscan-SE, respectively (Lowe 
& Eddy, 1997). Artemis software (Rutherford et al., 2000) was used to identify potential 
genes of interest in the B. longum DPC 6315 genome. Artemis comparison tool (ACT) 
was used to compare the B. longum DPC 6315 sequenced genome with the published B. 
longum NCC2705 genome (Schell et al., 2002), to identify regions of difference between 
the two genomes. Putative genes in the regions of difference within the B. longum DPC 
6315 genome were further identified by BLASTP and domain analysis. 
 
3.3.4 Phenotypic analysis of EPS producing B. longum DPC 6315. 
For the detection of the EPS phenotype, strains were incubated for 72 h in 30ml 
mMRS with 7% (w/v) lactose broth. The mMRS with 7% (w/v) lactose broth was 
centrifuged at 3,500 g × 10 min. In strains possessing an EPS positive phenotype, the cell 
pellet was detected at the bottom of the tube and the EPS layer suspended in the 
supernatant. In a strain with an EPS negative phenotype the cell pellet was detected at the 
bottom of the tube and the supernatant remained clear (Fig. 3.8). 
 
3.3.5 Viscosity measurements of an EPS positive and EPS negative phenotype. 
The viscosity of the cultures was determined as follows - the strains were 
inoculated at 2% (v/v) into 30 ml mMRS with 7% (w/v) lactose broth for 72 h at 37°C. 
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These broths were then centrifuged at 3,500 g × 10 min and the viscosities of the 
supernatants measured. Viscosity was measured using an AR-G2 rheometer (TA 
instruments, Crawley, United Kingdom) fitted with a 60-mm aluminium parallel plate. 
Following equilibration for 5 min at 20°C, the shear rate was increased from 0.01 to 300 
s
-1
, held for 1 min at 300 s
-1
, and then decreased from 300 to 0.01s
-1
. Samples were held 
at 20°C throughout the run.  
 
3.3.6 Immunological analysis.  
Agglutination tests were performed using Streptococcus pneumoniae type 37-
specific antisera (Statens, Serum Institut, Denmark) as previously reported, with slight 
modifications (Walling et al., 2005). Briefly, overnight cultures (24 h) were centrifuged 
(at 13,000 × g for 5 min), the resultant pellet resuspended in an equal volume of high-
performance liquid chromatography (HPLC) water. Subsequently, 5 µl of antiserum was 
added and incubated for 30 min at 4°C. When agglutination occurs, cells form 
agglomerates observed using phase-contrast microscopy. 
 
3.3.7 EPS isolation. 
EPS was isolated from B. longum DPC 6315 cultures grown in mMRS with 7% 
(w/v) lactose broth for 72 h at 37°C following the isolation method of Mårtensson et al. 
(2002) with the following modifications. The pH of the samples were adjusted to pH 6.2 
with 4M NaOH and then overnight hydrolysis was performed using 0.2 mg/ml proteinase 
K (Sigma-Aldrich, Wicklow, Ireland) at 37°C. To terminate the reaction, the mixture was 
heated at 90°C for 10 min and centrifuged at 4,000 × g for 30 min (Sorvall
®
LegendRT, 
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Thermo Scientific, Loughborough, UK). The supernatant was then collected and 
precipitated with 4 volumes of chilled ethanol and agitated (100 rpm) overnight at 4°C. 
To recover the precipitate, the mixture was centrifuged at 4,500 × g for 30 min. The 
pellet was dissolved in 10 ml of sterile deionised water and dialysed (molecular mass cut-
off of 12, 000 Da) against deionised water for 3 d at 4°C (with two daily washing steps). 
The mixture was lypholised (VirTis AdVantage
TM
 Freeze Dryer, SP Industries, NY, 
USA) and the generated powder was kept at -20°C for further analysis.  
 
3.3.8 EPS characterization. 
The monosaccharide composition of isolated freeze-dried EPS was determined by 
sugar compositional analysis using GC-MS analysis (Price, 2004). Prior to analysis, EPS 
samples were refluxed in 2N trifluoroacetic acid (TFA) and converted into pre-acetylated 
aldonitrile acetates (PAANS). EPS structure characterisations were performed by Dr. N. 
Price, US, Department of Agriculture, IL, USA.   
 
3.3.9 Phenotypic analysis of B. longum DPC 6315 lantibiotic production. 
The method described by Lee et al. (2011) was used to isolate and purify the 
potential lantibiotic produced by B. longum DPC 6315. B. longum DPC 6315 was 
inoculated onto BLIM + Fe or mMRS media supplemented with 0.5% agar (Difco) and 
incubated anaerobically at 37°C for 48 h. Cultured agar media were collected and crushed 
in a beaker, and an equal volume of 95% methanol solution (w/v) was added. After 
stirring of the mixture with magnetic bars at 4°C for 24 h, the agar debris and cells were 
removed by centrifugation at 8, 000 × g at 4°C for 20 min and the supernatant filtered 
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using a Corning 115 ml vacuum filter system with 0.22 µm diameter filter (Corning, 
Lowell, MA). Methanol was then removed by concentration using a Savant SPD2010 
SpeedVac concentrator at 45°C until completely dried (Thermo Scientific, Waltham, 
MA). The dried pellets containing the potential lantibiotic were rehydrated with 0.05 
volume of molecular grade water (Sigma-Aldrich Limited, Wicklow, Ireland). Further 
purification and concentration was conducted by size fractionation using CentriPrep filter 
units with 50, 30 and 10 kDa cut-off filters in sequence (Millipore, Billerica, MA).  
The bioactivity of the crude lantibiotic preparation was assayed using standard 
well diffusion assays (Tagg & McGiven, 1971). Indicator strains used to assess zones of 
inhibition included B. longum DJ010A, B. breve DPC 702258, B. breve DPC 6330, 
Bifidobacterium longum subsp. infantis ATCC 15697, and the gram positive pathogens S. 
aureus, Streptococcus thermophilus ST20, C. difficile, Lactococcus lactis subsp. lactis 
LM0230 and the gram negative pathogen Escherichia coli DH5a.  
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3.4 RESULTS. 
 In chapter 2, B. longum DPC 6315 was previously found to produce an EPS, CLA 
(Barrett et al., 2007) and contain a lantibiotic prepeptide lanA gene (Chapter 2). The 
strain was considered to have potential as a probiotic strain based on these findings and 
as a result its genome was sequenced. 
 
3.4.1 DNA sequencing. 
Initial automatic assembly of the 454 reads generated a non-redundant sequence 
of 2.4 Mb with a 59% G + C content, encoding 10 scaffolds, comprised of 90 large 
contigs. Four predicted rRNA operons were found to be encoded within the genome. A 
comparison with the published completely sequenced genome of B. longum NCC2705 
revealed a number of significant regions of difference (Fig. 3.1). These regions of 
difference were then further investigated for novel genes in the B. longum DPC 6315 
genome which revealed plasmid DNA and putative genes encoding EPS, bacteriocin and 
CLA production. Two plasmids of ~10.2 kb and ~8.2 kb respectively, were identified in 
the B. longum DPC 6315 genome with high identities (~99.5%) to previously isolated B. 
longum plasmids pNAC3 (Corneau et al., 2004) and pNAL8L (Guglielmetti et al., 2007), 
(Fig. 3.2). These plasmids were found to contain genes coding for replication, 
mobilisation and transposase functions, in addition to coding for a number of 
hypothetical proteins.  
A putative EPS operon (~16 kb) (Fig. 3.3) was also identified in the genome of B. 
longum DPC 6315 – this potentially contained all the genes necessary for EPS 
biosynthesis i.e. chain length determination and export (Audy et al., 2010). These genes 
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had high sequence identities to EPS production encoding genes located in B. longum 
CRC 002, with genes wblE and wblD having ~95% sequence identity to genes wblE and 
wblD found in B. longum CRC 002, and genes wblA, wblB and wblC having ~76% 
sequence identity to genes wblA, wblB and wblC found in B. longum CRC 002. 
Interestingly, the EPS operon located in the genome of B. longum DPC 6315 has a 
different gene organization compared to the EPS operon found in B. longum CRC 002. 
A putative lantibiotic operon (~10.2 kb) was identified in the draft genome of B. 
longum DPC 6315 with ~99% sequence identity to the lantibiotic gene cluster found in B. 
longum DJO10A (Lee et al., 2008). This lantibiotic gene operon was found to encode 
eight genes (Fig. 3.4). Lee et al. (2011) reported that this gene cluster contained all the 
potential genes required for lantibiotic production, as well as a dedicated two component 
system (lanR2 and lanK), which is characteristic of lantibiotic gene clusters in other 
bacteria (Klaenhammer, 1993). A second predicted transcription regulator (lanR1) was 
found which is an analogous organization to the mersacidin gene cluster from a Bacillus 
species (Altena et al., 2000). The potential lantibiotic produced by B. longum DPC 6315 
was isolated and purified using a method described by Lee et al. (2011). However, no 
lantibiotic activity was observed from B. longum DPC 6315 supernatants using well 
diffusion assays against other B. longum (Chapter 2) and various gram-positive and 
gram-negative pathogenic indicator strains. 
With regards to CLA production, an open reading frame (ORF) homologous to 
the MCRA protein ORF found in B. longum NCC2705 (Fig. 3.5) was also identified in 
the draft genome of B. longum DPC 6315. An intact DNA polymerase III protein ORF 
was located upstream of the MCRA ORF. The MCRA and the DNA polymerase III 
 142 
proteins share ~97% and ~96% amino acid identities respectively, to the MCRA and the 
DNA polymerase III proteins located in the CLA producing B. breve DPC 6330. 
Interestingly, a gene encoding a hypothetical protein was located between the mcra and 
the DNA polymerase III encoding genes, that possessed ~99% amino acid identity to a 
narrowly conserved hypothetical protein found in Bifidobacterium longum subsp. infantis 
ATCC 15697 (Fig. 3.5). Located just downstream of the MCRA ORF were potential 
genes encoding histone acetyltransferase HPA2 protein and related acetyltransferase 
proteins. Further downstream was an ORF encoding a ribosomal protein with ~100% 
homology to the 50S ribosomal protein L1 found in Bifidobacterium longum subsp. 
longum JDM 301 (Fig. 3.5). 
  
3.4.2 EPS characterization. 
The EPS produced by B. longum DPC 6315 is most likely not of the beta glucan 
type EPS as the producing cells did not aggregate after treatment with Streptococcus 
pneumoniae type 37-specific antisera (Fig. 3.6 (a)) compared to the beta glucan 
producing Lactobacillus paracasei subsp. paracasei 338 control (Fig. 3.6 (b)). 
Characterisation of the monosaccharide structure of the EPS produced by B. 
longum DPC showed it is composed of 12:6:3:1 of mannose: glucose: galactose: 
rhamnose whereas the EPS produced by B. longum CRC 002 is composed of 2:3 
galactose: glucose. B. longum DPC 6315 displayed a ropy phenotype in mMRS with 7% 
(w/v) lactose, sucrose or glucose broths and agar plates. The strain was found to be most 
ropy when grown on mMRS with 7% (w/v) lactose. Fig. 3.7 displays the EPS phenotype 
of B. longum DPC 6315 in mMRS with 7% (w/v) lactose broth. 
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A clear phenotypic difference in EPS production was observed when 72 h cultures 
grown in mMRS with 7% (w/v) lactose broth of both B. longum DPC 6315 (EPS +ve) 
and B. longum DPC 6316 (EPS -ve) (Chapter 2) were centrifuged (3,500 g × 10 min) 
(Fig. 3.8). B. longum DPC 6315 displayed a positive EPS phenotype, giving a cloudy 
supernatant with the cell pellet settling at the bottom of the tube (Fig. 3.8 (EPS +ve)). In 
constrast, B. longum DPC 6316 displayed a negative EPS phenotype and yielded a clear 
supernatant with the cell pellet settling at the bottom of the tube after centrifugation (Fig. 
3.8 (EPS –ve)). These images clearly show that in an EPS positive phenotype the EPS 
layer remains suspended throughout the supernatant after centrifugation (Fig. 3.8). The 
generated supernatants also showed differing viscosities with that from B. longum DPC 
6315, having a significantly (P<0.001) higher value of 2.9 mPa.S compared to of 1.74 
mPa.S for the control strain (Fig. 3.9). 
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3.5 DISCUSSION 
 Of the published B. longum genome sequences available, the genome of B. 
longum DPC 6315 appears to be the only genome that contains the genes for EPS, 
bacteriocin and CLA production.  
The EPS produced by B. longum DPC 6315 appears to be a unique bifidobacterial 
EPS containing the monosaccharides mannose, glucose, galactose, and rhamnose in an 
approximate ratio of 12:6:3:1. The high levels of mannose in bifidobacterial EPS have 
only been previously reported for three other Bifidobacterium species - namely B. longum 
DSM 21062, CHCC8773 and CHCC8818 (Kildsgaard et al., 2011). The EPS produced 
by B. longum DSM 21062 was found to contain the monosaccharides glucose, mannose, 
galactose, fucose in an approximate ratio of 107:34:1.5:1 with only a trace of rhamnose, 
while the EPS of B. longum CHCC8773 contained mannose at the highest concentration 
of any monosaccharide present with an approximate ratio of mannose: glucose: galactose: 
fucose of 23:11:3:1. The EPS produced by B. longum CHCC8818 also contained 
mannose as the monosaccharide with the highest concentration with an approximate ratio 
of mannose: glucose: galactose: fucose of 36:17:3:1. It is tempting to suggest that the 
high concentration of mannose in the EPS produced by B. longum DSM 21062 could 
possibly be responsible for the strain’s immunodulatory effects. This strain was reported 
to possess anti-inflammatory effects in a trinitrobenzene sulfonate (TNBS)-induced 
colitis model in mice (Kildsgaard et al., 2011). In this murine model, it reduced the 
TNBS-induced injury by 44% (P=0.007) when fed to mice at 1 × 10
9
 live bacteria daily 
for 5 consecutive days - compared to the two other B. longum strains tested which were 
CHCC8773 and CHCC8818. It has also been previously reported that complex polymers 
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containing mannose (mannans) possess significant biological activity when administered 
to mammals particularly including the activation of the immune system following the 
binding of mannose to recognition molecules such as the mannose receptor (CD206) 
expressed on macrophages and dendritic cells (Carroll & Prodeus, 1998; Diebold et al., 
2002; Stahl & Ezekowitz, 1998). Likewise, it is also possible that the EPS produced by B. 
longum DPC 6315 could have positive immunodulatory effects in vivo as it produces an 
EPS with high levels of mannose.   
EPS produced by some strains of LAB can be used to increase the viscosity of 
fermented food products (Cerning, 1995; De Vuyst, 1999; Goh et al., 2005). In mMRS 
containing 7% (w/v) lactose broth, the EPS produced by B. longum DPC 6315 had a 
significant effect on the viscosity of the crude supernatant. These results demonstrate that 
under the proper conditions for EPS production and maintenance, the EPS produced by 
B. longum DPC 6315 could enhance the viscosity of a food product leading to a more 
desirable texture which could be of commercial value. Indeed, the EPS produced by B. 
longum DPC 6315 could possibly be used as a natural additive in food products, which 
are preferred by some consumers over stabilisers of plant or animal origin. 
 The lantibiotic gene operon identified in the genome of B. longum DPC 6315 was 
previously identified in B. longum DJO10A (Lee et al., 2008).  Using well diffusion 
assays and spot plate overlays, however, no antimicrobial activity of the B. longum DPC 
6315 supernatants was found against other B. longum strains (Chapter 2) – nor were 
various Gram-positive and Gram-negative pathogenic bacteria inhibited or killed. This 
could be due to one of the genes essential for lantibiotic production being switched off in 
B. longum DPC 6315 or that the level of the lantibiotic produced by the strain were too 
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low to detect any activity against indicator strains in vitro – in other words being below 
the minimum inhibitory concentration. It is possible production of a lantibiotic in vivo 
could confer an advantage on B. longum DPC 6315 over other bacterial strains in vivo. In 
this respect, production of the lantibiotic might be very different in the gut compared to 
that seen in pure culture as the environments are so different.  
The identification of the MCRA protein in the draft genome of B. longum DPC 
6315 suggests it performs a function in the bacterial strain’s conversion of linoleic acid to 
CLA. The MCRA and the DNA polymerase III proteins in B. longum DPC 6315 were 
found to have ~97% and ~96% identity respectively to those in B. breve DPC 6330, 
which would suggest that these proteins are highly conserved in different CLA producing 
Bifidobacterium species.   
In conclusion, the identified probiotic traits in the draft genome of B. longum DPC 
6315 make it an attractive potential probiotic bacterium strain. As it was originally 
isolated from adult faeces (Barrett et al., 2007), and has been found to survive passage 
through the murine intestine (Wall et al., unpublished results), it has the ability to survive 
passage through the gastrointestinal tract which is a prerequisite for any probiotic 
bacterial strain. The production of EPS, CLA and the potential production of a lantibiotic 
by B. longum DPC 6315 make it a possible future candidate strain as a probiotic. 
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Figure 3.1 ACT alignment of draft genome of B. longum DPC 6315 and B. longum 
NCC2705 (Regions of difference in white). Red lines indicate regions of similar 
sequence with the same orientation in both genomes. Blue lines indicate regions of 
similarity that have an inverted configuration. 
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Figure 3.2 Plasmids identified in draft genome of B. longum DPC 6315. 
Almost identical (~99.5%) to previously isolated B. longum plasmids pNAC3 (~10.2 kb) 
(Corneau et al., 2004) and pNAL8L (~8.2 kb) (Guglielmetti et al., 2007). 
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Figure 3.3 Organisation of putative EPS producing operon in B. longum DPC 6315.  EPS 
operon is compared to the operon in B. longum CRC 002 (Audy et al., 2010).  
Percentages are representative of nucleotide identification. 
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Figure 3.4 Organisation of putative lantibiotic operon in B. longum DPC 6315. 
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Figure 3.5 MCRA protein and related proteins identified in the draft genome of B.  
                  longum DPC 6315. 
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Figure 3.6 Immunological analysis of EPS producing B. longum DPC 6315 cells (a)  
                   compared to L. paracasei NFBC 338 beta glucan producing cells (b). 
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Figure 3.7 Image of B. longum DPC 6315 EPS phenotype in mMRS with 7% (w/v)  
                   lactose broth. 
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Figure 3.8 Image of B. longum DPC 6315 EPS positive (EPS +ve) phenotype and B.  
                  longum DPC 6316 EPS negative phenotype (EPS –ve). 
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Figure 3.9 Viscosity analysis of centrifuged crude supernatant (3,500 g × 10 min) EPS 
positive B. longum DPC 6315 (EPS+) and EPS negative (EPS-) B. longum DPC 6316 
grown in mMRS with 7% (w/v) lactose broth. 
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CHAPTER 4 
 
The effect of exopolysaccharide producing Bifidobacterium longum DPC 6315 on the 
functional properties of yoghurt. 
 
 
 
 
 
 
 
 
 162 
4.1 ABSTRACT 
The influence of the EPS-producing adjunct strain, Bifidobacterium longum DPC 
6315 on the functional properties of yoghurt was examined. In situ production of EPS by 
B. longum DPC 6315 during product manufacture and up to 14 days of cold storage at 
4°C was found to significantly (P<0.05) increase (from 36.9 (± 2.9) mg/l on day 0 to an 
average of 51.4 (± 9.4) mg/l EPS on day 7). In contrast, the concentration of EPS in the 
EPS containing yoghurt slightly declined on day 14,  and significantly decreased on 21 
(P<0.01) and 28 (P<0.01) of cold storage, to an average of 19.3 (± 4.4) mg/l EPS on day 
28. The performance and viability of the yoghurt cultures were not affected by addition 
of B. longum DPC 6315, with Lactobacillus delbrueckii ssp. bulgaricus and 
Streptococcus thermophilus detected at 1.7 × 10
7
 CFU/g and 2.8 × 10
5
 CFU/g, 
respectively, following 28 days of storage at 4°C. The viability of the EPS-producing B. 
longum DPC 6315 was 2 × 10
6
 CFU/g after 28 days of storage at 4°C, which is above the 
minimum of 10
6
 CFU/g recommended by the FAO/WHO guidelines (FAO/WHO, 2002) 
for a probiotic bacterium in a fermented food. During yoghurt manufacture and at 14 
days of storage at 4°C, a significant decrease (P<0.05) in syneresis was obtained in 
yoghurt containing the EPS producing strain compared with the control. No significant 
difference was found in viscosity after fermentation and during 28 days of storage at 4°C 
between the yoghurt manufactured with the EPS-producing B. longum DPC 6315 and the 
control yoghurt. Confocal laser scanning microscopy (CLSM) of unstirred yoghurt 
samples demonstrated that the EPS was present around the edges of the pores of the 
yoghurt network but not in the control yoghurt. This study demonstrates that the use of B. 
longum DPC 6315 as an adjunct culture during yoghurt manufacture resulted in lower 
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levels of syneresis and higher levels of EPS, and as such use of the adjunct offers some 
technological improvements to the product over and above its probiotic characteristics.  
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4.2 INTRODUCTION 
Yoghurt has been consumed in many cultures as part of the daily diet for 
centuries. Yoghurt is a protein coagulum of a casein network in which serum, fat 
globules, and bacterial cells are entrapped. The distribution of the ‘filling compounds’ 
such as EPS and their interactions with casein micelles can have a positive influence on 
the rheological properties of yoghurt since it can strengthen the relatively weak structure 
of the casein network (Hassan et al., 2002). The addition of stabilisers of plant or animal 
origin to natural yoghurts is prohibited in most European Union countries (Degeest & De 
Vuyst, 1999), and consequently EPS produced by LAB have been commonly used to 
enhance the texture and viscosity of dairy products (Costa et al., 2012).  
The function of EPS in fermented milk and yoghurt is affected by a number of 
factors including monosaccharide composition, charge, linkage types, branching, 
molecular weight, and the ability to interact with milk protein (Duboc & Mollet, 2001; 
Kleerebezem et al., 1999; Ruas-Madiedo et al., 2002a). EPS produced by LAB such as 
lactobacilli, streptococci and lactococci can be used as a natural thickener, to increase the 
viscosity and to decrease syneresis of fermented milk products (Cerning, 1995; De Vuyst, 
1999; Goh et al., 2005). Syneresis or whey separation is the spontaneous appearance of 
whey on a milk gel surface and is considered a major defect in the yoghurt industry 
(Tamime & Robinson, 2007b). Studies carried out by London et al. (submitted 2013) and 
Kearney et al. (2011) found that EPS produced by different Lactobacillus strains used in 
yoghurt fermentations increased the viscosity and decreased the syneresis in the product. 
Bifidobacteria in general have been reported to exhibit poor growth in dairy based 
foods when compared with traditional LAB used in fermented dairy products, which 
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could possibly hinder their potential applications (Prasanna et al., 2011). In this respect, 
they generally require long fermentation times, anaerobic conditions, and low redox 
potential for growth when grown in milk (Gomes & Malcata, 1999; Hughes & Hoover, 
1995; Jayamanne & Adams, 2009). In addition, Samona and Robinson (1994), reported 
that the growth of Bifidobacterium species was adversely affected by the presence of 
yoghurt cultures. In contrast, the yoghurt starter culture S. thermophilus was reported to 
stimulate the growth of Bifidobacterium species in yoghurt as it acts as an oxygen 
scavenger by reducing the level of dissolved oxygen in the yoghurt (Ishibashi & 
Shimamura, 1993). L. delbrueckii subsp. bulgaricus has also been found to have a 
stimulatory effect on B. bifidum possibly due to its proteolytic activity (Rybka, 1994). A 
further major drawback to the use of bifidobacteria as probiotic cultures in the production 
of yoghurt and fermented milk is their poor survival at low pH (the pH of yoghurt ranges 
from 4.2 to 4.7) (Dave & Shah, 1998; Hughes & Hoover, 1995; Lamoureux et al., 2002; 
Roy et al., 1997). The addition of bifidobacteria to yoghurt can also improve its health 
enhancing value (Kailaspathy & Rybka, 1997). For example, yoghurt containing 
Bifidobacterium species have been reported to improve lactose utilization (He et al., 
2007) and increase HDL cholesterol or (the so called ‘good cholesterol’) following 
consumption (Kiessling et al., 2002). Wang et al. (2004) also reported that the 
consumption of yoghurt for six weeks containing B. lactis Bb12 and Lactobacillus 
acidophilus La5 by patients infected with H. pylori significantly decreased the values of 
the urea breath test which is the standard test for measuring H. pylori infection. This 
study also reported a significant decrease in gastritis activity and H. pylori from 
endoscopic biopsies of gastric mucosa taken from the antrum of 14 patients who had 
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consumed the B. lactis Bb12 and L. acidophilus La5 containing yoghurt (Wang et al., 
2004). In another study, Matsumoto and Benno (2004) reported that the consumption of 
yoghurt containing Bifidobacterium lactis LKM512 for two weeks reduced gut 
mutagenicity by increasing the levels of polyamines in healthy adult subjects. Colombel 
et al. (1987) reported that consumption of yoghurt containing B. longum decreased faecal 
excretion of clostridia and abolished erythromycin-induced abdominal discomfort. 
Regular consumption of yoghurt (400-500g/week) containing at least 1 × 10
6
 CFU/g of 
Bifidobacterium species which are capable of surviving in the upper GIT, is 
recommended to achieve therapeutic benefits (Tamime et al., 1995).  
In this study the effects of the adjunct strain B. longum DPC 6315 were examined 
during yoghurt manufacture. This strain was selected based on its ability to produce EPS 
and give a ropy phenotype. In addition, the strain has additional potential as a probiotic 
strain in that it produces CLA from linoleic acid and also has the potential to produce a 
lantibiotic based on its genotype. 
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4.3 MATERIALS AND METHODS 
4.3.1 Starter microorganisms 
B. longum DPC 6315 was isolated from the human GIT (Barrett et al., 2007) and 
identified as an EPS producer (Chapter 2). In this study, B. longum DPC 6315 was used 
as a ropy and EPS-producing adjunct culture during yoghurt manufacture.  Prior to 
yoghurt manufacture, B. longum DPC 6315 was propagated three times in Lactobacillus 
MRS (Difco) containing 0.05% (w/v) L-cysteine hydrochloride (Sigma) at 37°C, 
anaerobically. The thermophilic yoghurt starter, CH-1 (non-EPS-producing) consisted of 
a defined mixed single strain of S. thermophilus and L. delbrueckii ssp. bulgaricus in a 
freeze-dried pellet form (Chr. Hansen, Horsholm, Denmark). Before use, the CH-1 
culture was activated by adding a 50 U sachet (consisting of ~ 1 × 10
6
 CFU/g
 
of S. 
thermophilus and ~ 1 × 10
8
 CFU/g
 
of L. delbrueckii ssp. bulgaricus) to 500 ml of sterile 
14% (w/v) reconstituted medium-heat skimmed milk (RSM; Kerry Ingredients Ltd., 
Kerry, Ireland) and agitated for 15 min to achieve a homogenous culture, according to the 
manufacturer’s instructions. The freeze-dried cultures were stored at -20°C until use. 
 
4.3.2 Yoghurt Manufacture 
The fermentation substrate consisted of 14% (w/v) RSM (Kerry Ingredients Ltd.) 
supplemented with 1% (w/v) yeast extract. The fermentation substrate was heat treated at 
121°C for 5 min prior to inoculation. The mixture was then cooled to 37°C and 3 l 
aliquots were transferred aseptically into separate sterile bottles. Overnight cultures (18 
h) of B. longum DPC 6315 were centrifuged (Sorvall
®
 RC-5B Plus, Thermo Scientific, 
Waltham, MA, USA) at 10,000 × g for 10 min at 4°C, washed with sterile Milli-Q water 
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and resuspended with an aliquot of the fermentation substrate. Into separate aliquots of 
RSM, representing the control and B. longum DPC 6315 containing yoghurts, 
fermentation substrate was inoculated at 0.2% (v/v) with either the activated CH-1 
culture (control) or the activated CH-1 culture in combination with B. longum DPC 6315 
and agitated for 10 min to achieve adequate mixing. The samples were distributed in 125 
ml sterile plastic containers (VWR International, Dublin 15, Ireland) and incubated in an 
anaerobic gas chamber (Don Whitley Anaerobic Cabinet MACS 500, Davidson and 
Hardy, Dublin 4, Ireland) at 37°C. The fermentation was performed under anaerobic 
conditions (as oxygen negatively affects the growth of B. longum DPC 6315, as it is an 
anaerobic culture (Barrett et al., 2007)) for 6.5 h and was terminated at pH 4.7 when the 
yoghurt samples were immediately stored at 4°C for 28 days. All data are based on 
triplicate yoghurt trials.  
 
4.3.3 Determination of culture viability 
For enumeration of viable microorganisms, aliquots of milk or yoghurt, taken at 
selected time points, were serially diluted in maximum recovery diluent (MRD; Oxoid 
c/o Fannin Healthcare, Dublin, Ireland) and plated onto the appropriate selective medium 
for each strain. S. thermophilus and L. delbrueckii ssp. bulgaricus were enumerated on 
LM17 and MRS (adjusted to pH 5.2; Difco), containing 2% (w/v) agar (Oxoid), 
respectively (Kearney et al., 2009). B. longum DPC 6315 was enumerated anaerobically 
on mMRS (Difco) medium supplemented with 0.05% (w/v) L-cysteine hydrochloride 
(Sigma), 1.5% (w/v) agar (Oxoid) containing mupirocin (50 mg/l) (Oxoid) from 
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antimicrobial susceptibility test discs as previously described by (Rada, 2000)  at 37°C 
for 48 h. 
 
4.3.4 Isolation and quantification of EPS 
The isolation and quantification of EPS in yoghurt was performed as previously 
reported (Amatayakul et al., 2006; Zisu & Shah, 2003). A 25 ml sample of yoghurt was 
diluted (1:1) with Milli-Q water. The casein fraction was precipitated by adding 4 ml 0.2 
M trichloroacetic acid (TCA; Sigma Aldrich), followed by centrifugation (Sorvall
®
 
Legend RT, Thermo Scientific) at 3,310 × g for 30 min at 4°C to remove the precipitate 
and the bacterial cells. The pH of the supernatant was adjusted to 6.8 with 4 M NaOH, 
boiled in a sealed container for 30 min and centrifuged (3,310 × g for 30 min at 4°C) to 
remove the whey proteins. An equal volume of chilled ethanol was then added to the 
supernatant to precipitate the carbohydrates and agitated (100 rpm) overnight at 4°C. The 
overnight sample was centrifuged at 3,310 × g for 30 min at 4°C - the carbohydrate pellet 
was then resuspended in 10 mL of Milli-Q water and sonicated for 1 h at room 
temperature using a sonication bath (Decon FS100B, Decon Laboratories, East Sussex, 
UK). The sample was vortex mixed to a uniform solution and dialysed (molecular mass 
cut-off of 1200 Da) against deionised water at 4°C for 7 days (with two daily changes of 
water). The dialysate was stored at -20°C until assayed. The EPS concentration in the 
suspension was quantified using the phenol-sulphuric method and was expressed as the 
glucose equivalent (DuBois et al., 1956). The concentrations of EPS for B. longum DPC 
6315 was determined by subtracting the total amount of glucose detected in unfermented 
culture medium (which was used as a blank) from total amount of glucose detected in the 
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inoculated fermentation medium. The concentration of EPS in the yoghurt samples was 
determined by subtracting the total amount of glucose detected in the control yoghurt 
(used as a blank) from the total amount of glucose detected in the B. longum DPC 6315 
containing yoghurt, at each storage point assayed.  
 
 4.3.5 Chemical and physical properties of yoghurt 
The pH change of yoghurt during fermentation and storage was monitored using a 
pH meter (model MP220, Mettler-Toledo, Greifensee, Switzerland), with a calibrated 
electrode (Mettler-Toledo InLab
®
 413, Mettler-Toledo). The titrable acidity of the 
yoghurt was assessed by adding one drop of phenolphthalein (Sigma Aldrich) to 10 g of 
yoghurt and titrating with 0.1 M NaOH (Sigma Aldrich) until a light rose to pink colour 
persisted (Tamime & Robinson, 2007a). Titratable acidity was expressed as percentage of 
lactic acid, calculated as follows: 
 
% Lactic acid = Alkali (ml)/10                                                                                   (1) 
 
The extent of syneresis during storage was assessed by a centrifugation method 
outlined in a previous study (Amatayakul et al., 2006). Synereis was expressed as:  
 
Syneresis (%) = Weight of the whey separated from the gel × 100                            (2)        
                           Initial weight of the yoghurt sample 
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Viscosity measurements of the yoghurt samples were perofrmed using an AR-G2 
ex rheometer (TA Instruments, Crawley, UK) equipped with a parallel plate geometry 
(diameter 60 mm). Prior to analysis, the samples were stirred with a spatula 20 times to 
achieve a homogenous mixture. The samples were then pre-sheared at 200 s
-1
 for 1 min to 
remove any residual structure (Vasiljevic et al., 2007), allowed to equilibrate for 1 min, 
sheared from 0.01 to 200 s
-1 
over 2 min, held at 200 s
-1
 for 1 min and sheared from 200 to 
0.01 s
-1
 over 2 min. All tests were performed at 20°C.  
 
4.3.6 Confocal laser scanning microscopy (CLSM). 
The microstructure of the yoghurt samples was examined following 28 days of 
storage following staining using CLSM. The labelling fluorescent stain, Fast Green FCF 
(Sigma Aldrich), was used to label the protein. A 20µl volume of a 0.1 g/l
 
aqueous 
solution of Fast Green FCF was applied to the surface of the yoghurt sample. Fast Green 
FCF was applied to the surface of the yoghurt sample. Fast Green FCF labelled the 
protein and displayed the protein as a red colour. Fast Green FCF label proteins when 
excited at 633 nm (Auty et al., 2001). The lectin Wheat Germ Agglutinin Alexafluor 555 
conjugate (WGA; Invitrogen) – was used to visualise the bacterial EPS. The Wheat Germ 
Agglutinin 555 stock solution was freshly prepared by dissolving 1 mg of the lectin 
Wheat Germ Agglutinin Alexafluor 555 conjugate in a mixture of 1.5 ml phosphate 
buffer at pH 6.3 and 0.5 ml ethanol. The lectin Wheat Germ Agglutinin Alexafluor 555 
labels EPS when excited at 561 nm. The EPS was labelled with Wheat Germ Agglutinin 
Alexafluor 555 and displayed the EPS as a blue colour. To label the bacteria, the SYTO9 
solution was used (excitation and emission maxima, 480 and 500 nm respectively) and 
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penetrated both viable and non-viable bacteria. A 10 µl aliquot of the SYTO9 solution 
was added to the surface of the yoghurt. The argon ion laser was used to generate the 488 
line for excitation and visualization of the bacteria. Syto 9 labelled live and dead bacteria 
and the cultures were visualized as a green colour. The argon ion laser was used to 
generate the 488 line for excitation and visualisation of the bacteria. All samples were 
gently stirred after adding the dyes. Imaging was performed using a Leica TCS SP3 
confocal laser scanning microscope (Leica Microsystems, Heidelberg GmbH, Mannheim, 
Germany) with a 63x oil immersion objective (AN  = 1.4). RGB colour images (24 bits), 
512 × 512 pixel resolution, in TIFF format were acquired. A minimum of 4 z-stacks were 
taken per sample with representative cross sections of micrographs shown.  
 
4.3.7 Statistical analysis 
Data from triplicate trials were subjected to unpaired T-test analysis. Results are 
considered significant as follows:  
* P<0.05; ** P <0.01; *** P<0.001. 
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4.4  RESULTS 
4.4.1 Culture viability during yoghurt fermentation and storage 
Prior to yoghurt fermentation, the optimal growth conditions for B. longum DPC 
6315 in the yoghurt base were determined. The addition of 1% (w/v) yeast extract to 14% 
(w/v) RSM was found to promote the growth of B. longum DPC 6315 as it grows poorly 
in 14% (w/v) RSM (Fig. 4.1). Following 12, 18 and 24 h of growth in 14% (w/v) RSM 
with 1% (w/v) yeast extract, cell numbers of B. longum DPC 6315 were one log higher 
(>9 log CFU/ml) compared with B. longum DPC 6315 grown in 14% (w/v) RSM without 
yeast extract (Fig. 4.1). Similar findings were reported for the strain B. breve NCIMB 
702258 by Hennessy et al. (2009), where an increase of ~ 10 fold was recorded after 43 h 
of anaerobic growth in 20% RSM when 20 mg/ml yeast extract was added to the growth 
medium compared to growth of the strain in 20% RSM with no supplementation. 
The pH values recorded of the B. longum DPC 6315 fermentate after 6, 12, 18 and 
24 h of growth in 14% (w/v) RSM with 1% yeast extract was significantly (P<0.01-
0.001) lower than the pH values of B. longum DPC 6315 grown in 14% (w/v) RSM alone 
and with 0.05%, 0.1%, 0.3%, 0.5%, 0.75% (w/v) yeast extract (Fig. 4.2). There was no 
further significant decrease in the pH values recorded for B. longum DPC 6315 grown on 
higher levels of yeast extract.  
The B. longum strain was added to the fermentation substrate at ~ 2 × 10
9 
CFU/ml 
and by the end of fermentation no reduction in viability was observed (Fig. 4.3). 
Following 28 days of storage at 4ºC, the B. longum strain had declined to ~ 2 × 10
6
 
CFU/ml (Fig. 4.3). Furthermore, the sum of the yoghurt bacterial strains, L. delbrueckii 
ssp. bulgaricus and S. thermophilus, was above the minimum requirement of 10
7
 viable 
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microorganisms per gram of a fermented dairy food such as yoghurt (FAO/WHO, 2003) 
(Fig. 4.3). 
 
In the yoghurt containing the B. longum strain, the viable cell numbers of L. 
delbrueckii ssp. bulgaricus increased from ~ 2 × 10
6 
to 2.5 × 10
8
 CFU/ml and in the 
control yoghurt increased from 5.6 × 10
6
 to 3.6 × 10
8 
CFU/ml (Fig. 4.3). S. thermophilus 
in the B. longum DPC 6315 containing yoghurt increased from 4.6 × 10
5
 to 2.5 × 10
7
 
CFU/ml,
 
and in the control yoghurt increased from 3.7 × 10
6 
to ~ 6 × 10
7 
CFU/ml. By the 
end of the storage period, the viable cell numbers of L. delbrueckii ssp. bulgaricus
 
in the 
B. longum DPC 6315 containing yoghurt and the control yoghurt had declined to ~ 2 × 
10
7
 and ~ 4 × 10
6 
CFU/ml, respectively. The viable cell numbers of S. thermophilus at the 
end of the storage period in the EPS containing yoghurt and the control yoghurt had 
declined to ~ 3 × 10
5 
and to ~ 3 × 10
6 
CFU/ml, respectively (Fig. 4.3). 
 
4.4.2 EPS yields 
When grown at 37ºC in 14% (w/v) RSM with 1% (w/v) yeast extract the EPS 
concentration associated with B. longum DPC 6315 addition was found to significantly 
increase (P<0.01) from day 0 to day 1, and to significantly increase (P<0.001) from day 1 
to day 28 of storage at 4°C (Fig. 4.4). In the yoghurt manufacture, the amount of EPS 
obtained at the end of fermentation (hereafter referred to as day 0) was 36.9 (± 2.9) mg/l 
(Fig. 4.5), similar levels were found in reduced-fat yoghurts for EPS-producing strains of 
S. thermophilus and L. delbrueckii ssp. bulgaricus (Guler-Akin et al., 2009). The 
production of EPS increased during the first week of storage with concentrations reaching 
51.4 (± 9.4) mg/l on day 7 (Fig. 4.5). After day 7 of cold storage, EPS concentrations 
declined with a significant decrease on day 21 (P<0.01) and day 28 (P<0.01) compared 
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to day 14 (Fig. 4.5). The lowest concentration of EPS in the B. longum DPC 6315 
containing yoghurt was recorded on day 28 of cold storage at 19.3 (± 4.39) mg/l (Fig. 
4.5). 
 
4.4.3 Microstructure 
The microstructure of the yoghurt samples at day 28 was then evaluated by 
CLSM. For both yoghurts, protein networks with large pores (black areas) (Fig. 4.6) and 
(Fig. 4.7) containing serum had formed during fermentation. The bacterial cells for both 
yoghurts were predominantly located in the pores. EPS, as indicated by staining with 
Wheat Germ Agglutinin Alexafluor 555, was mainly associated around the edges of the 
pores and most likely connected within the protein matrix in the yoghurt fermented with 
B. longum DPC 6315 (Fig. 4.6). No EPS was observed in the yoghurt fermented with 
CH1 starter cultures (Fig. 4.7). 
 
4.4.4 Syneresis 
In commercial manufacturing of set yoghurt syneresis is an important issue, as it 
can lead to the accumulation of whey (serum) on the surface of the gel, which in turn can 
lead to poor consumer acceptance (Ghasempour et al., 2012). The extent of syneresis was 
determined by measuring the quantity of liquid separated from yoghurt after 
centrifugation. The values of syneresis recorded in both the B. longum DPC 6315 
containing yoghurt and the control yoghurt are shown in Fig. 4.8. The yoghurt 
manufactured with B. longum DPC 6315 exhibited a lower syneresis compared to the 
control yoghurt. It was observed that the yoghurt made using the EPS producing culture 
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had a significantly lower level of syneresis (P<0.05) than the control yoghurt on day 0, 1, 
7 and 14 of cold storage. Moreover, the B. longum DPC 6315 containing yoghurt 
exhibited a decrease in the amount of whey separation for days 0, 1, and 7 from 63.7 (± 
2.1) % to 49.7 (± 2.1) % (Fig. 4.8). During cold storage on day 14, the syneresis of the B. 
longum DPC 6315 containing yoghurt increased to 50.9 (± 2.6) % and on day 21 to 51.8 
(± 2.4) %. On day 28 of cold storage, syneresis in the B. longum DPC 6315 containing 
yoghurt dropped to 49.7% (± 2.1). The control yoghurt displayed a decrease in the 
amount of whey separation over the 28 days of storage from 69.2 (± 3.3) % to 51.6 (± 
1.3) % (Fig. 4.8). This is probably due to protein rearrangement where more protein-
protein contacts are being established, which leads to improved gel strength of the control 
yoghurt (Isleten & Karagul-Yuceer, 2006; Ramchandran & Shah, 2009).  
 
4.4.5 Acidifying kinetics and post-acidification 
Residual acidification activity was observed for the B. longum DPC 6315 
containing yoghurt at day 0, 1 and 7 and for the control yoghurt at day 0, 1, 7 and 14 of 
cold storage (Fig. 4.9). The titratable acidity, expressed as the amount of lactic acid, was 
significantly higher for the B. longum DPC 6315 containing yoghurt on day 0 (P<0.01) 
and day 1 (P<0.05) of cold storage. However, on day 14 (P<0.05), day 21 (P<0.05) and 
on day 28 (P<0.01) of cold storage the control yoghurt had a significantly higher 
titratable acidity than the B. longum DPC 6315 containing yoghurt (Fig. 4.9).  
The pH of the control yoghurt was lower than that of the EPS containing yoghurt 
during storage indicating a slower acidity development in the yoghurt containing the 
EPS-producing strain. The control yoghurt displayed a significantly lower pH than the B. 
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longum DPC 6315 containing yoghurt on day 1 (P<0.01), day 7 (P<0.001), day 14 
(P<0.001), day 21(P<0.01) and day 28 (P<0.01) of cold storage (Fig. 4.10).  
 
4.4.6 Viscosity 
The texture quality of the produced yoghurt samples is expressed as viscosity of 
samples in millipascal seconds (mPa.S). No significant difference in viscosity between 
the EPS containing yoghurt and the control yoghurt was observed over 28 days of storage 
(Fig. 4.11). 
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4.5 DISCUSSION  
The Bifidobacterium strain used in this study B. longum DPC 6315 displayed a 
ropy phenotype (Chapter 2) and was therefore chosen as an adjunct culture for yoghurt 
production. Previous analysis revealed that EPS production appeared to be growth 
associated and optimal in the presence of lactose (5% and 7% (w/v) at 37ºC (Chapter 2). 
No additional lactose was added to the fermentation substrate as 14% (w/v) RSM 
contains approximately 8% (w/v) lactose as its main sugar source. The addition of 1% 
(w/v) yeast extract to the fermentation medium was shown to improve the growth rate of 
B. longum DPC 6315 in this study. Yeast extract has previously been reported to improve 
the growth and consequently EPS production of other EPS producing cultures such as 
certain S. thermophilus strains (De Vuyst et al., 2003; Degeest & De Vuyst, 1999).  
The effect of in situ produced EPS by B. longum DPC 6315 on starter culture 
activity and viability was minimal. A number of studies have reported poor growth and 
survival of bifidobacterial strains in fermented milk due to the poor proteolytic activities 
and the low pH values of these products. For instance, Hughes and Hoover, (1995) 
reported that the B. longum strain used in the fermentation of skim milk in their study 
showed a marked 1000 fold reduction after 7 days of storage and displayed slow growth 
in skim milk. Dave and Shah, (1997) also reported that the bifidobacteria strains used in 
their study displayed a reduction in cell counts of greater than 1000 fold when the pH of 
the yoghurt reached 4.5. In a study undertaken by Lamoureux et al. (2002), the B. longum 
strain used declined by more than 4 log cell counts after 28 days of storage. In general, B. 
longum strains display a poor tolerance to low pH which is commonly found in fermented 
food products such as yoghurt. The EPS producing B. longum strain used to produce 
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yoghurt in this study had cell counts above the FAO/WHO guidelines (FAO/WHO, 2003) 
after 28 days of cold storage at 4°C, albeit with a 3 log reduction in viability compared to 
the level at which they were inoculated.  
Post-acidification, expressed as the pH value of the yoghurt samples at the end of 
cold storage at 4°C was significantly higher (~0.2 pH units) for the control yoghurt 
compared to the EPS containing yoghurt. The higher post-acidification for the control 
yoghurt may have resulted from organic acid production of the starter culture CH-1 
whereas B. longum DPC 6315 in the EPS containing yoghurt used the available sugars to 
produce EPS rather than organic acids, leaving less available sugars for the CH-1 cultures 
in the EPS containing yoghurt to produce lactic acid (Ozer & Atasoy, 2002). The 
significant difference in pH values during cold storage between the B. longum DPC 6315-
containing yoghurt and the control yoghurt did not appear to affect the starter cultures’ 
viability, the viscosity, microstructure or appearance (including syneresis at end of cold 
storage) of the two yoghurts. Lactic acid concentrations for the EPS containing yoghurt 
were significantly higher than the control yoghurt on day 0 of cold storage - after this 
time-point the control yoghurt displayed a higher lactic acid concentration (with 
significantly higher values on day 21 and day 28 of cold storage) corresponding to its 
significantly lower pH values compared to the EPS containing yoghurt. These results 
suggest that the EPS produced by B. longum DPC 6315 is not being used by the yoghurt 
starter strains to produce lactic acid as the pH value is not significantly higher than the 
control. Lactic acid production could possibly be affected by the concentration of 
available nutrients (Amatayakul et al., 2006), and activity of the yoghurt cultures. This 
would explain why the control yoghurt exhibited a significantly higher lactic acid 
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concentration compared to the EPS containing yoghurt after day 0, as in the control 
yoghurt more nutrients are available for lactic acid production as they are not being used 
by the yoghurt cultures for EPS production. 
EPS-yields were taken during cold storage for 28 days. The EPS concentration 
significantly increased during cold storage up to day 7 for the B. longum DPC 6315 
containing yoghurt. It has been reported that EPS concentrations in fermented dairy 
products range from 40-400 mg/L (De Vuyst et al., 2003; Guler-Akin et al., 2009; 
Marshall & Rawson, 1999). The wide range of EPS-concentrations in different studies 
could be due to differences in the EPS-producing strain used for product manufacture, the 
level of inoculation, fermentation conditions, the isolation method, and the EPS 
purification and quantification methods between studies (Amatayakul et al., 2006). In this 
study B. longum DPC 6315 produced relatively low amounts of EPS in the yoghurt 
compared with the lactobacilli strains used by Kearney et al. (2011) and London et al. 
(submitted 2013), although this B. longum EPS producing strain was found to produce 
significantly higher concentrations of EPS when grown in 14% (w/v) RSM and 1% (w/v) 
yeast extract without the CH-1 yoghurt starter cultures. The levels of EPS produced in the 
yoghurt manufactured in this study by B. longum DPC 6315 correlated well with levels 
produced by EPS-producing strains of S. thermophilus and L. delbrueckii ssp. bulgaricus 
in reduced-fat yoghurt (Guler-Akin et al., 2009). The decrease in EPS levels after day 7 
of cold storage in the yoghurt made with B. longum DPC 6315, is in contrast to that seen 
in the study of Prasanna et al. (2013), where EPS levels produced in two separate low fat 
set yoghurts made with two different Bifidobacterium strains, one a B. longum and the 
other a B. infantis strain were not found to change significantly over 28 days of cold 
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storage at 4ºC.  With prolonged storage a decrease in EPS-concentrations for the EPS-
containing yoghurt was reported by Purwandari et al. (2007), where the EPS 
concentrations in all batches of yoghurt made with two different strains of Streptococcus 
thermophilus declined substantially (P<0.05), especially in the first week. The significant 
(P<0.05) reduction of the EPS concentration reported in these yoghurt batches during the 
first weeks of cold storage could be due to the activity of enzymes capable of degrading 
EPS (Degeest et al., 2002). It is possible that EPS degradation may be activated due to 
the cell’s requirements for energy maintenance, as the EPS may serve as an energy store 
in the presence of an excess of nutrients, which may be used later in the cell metabolism 
(Tolstoguzov, 2003). Many studies have demonstrated the reduction in EPS 
concentrations after prolonged incubation of S. thermophilus (Cerning, 1990; Cerning et 
al., 1988; De, 1998; De Vuyst, 1999; Gancel & Novel, 1994; Macura & Townsley, 1984; 
Pham et al., 2000). It has been suggested that EPS degradation during fermentation is 
possibly due to a change in the physical or chemical factors linked to glycosylhydrolase 
activity. In the study performed by Pham et al. (2000), a greater reduction in EPS yields 
was observed in the case of lactose-grown Lactobacillus rhamnosus R cells than in 
glucose-grown cells. It has been suggested by Cerning et al. (1988), that EPS degradation 
is due to an enzyme, possibly a glycohydrolase, which gradually leads to the destruction 
of the polymer. The only clear evidence of the existence and effect of glycosylhydrolases 
(degrading heteropolysaccharides from LAB) has been shown in studies performed using 
the strains L. rhamnosus R (Pham et al., 2000) and S. thermophilus LY03 (Degeest et al., 
2002). Pham et al. (2000) suggested that the slow rate of reduction in viscosity of EPS-
containing media is due to the mode of enzymatic action involving exotype mechanisms, 
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which progressively split glycosidic linkages leading to polymers with lower molecular 
masses. In their study, it was reported that there was up to 82% reduction in EPS quantity 
if the EPS producing L. rhamnosus R strain was incubated for up to 48 h. It is likely that 
this EPS degradation is also taking place in the EPS containing yoghurt produced in this 
study as no reduction in EPS concentration was observed when B. longum DPC 6315 was 
grown in 14% (w/v) RSM and 1% (w/v) yeast extract without the addition of the CH-1 
starter cultures. Glycosylhydrolases released from cells of the S. thermophilus yoghurt 
starter strain used in this study could potentially be acting on the EPS produced by B. 
longum DPC 6315 leading to EPS degradation.   
The yoghurt made with the EPS producing culture had a positive effect in 
reducing syneresis on day 0, 1, 7 and 14 of cold storage without significant difference in 
syneresis between the control and EPS containing yoghurt on days 21 and 28. This is 
possibly due to the degradation of EPS in the EPS containing yoghurt with a reduction of 
EPS on day 14, 21 and 28 of cold storage, respectively. Syneresis is considered a major 
defect in the yoghurt industry and is directly related to the extent of physical disturbance 
to the network of protein micelles (Tamime & Robinson, 2007a). It has been previously 
reported that ropy EPS has a greater ability to retain serum, resulting in lower syneresis 
(Folkenberg et al., 2005; Lucey et al., 1998). Some other studies have previously 
reported that the intensity of syneresis decreased in set-type yoghurts during prolonged 
storage (Guzel-Seydim et al., 2005; Kearney et al., 2009; Purwandari et al., 2007; 
Robitaille et al., 2009). The EPS containing yoghurt in this study did show a significant 
reduction in the amount of syneresis up to day 14 of storage compared to the control 
yoghurt, which demonstrates that at a certain level the EPS produced by B. longum DPC 
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6315 has the ability to bind free water and reduce syneresis in yoghurt. It is possible that 
this EPS-producing strain could have potential in reducing syneresis levels in commercial 
yoghurt production if a manufacturing process is found that prevents its EPS degradation.  
The microstructural analysis of the B. longum DPC 6315 containing yoghurt 
reveals that the EPS was well distributed in the product and was generally located around 
the edges of the pores. A similar microstructure was also observed in the studies 
performed by Folkenberg et al. (2005) and Kearney et al. (2009), where an overlap of 
protein and EPS was observed and the yoghurt product was described as being very 
shiny, very ropy, with low serum separation and being resistant to mechanical treatment, 
which correlates positively with the results of this study. The extent of the interaction 
between the EPS produced by B. longum DPC 6315 and the yoghurt network is unknown, 
however the association between EPS and protein appears to be positive, as 
incompatibility between EPS and protein would lead to phase separation, with EPS being 
expelled into the serum phase (Hassan et al., 2003a).  
  It was visually observed that both the B. longum DPC 6315 containing and control 
yoghurts were slightly ropy and shiny. No significant difference between the viscosity of 
the B. longum DPC 6315 containing yoghurt and the control yoghurt was found. This was 
possibly due to the amount of EPS present in the yoghurt being too low to influence 
viscosity, although previously in other studies no clear relationship between EPS 
production yields and viscosity in yoghurt and fermented milks have been observed 
(Bouzar et al., 1997; De Vuyst et al., 2003; Wacher-Rodarte et al., 1993). It is also 
possible that the type of EPS produced by B. longum DPC 6315, its molecular mass, 
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charge, radius of gyration and polymer stiffness might not be conductive to increased 
viscosity in yoghurt.  
Overall, this study demonstrated that the production of EPS by B. longum DPC 
6315 in yoghurt reduced the syneresis of the yoghurt up to day 14 of cold storage.  Not 
surprisingly, the presence of this strain in the yoghurt led to significantly higher levels of 
EPS compared to the control yoghurt up to day 28 of cold storage. The levels of EPS did 
significantly decline after day 7 of cold storage which suggests the presence of EPS 
degrading enzymes possibly originating from the yoghurt starters. The EPS producing 
bifidobacterial strain used to manufacture yoghurt in this study did survive to the 
FAO/WHO minimum required levels of a probiotic culture in a fermented food such as 
yoghurt after 28 days of cold storage. However, it is important to emphasize that this is a 
general level and not one which is supported by clinical studies with dose response levels 
for each particular strain. The EPS produced in the B. longum DPC 6315 containing 
yoghurt did not significantly increase the viscosity of this yoghurt compared to the 
control, although both yoghurts displayed a shiny, slightly ropy appearance. These results 
suggest that addition of the adjunct strain offers some technological improvements to the 
product over and above its probiotic characteristics. 
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Figure 4.1 Growth of B. longum DPC 6315 at 37°C in 14% (w/v) RSM and 14% RSM  
                   with 1% (w/v) yeast extract (Y.E.) for 24 h under anaerobic conditions. 
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    Figure 4.2 pH values of B. longum DPC 6315 grown at 37º in 14% (w/v) RSM with  
                      different  concentrations of Y.E. (0%-2%) for 24 h under anaerobic conditions. 
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Figure 4.3 Survival of B. longum DPC 6315 and CH-1 yoghurt starter cultures during  
                   yoghurt manufacture and over 28 days of cold storage. 
Fermentation = 37ºC under anaerobic conditions for 6.5 h. Storage temperature = 4 ºC. 
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Figure 4.4 EPS concentrations of B. longum DPC 6315 grown at 37°C in 14% (w/v)  
                  RSM with 1% (w/v) yeast extract during cold storage at 4°C over 28 days. 
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Figure 4.5 Glucose concentrations of B. longum DPC 6315 containing and control  
                   yoghurt over 28 days of cold storage. 
 
EPS concentrations of B. longum DPC 6315 containing yoghurt = Test yoghurt glucose 
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Figure 4.6 Confocal laser scanning microscope (CLSM) image of the B. longum DPC 
6315 containing yoghurt at 28 days of cold storage. The bacteria, the EPS, and the protein 
aggregates were labeled with Syto 9, Wheat Germ Agglutinin Alexa Fluor 555 and Fast 
Green FCF, respectively. Therefore, the bacteria appear green, the protein network 
appears red and the EPS fluoresces blue. The yoghurt pores appear as black in the image. 
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Figure 4.7 CLSM image of the control yoghurt at 28 days of cold storage. The bacteria 
and the protein aggregates were labeled with Syto 9 and Fast Green FCF, respectively. 
Therefore, the bacteria appear green and the protein network appears red. The yoghurt 
pores appear as black in the image. 
 
 201 
40
45
50
55
60
65
70
75
0 1 7 14 21 28
Storage Time (days)
S
y
n
e
r
e
s
is
 (
%
)
Control
Test
 
 
 
 
Figure 4.8 Percentage of syneresis of B. longum DPC 6315 containing and control  
                   yoghurt over 28 days of cold storage. 
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Figure 4.9 Percentage lactic acid concentration of B. longum DPC 6315 containing and  
                   control yoghurt over 28 days of cold storage. 
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Figure 4.10 pH of B. longum DPC 6315 containing and control yoghurt over 28 days of  
                    cold storage. 
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Figure 4.11 Viscosity of B. longum DPC 6315 containing and control yoghurt over 28  
                     days of cold storage. 
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CHAPTER 5 
 
 
Effect of Bifidobacterium longum DPC 6315 ingestion on fatty acid 
metabolism and intestinal microbiota in a murine model. 
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5.1 ABSTRACT 
B. longum DPC 6315 has previously been found to be an efficient producer of 
EPS (Chapter 2), CLA (Barrett et al., 2007), possess the lanA gene (Chapter 2) and a 
lantibiotic operon (Chapter 3). In this study, B. longum DPC 6315 was fed along with a 
high fat diet enriched with α-linolenic acid (test group) to BALB/c mice. In the control or 
unsupplemented group, BALB/c mice were fed with the high fat diet enriched with α-
linolenic acid but without the strain. B. longum DPC 6315 was found to survive passage 
through the mouse GIT. Following 6 weeks of feeding B. longum DPC 6315, it was 
recovered at ~4.4 × 10
4
 CFU/g faeces in the test group. Fatty acid composition analysis 
revealed that mice that received B. longum DPC 6315 had significantly lower (P<0.01) 
levels of linoleic acid and γ-linolenic acid (P<0.001) acid in the liver, and stearic acid 
(P<0.05) levels in the brain compared with unsupplemented mice. In contrast, mice that 
received B. longum DPC 6315 had significantly higher concentrations of stearic acid 
(P<0.05), EPA, (P<0.05) and DPA, (P<0.05) in the liver. The microbial diversity of the 
caecal samples from the two mouse groups was determined using 16S rRNA amplicon 
pyrosequencing technology. In total 425,285 sequences were obtained from 19 caecal 
samples collected from the two mouse groups. The mouse microbiota samples taken from 
both groups fed B. longum DPC 6315 and α-linolenic acid and the unsupplemented group 
were dominated by Firmicutes (72% and 61% respectively), followed by Bacteroidetes 
(17% and 29% respectively). Firmicutes were found at a significantly (P=0.0076) higher 
(0.2 fold increase) relative abundance in the group that received B. longum DPC 6315, 
while Bacteroidetes were found at a significantly (P=0.0057) higher (0.7 fold increase) 
proportions in the unsupplemented group. At the genus level, Alistipes was detected at a 
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significantly (P=0.04) higher (0.8 fold increase) relative abundance in the 
unsupplemented group, while Roseburia was detected at a significantly (P=0.04) higher 
(0.5 fold increase) relative abundance in the group that received B. longum DPC 6315. In 
conclusion, supplementation with B. longum DPC 6315 led to significant differences in 
fatty acid composition in both the murine liver and brain tissues compared to 
supplementation with α-linolenic acid alone. B. longum DPC 6315 supplementation also 
led to significant differences in caecal microbiota composition at both the phylum and 
genus level.     
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5.2 INTRODUCTION  
It is estimated that the healthy human adult GIT contains approximately 10
14
 
microorganisms (Vaughan et al., 2000; Zboril, 2002). These microbial cells outnumber 
host cells by a factor of 10, and contain at least 100-fold more genes than the human 
genome. This microbial community is thought to play a key role in providing regulatory 
signals for immune and gastrointestinal maturation in early life (O'Hara & Shanahan, 
2006; Round & Mazmanian, 2009; Shanahan, 2009). The collective genome of these 
microorganisms (the metagenome) supplies a wide range of metabolic and biochemical 
functions that otherwise could not be performed by the host (Ley et al., 2006). These 
functions include metabolism (i.e. CLA, SCFA and bacteriocin production and prebiotic 
utilisation) epithelial development, immune modulation, regulation of fat storage and 
protection against pathogens (Arunachalam et al., 2000; Backhed et al., 2004; Claus et 
al., 2008; Corr et al., 2007; Wang et al., 2004; Wells et al., 2010). The dominant 
populations present in the adult microbiotia are Firmicutes (including genera of 
Clostridia and LAB) and Bacteriodetes, while Proteobacteria, Actinobacteria, 
Fusobacteria and Verrucomicrobia being present to a lesser extent (Eckburg et al., 
2005). 
Bifidobacteria are naturally found in the human GIT and are present in particularly 
higher numbers in early infancy (Chierici et al., 2003), and in breast-fed infants where 
they can constitute >50% of the intestinal microbiota (Yoshioka, 1991). The presence of 
bifidobacteria throughout life in the human GIT and their metabolic activities are 
considered integral to the maintenance of human health and well being (Van der Werf & 
Venema, 2001). Bifidobacteria are used globally as probiotics (‘live microorganisms, 
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which when administered in adequate amounts confer a health benefit on the host’ 
(FAO/WHO, 2002) in many food products such as yoghurt, milk, infant formula, cheese, 
and dietary supplements (Champagne et al., 2005; Charalampopoulos et al., 2002; 
Mattila-Sandholm et al., 2002; Phillips et al., 2006; Vinderola et al., 2000). 
Numerous strains of bifidobacteria such as B. longum, B. animalis, B. adolescentis 
and B. pseudocatenulatum produce exopolysaccharides (Ruas-Madiedo et al., 2007). EPS 
isolated from bifidobacteria have been found to possess prebiotic, immune stimulatory 
and anti-microbial properties as described below. Salazar et al. (2008) found that some 
EPS produced by human intestinal bifidobacteria possessed prebiotic abilities on other 
bifidobacteria when tested in a non-pH controlled faecal batch fermentation. This 
prebiotic effect was seen as an increase in the levels of bifidobacteria comparable to the 
prebiotic inulin, this effect was observed with EPS isolated from 11 different strains of 
bifidobacteria, which included 2 B. animalis strains, 5 B. pseudocatenulatum strains and 
4 B. longum strains after 1 or 5 days of incubation.  
Furthermore, a shift in the short chain fatty acid profile of the faecal cultures was 
observed after incubation with the EPS isolated from the 11 bifidobacteria strains tested, 
causing a decrease in the molar proportions of acetic acid, an increase in propionic acid 
levels, decreases or moderate increases in butyric levels, and a reduction in the acetic 
acid-to-propionic acid ratio with time (Salazar et al., 2008). The reduction in the acetic 
acid-to-propionic acid ratio has been proposed as a potential indicator of the 
hypolipidemic effect (inhibition of cholesterol and fatty acid biosynthesis in the liver, 
resulting in a decrease in lipid levels in blood) of prebiotics (Delzenne & Kok, 2001).  
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Salazar et al. (2009) also performed a study using two EPS’s one isolated from B. 
longum subsp. longum IPLA E44 from the study (Salazar et al., 2008) and one from B. 
animalis subsp. lactis IPLA R1 to test their prebiotic effects in pH-controlled batch 
culture fermentation. It was reported that both the EPS’s tested in this study promoted a 
rapid increase in the amount of acetic and lactic acids during the early stages of 
fermentation (until 10 h and in some cases until 24 h of fermentation) and of total 
bacteria during fermentation. Fluorescent in situ hybridization analysis clearly showed 
that both the EPS tested stimulated the growth of Lactobacillus/Enterococcus and the 
genus Bifidobacterium, which was also reported by this group in their previous study 
(Salazar et al., 2008). Wu et al. (2010) reported that EPS isolated from a B. longum strain 
tested in their study stimulated growth and induced IL-10 secretion in the murine 
macrophage/monocyte-like cell line J774A.1 cells when exposed to lipopolysaccharide 
(LPS). EPS treatment also induced lower levels of TNF-α secretion by LPS and 
decreased the LPS-induced morphological changes in J774A.1 cells. The EPS isolated 
from this particular B. longum strain was also found to inhibit seven different bacterial 
pathogens and food spoilage bacteria such as a particular strain of E. coli, S. 
typhimurium, Pseudomonas aeruginosa, Vibrio parahaemolyticus, S. aureus, Bacillus 
subtilis and Bacillus cereus. P. aeruginosa and V. parahaemolyticus were not inhibited 
by 20 ppm (µg/ml) EPS treatment but all 7 of the tested pathogens and food spoilage 
bacteria were inhibited by 80 ppm (µg/ml) EPS, although EPS did not inhibit P. 
aeruginosa effectively.   
Bacterially-produced antimicrobial peptides are called bacteriocins. Two major 
classes of gram-positive bacteriocins have been recognized, Class I undergo significant 
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post-translational modifications while Class II are unmodified (Cotter et al., 2005; Rea et 
al., 2011). Lantibiotics which are small peptides containing internal bridges resulting 
from the formation of (β-methyl) lanthionine residues make up the majority of Class I 
bacteriocins. The first lantibiotic produced by a Bifidobacterium species was identified by 
Lee et al. (2008) in the strain B. longum subsp. longum DJO10A.  
This lantibiotic operon was found to contain all the genes necessary for lantibiotic 
production including the lanA gene which encodes the prepeptide involved in lantibiotic 
production (Lee et al., 2011). It was reported that lantibiotic production by B. longum 
subsp. longum DJO10A only occurred on agar media and not in broth media unless an 
inducer such as the purified lantibiotic itself was first added to the broth media (Lee et 
al., 2011). The lantibiotic produced by B. longum subsp. longum DJO10A was collected 
from agar cultures and purified and it was found to possess a broad spectrum of inhibition 
activity against various gram-positive and gram-negative bacteria. Lantibiotics can confer 
a selective advantage to the producer organism by inhibiting the growth of other 
organisms found in the same habitat. Lantibiotics have the potential to be used as natural 
food preservatives due to their high stability and broad inhibition spectrum, e.g. Nisin 
(Chen & Hoover, 2003; Deegan et al., 2006).  
This study investigated the possible effects of feeding B. longum DPC 6315 on the 
fatty acid composition of the murine liver and brain, and its effect on the overall 
microbiota of the mouse caecal contents in vivo using 454 pyrosequencing analysis. The 
caecum was chosen as the gut habitat for sampling because it is an anatomically distinct 
structure, situated between the distal small intestine and colon, and is colonized with high 
quantities of a readily harvested microbiotia for metagenomic analysis (Turnbaugh et al., 
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2006). As such the microbiota from this site may provide a better representation of 
microbiota than from faecal samples. 
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5.3 MATERIALS AND METHODS 
5.3.1 Animals and treatment 
Female BALB/c mice were purchased from Harlan (Briester, Oxon, UK) at 8 
weeks of age and housed under barrier-maintained conditions within the Biological 
Services Unit, University College Cork (UCC). All animal experiments were approved 
by the UCC Animal Ethics Committee, and experimental procedures were conducted 
under the appropriate license from the Irish Government. Mice were allowed to 
acclimatize for 1 week before the start of the study and were fed ad libitum with Teklad 
Global rodent standard diet (Harlan Laboratories, Madison, WI, USA #2018S) and 
allowed free access to water at all times. Mice were housed in groups of 5 per cage and 
kept in a controlled environment at 25°C under a 12-h-light/12-h-dark cycle. After 1 
week of acclimatization, the mice were divided into 2 groups (n =10/group): a group fed 
flaxseed-oil enriched diet and B. longum DPC 6315 (approximate daily dose of 10
9
 
microorganisms) and a group fed flaxseed-oil enriched diet and placebo freeze-dried 
powder (15% w/v trehalose in dH2O). The flaxseed-oil enriched diet contained the 
following nutrient composition: corn starch (32.45%), casein (20.0%) sucrose (15%), 
maltodextrin (12.0%), cellulose (5.0%), L-cysteine (0.3%), choline bitartrate (0.25%), 
TBHQ antioxidant (0.002%), mineral mix (3.5%) and vitamin mix (1.5%) and the 
following composition of fat: flaxseed oil (5.5%), palm oil (1.5%), safflower oil (1.5%), 
olive oil (1.5%). Body weight and food intake were assessed weekly. After 6 weeks on 
the experimental diets, the animals were killed by decapitation. Liver, brain, fat pads 
(epididymal, perirenal, and mesenteric), GIT from stomach to anus, and caecal contents 
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were removed, blotted dry on filter paper, weighed, and flash-frozen immediately in 
liquid nitrogen. All samples were stored at -80°C until processed.  
 
5.3.2 Preparation and administration of B. longum DPC 6315 
Rifampicin-resistant variants of B. longum DPC 6315 were isolated by spread-
plating ~10
9
 CFU from an overnight culture onto mMRS agar (Difco) supplemented with 
0.05% (w/v) L-cysteine hydrochloride (98% pure; Sigma) containing 500 µg 
rifampicin/ml (Sigma). After anaerobic incubation (anaerobic jars with Anaerocult A gas 
packs; Merck) at 37°C for 3 days, colonies were stocked in mMRS broth containing 40% 
(v/v) glycerol and stored at -80°C. To confirm that the rifampicin-resistant variant was 
identical to the parent strain, PFGE was used for molecular fingerprinting.  
Before freeze-drying, B. longum DPC 6315 was grown in mMRS by incubating 
overnight at 37°C under anaerobic conditions. The culture was washed twice in 
phosphate-buffered saline and resuspended at a concentration of ~2 × 10
10
 cells/ml in 
15% (w/v) trehalose (Sigma) in dH2O. One-milliliter aliquots were freeze-dried by using 
a 24-h program (freeze temperature, -40°C; condenser set point, -60°C; vacuum set point, 
600 mTorr). Each mouse that received the bacterial strain consumed ~1 × 10
9
 live 
microorganisms/day. This was achieved by resuspending appropriate quantities of freeze-
dried powder in water, which mice consumed ad libitum. Mice that did not receive the 
bacterial strains received placebo freeze-dried powder [15% (w/v) trehalose in dH2O]. 
Water containing either the bacterial strains or placebo freeze-dried powder was the only 
water supply provided to the animals throughout the trial. Freeze-dried powders with the 
bacterial strains underwent continuous quality control of cell counts for the duration of 
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the trial by plating serial dilutions on MRS agar supplemented with 100 µg mupriocin/ml 
(Oxoid) and 100 µg rifampicin/ml (Sigma) and incubating plates anaerobically for 72 h at 
37°C.  
 
5.3.3 Culture-dependent microbial analysis 
Fresh faecal samples were taken from BALB/c mice every second week for 
microbial analysis. Microbial analysis of the faecal samples involved enumeration of the 
B. longum DPC 6315 strain by plating serial dilutions on MRS agar supplemented with 
100 µg mupriocin (Oxoid)/ml, 100 µg rifampicin/ml (Sigma), and 50 U nystatin/ml at 
37°C. Agar plates were incubated anaerobically for 72 h at 37°C. 
 
5.3.4 Lipid extraction and fatty acid analysis 
Lipids were extracted with chloroform:methanol (2:1, v/v; Fisher Scientific, 
Dublin, Ireland) according to the method of (Folch et al., 1957). Fatty acid methyl esters 
(FAMEs) were prepared by using first adding 10 ml 0.5 N NaOH (Sigma) in methanol 
for 10 min at 90°C followed by 10 ml 14% BF3 in methanol (Sigma) for 10 min at 90°C 
(Park & Goins, 1994). FAMEs were recovered with hexane (Fisher Scientific). Before 
gas-liquid chromatographic analysis, samples were dried over 0.5 g anhydrous sodium 
sulphate (Sigma) for 1 h and stored at -20°C. FAMEs were separated by gas-liquid 
chromatography (Varian 3800; Varian, CA, USA) fitted with a flame-ionization detector 
by using a Chrompack CP Sil 88 column (Chrompack; 100 m × 0.25 mm internal 
diameter, 0.20-µm film thickness) and helium as the carrier gas. The column oven was 
programmed to be held initially at 80°C for 8 min and then increased by 8.5°C/min to a 
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final column temperature of 200°C. The injection volume used was 0.6 µl, with 
automatic sample injection on a SPI 1093 splitless on-column temperature-programmable 
injector. Peaks were integrated by using the Varian Star chromatography Workstation 
version 6.0 software, and peaks were identified by comparison of retention times with 
pure FAME standards (Nu-Chek Prep, Minnesota, USA). The percentage of individual 
fatty acids was calculated according to the peak areas relative to the total area (total fatty 
acids were set at 100%). All fatty acid results are shown as means ± SEMs in g/100 g 
FAME.  
 
5.3.5 Generation of 16S rRNA amplicons for high-throughput sequencing 
The generation of 16S rRNA amplicons was performed as described previously 
(O' Sullivan et al., 2011). DNA was extracted from samples according to a previously 
described protocol (Zoetendal et al., 2006) using the QIAamp DNA stool Mini kit 
(Qiagen) with the addition of a bead beating step. Universal 16S rRNA primers, as 
previously described (Claesson et al., 2009), were used to amplify from highly conserved 
regions corresponding to those flanking the V4 region. Pyrosequencing was performed at 
the Teagasc Moorepark 454 Sequencing facility on a Genome Sequencer FLX platform 
(Roche Diagnostics Ltd, West Sussex, UK) according to the manufacturer’s protocols.   
 
5.3.6 Bioinformatic analysis 
Resulting raw sequence reads were quality trimmed as previously described 
(Claesson et al., 2009). Trimmed FASTA sequences were then BLASTed (Altschul et al., 
1997) against a locally installed version of SILVA 16S rRNA database (Pruesse et al., 
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2007), with the top 50 hits against the database selected using default parameters. The 
taxonomic distribution of reads was determined using MEGAN (Huson et al., 2007a), 
with modified accession look-up tables for mapping the SILVA assignments to NCBI 
taxonomy. MEGAN assigns reads to NCBI taxonomies by using the Lowest Common 
Ancestor algorithm. Bit scores were used from within MEGAN for filtering the results 
before tree construction and summarization. A bit score of 86 was selected as previously 
used for 16S ribosomal sequence data (Urich et al., 2008). Phylum and family counts for 
each subject were extracted from MEGAN. Sequence reads were clustered into 
operational taxonomical units (OTU’s) using the QIIME suite of software tools 
(Caporaso et al., 2010), and OTU’s were aligned and chimeric OTU’s were removed 
using the ChimeraSlayer (Haas et al., 2011) program. A phylogenetic tree was generated 
using the FastTreeMP (Price et al., 2010) tool. Subsequently alpha and beta diversities of 
the samples were calculated. Principal coordinate analysis (PCoA) and hierarchial 
clustering of samples were implanted; PCoA plots were visualized with the KiNG viewer 
(Chen et al., 2009)) and unweighted pair group method with arithmetric mean (UPGMA) 
plots were visualized using DENDROSCOPE (Huson et al., 2007b). 
 
5.3.7 Statistical analysis 
Results in the text, tables, and figures are presented as means ± SEMs (per group). 
To investigate the effect of dietary supplementation with B. longum DPC 6315 on host 
tissue fatty acid composition between the two groups, data was analysed using unpaired 
T-test. 
 218 
  To assess whether differences in microbiota composition between groups were 
significant, data were analysed using GraphPad Prism version 6.0 for Windows 
(GraphPad Software). The non-parametric Mann-Whitney test was used to estimate the 
relations between the two groups followed by the Benjamini and Hochberg multiple 
correction procedure. Statistical significances were accepted at P<0.05. 
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5.4 RESULTS 
5.4.1 Survival and transit of B. longum DPC 6315 in BALB/c mice 
Quantification of the numbers of the administered B. longum DPC 6315 strain in 
the faeces of mice confirmed its gastrointestinal transit and survival. Stool recovery of B. 
longum DPC 6315 was ~4.4 × 10
4
 CFU/g faeces after 6 weeks of feeding the 
administered strain.  
 
5.4.2 Effect of dietary supplementation with B. longum DPC 6315 on host tissue 
fatty acid composition 
To investigate the effects of dietary supplementation with B. longum DPC 6315 
on fatty acid composition of host tissues, fatty acid profiling was performed on liver and 
brain tissue.  
In mice supplemented with B. longum DPC 6315 and the unsupplemented group, 
no significant difference in fatty acid concentration between the two groups in the liver 
was observed for the following fatty acids (Table 5.1): palmitic acid (16:0), palmitoleic 
acid (16:1 c9), oleic acid (18:1 c9), linolenic acid (18:3n-3), c9, t11 CLA, dihomo-γ-
linolenic acid (20:3n-6), arachidonic acid (20:4n-6), DPA (22:5n-3) and DHA (Table 
5.1).  
In the brain, no significant difference in fatty acid concentration between the two 
groups was observed for the following fatty acids (Table 5.2): palmitic acid, palmitoleic 
acid, oleic acid, linoleic acid, γ-linolenic acid, dihomo-γ-linolenic acid, arachidonic acid, 
EPA, DPA and DHA (Table 5.2).  
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Some significant differences in the fatty acid composition were observed between 
the two mouse groups, as mice that received B. longum DPC 6315 had significantly lower 
(P<0.01) levels of linoleic acid in the liver, (14.0 ± 0.3 g/100g FAME) compared to the 
unsupplemented group (15.4 ± 0.4 g/100g FAME) (Table 5.1), significantly lower 
(P<0.001) levels of γ-linolenic acid in the liver (0.1 ± 0.01 g/100g FAME) compared to 
the unsupplemented group (0.2 ± 0.01 g/100g FAME) (Table 5.1) and significantly lower 
(P<0.05) levels of stearic acid in the brain (22.3 ± 0.4 g/100g FAME) compared to the 
unsupplemented group (23.2 ± 0.2)  (Table 5.2). In addition, mice that received B. 
longum DPC 6315 had significantly higher (P<0.05) concentrations of stearic acid (8.1 ± 
0.2 g/100g FAME) compared to the unsupplemented group (7.4 ± 0.4 g/100g FAME), 
EPA (1.2 ± 0.01 g/100g FAME) compared to unsupplemented group 0.9 ± 0.1 g/100g 
FAME), and DPA (0.3 ± 0.1) compared to the unsupplemented group (0.2 ± 0.02 g/100g 
FAME)  in the liver (Table 5.1). 
 
5.4.3 Microbial compositional analysis by pyrosequencing 
After removing low-quality 16S rRNA sequences, 425,285 from a total of 
509,878 (83.41%) sequences passed the quality check and were used for further analysis. 
The number of reads per sample is shown in Table 5.3. In total 424,724 (99.86%) 
sequences were classified at the phylum level, 373,513 (73.25%) at the family level and 
176, 228 (34.56%) at the genus level. Species-richness, coverage, and diversity 
estimations were calculated for each group (Table 5.3). 
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5.4.4 Alpha-diversity based analyses 
The rarefraction curves and alpha diversities were calculated for each group. 
Chao1, Simpson and the Shannon diversity indices for the OTU’s are shown in Table 5.3. 
The Shannon indices for the test group fed α-linolenic acid supplemented with B. longum 
DPC 6315 ranged from 6.81 to 7.82, while those for the group fed α-linolenic acid only 
ranged from 6.49 to 7.47. At the 97% similarity level, the Shannon index (a metric for 
community diversity) showed a high level of overall biodiversity within all samples with 
values exceeding 6.4 (Table 5.3).  
Chao1 richness also indicated a sufficient level of overall diversity (Table 5.3). 
Rarefaction curves for each data set were parallel or approaching parallel with the x axis, 
which indicated that the total bacterial diversity present within these was well represented 
and that additional sampling would yield only a limited increase in species richness (Fig. 
5.1). Sample 9 (fed high fat diet supplemented with B. longum DPC 6315) possibly 
possesses a considerably larger diversity than the other mouse caecal samples based on 
its Chao1 value (5230.9) (Table 5.3: Fig. 5.1) and observed species value (2645) (Table 
5.3). This sample could also possess a large number of OTU’s with single reads which 
would be recorded as single species which would lead to the sample’s high Chao1 and 
observed species values.  
 
5.4.5 Beta-diversity based analyses 
Beta-diversity of the two mouse groups were estimated using the phylogenetic 
based unweighted and weighted UniFrac distance metrics and the non-phylogenetic Bray-
Curtis dissimilarity distance metric. PCoA plots generated using Bray Curtis and both 
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UniFrac metrics, indicated that samples from the two mouse groups did not appear to 
cluster into distinct groups. A cladogram generated using UPGMA clustering of the 19 
mouse microbiota datasets showed no obvious clustering of the mouse samples. This held 
true for UPGMA clustering using all metrics. 
  
5.4.6 Analysis of the microbiota of mouse samples 
1. Phylum level 
The caecal contents of mice from the group fed a high fat diet supplemented with 
B. longum DPC 6315 contained significantly (p=0.0076) higher (0.2 fold increase) 
proportions of Firmicutes, 72% of the relative proportion (range 67.8%-77.6%) (Fig. 5.3 
(a)), compared to the unsupplemented group, 61% of the relative proportion (range 48%-
71.8%) (Fig. 5.3 (b)). The next dominant group was Bacteriodetes which were present at 
significantly (P=0.0057) higher (0.7 fold increase) proportions in the unsupplemented 
group (29.1%, range 17.8%-47.2%), than in the group fed B. longum DPC 6315 (17.2%, 
range 10.3%-23.5%). The microbiota of the two mouse groups also contained sub-
dominant levels of Deferribacteres (Supplemented group: 10%, range 5%-15.8%), 
(Unsupplemented group: 9%, range 3.8%-12.6%). The phylum Proteobacteria was 
detected at 1% of the relative proportion in both groups (Supplemented group: range 
0.3%-2.7%), (Unsupplemented group: range 0.4%-4%).   
Two phyla in both groups were detected below 1% of the relative proportion - 
these were Actinobacteria (Supplemented group: 0.4%, range 0%-3.6%), 
(Unsupplemented group: 0.08%, range 0%-2.9%) and Tenericutes (Supplemented group: 
0.04%, range 0%-0.1%) (Fig. 5.3 (a)), (Unsupplemented group: 0.03%, range 0%-0.07%) 
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(Fig. 5.3 (b)). The phylum Ascomycota was only detected in one of the mouse samples in 
the group supplemented with B. longum DPC 6315 and in two of those in the 
unsupplemented group. The phylum Candidate division TM7 was detected in three of the 
mouse samples in the group fed B. longum DPC 6315 and in two of those in the 
unsupplemented group. 
  
2. Family level 
At the family level, Lachnospiraceae were the dominant family in the two mouse 
groups making up 51% (range 31.54%-50.7%), (Fig. 5.4 (a)) in the group supplemented 
with B. longum DPC 6315 and 45% (range 27.4%-56.2%), (Fig. 5.4 (b)) in the 
unsupplemented group. This family was followed in abundance by Rikenellaceae 
(Supplemented group: 11.2%, range 5.18%-15.2%), (Unsupplemented group: 18.8%, 
range 11.67%-30.12%), Ruminococcaceae (Supplemented group: 15.5%, range 11.65%-
20.97%), (Unsupplemented group: 12.89%, range 8.7%-18.93%), Deferribacteraceae 
(Supplemented group: 9.7%, range 5.1%-15.77%), (Unsupplemented group: 8.5%, range 
3.84%-12.64%), Bacteriodaceae (Supplemented group: 1.74%, range 1.22%-3.77%), 
(Unsupplemented group: 3.56%, range 1.68%-6.24%), Porphyromonadaceae 
(Supplemented group: 0.77%, range 0.42%-1.13%), (Unsupplemented group: 1.36%, 
range 0.55%-2.58%).  
All the other families detected were below 1% of the total relative abundance in 
each group which included Peptococcaceae (Supplemented group: 0.87%, range 0.55%-
1.27%), (Fig. 5.4 (a)) (Unsupplemented group: 0.79%, range 0.42%-1.45%), (Fig. 5.4 
(b)), Peptococcaceae (Clostridiales) (Supplemented group: 0.49%, range 0.22%-1.07%), 
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(Unsupplemented group: 0.7%, range 0.29%-1.27%), Desulfovibrionaceae 
(Supplemented group: 0.52%, range 0.15%-0.8%), (Unsupplemented group: 0.46%, 
range 0.13%-0.92%) and Ersipelotrichaceae (Supplemented group: 0.61%, range 0.07%-
2.08%), (Unsupplemented group: 0.22%, range 0.04%-0.63%). 
All the other families detected were below 0.5% of the total relative abundance in 
both groups Moraxellaceae (Supplemented group: 0.11%, range 0%-1.02%), (Fig. 5.4 
(a)), (Unsupplemented group: 0.37%, range 0%-2.18%), (Fig. 5.4 (b), Lactobacillaceae 
(Supplemented group: 0.36%, range 0%-1.82%), (Unsupplemented group: 0.06%, range 
0%-0.31%), Bifidobactericaeae (Supplemented group: 0.35%, range 0%-3.55%), 
(Unsupplemented group: 0.03%, range 0%-0.16%), Clostridiaceae (Supplemented group: 
0.26%, range 0%-0.77%), (Unsupplemented group: 0.08%, range 0%-0.22%), 
(Unsupplemented group: 0.12%, range 0.02%-0.38%),  Streptococcaceae (Supplemented 
group: 0.13%, range 0.03%-0.3%), (Unsupplemented group: 0.12%, range 0.02%-
0.38%), Rhodospirillaceae (Supplemented group: 0.09%, range 0%-0.29%), 
(Unsupplemented group: 0.1%, range 0%-0.24%), Enterobactericeae (Supplemented 
group: 0.1%, range 0%-0.58%), (Unsupplemented group: 0.06%, range 0%-0.4%), and 
Leuconostocaceae (Supplemented group: 0.008%, range 0%-0.04%), (Unsupplemented 
group: 0.007%, range 0%-0.044%). 
 
3. Genus level 
The most abundant genus in both mouse groups was Alistipes which was detected 
at a significantly (P=0.04) higher (0.8 fold increase) abundance in the group fed the high 
fat diet only (15.84%, range 9.9%-24.8%), (Fig. 5.5 (b)) compared to 9%, (range 4.95%-
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11.79%) in the group fed the high fat diet supplemented with B. longum DPC 6315 (Fig. 
5 (a)). This genus was followed in abundance by Mucispirillum (Supplemented group: 
9.7%, range 5%-15.8%), (Unsupplemented group: 8.5%, range 3.84%-12.64%), 
Ruminococcaceae Incertae Sedis (Supplemented group: 6.84%, range 5%-8.8%), 
(Unsupplemented group: 5.8%, range 3.88%-8.3%), Oscillibacter (Supplemented group: 
2.75%, range 1.3%-5.85%), (Unsupplemented group: 1.8%, range 1.14%-3.24%), 
Bacteroides (Supplemented group: 1.7%, range 0.96%-3.8%), (Unsupplemented group: 
3.6%, range 1.4%-6.2%), Anaerotruncus (Supplemented group: 2.3%, range 1.8%-
3.18%), (Unsupplemented group: 2%, range 1.25%-2.96%), and Lachnospiraceae 
Incertae Sedis (Supplemented group: 1.9%, range 1.23%-2.17%), (Unsupplemented 
group: 1.6%, range 0.87%-2.2%) and Parabacteroides (Supplemented group: 0.48%, 
range 0.8%-0.33%), (Fig. 5 (A), (Unsupplemented group: 0.8%, range 0.3%-2.2%) (Fig. 
5.5 (b)). 
Other genera detected below 1% of the total relative abundance in both groups 
included Peptococcus (Supplemented group: 0.7%, range 0.39%-1.11%), 
(Unsupplemented group: 0.6%, range 0.33%-1.3%), Bilophila (Supplemented group: 
0.5%, range 0.15%-0.8%), (Unsupplemented group: 0.5%, range 0.13%-0.92%), 
Coprococcus (Supplemented group: 0.5%, range 0.23%-0.87%), (Unsupplemented 
group: 0.4%, range 0.17%-0.7%), Odoribacter (Supplemented group: 0.3%, range 
0.07%-0.8%), (Unsupplemented group: 0.56%, range 0%-2.2%) and Allobaculum 
(Supplemented group: 0.58%, range 0.06%-2.06%), (Unsupplemented group: 0.21%, 
range 0.04%-0.63%). The genus Roseburia was detected at a significantly (P=0.041) 
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higher abundance (0.5 fold increase) in the supplemented group (0.5%, range 0.14%-
1.05%) compared to the unsupplemented group (0.16%, range 0.04%-0.63%).  
All the other genera were detected below 0.5% of the total relative abundance 
which included Peptococcaceae Incertae Sedis (Supplemented group: 0.17%, range 
0.08%-0.44%), (Fig. 5.5 (a)), (Unsupplemented group: 0.37%, range 0%-0.9%), (Fig. 5.5 
(b)) Psychrobacter (Supplemented group: 0.1%, range 0%-1%), (Unsupplemented group: 
0.36%, range 0%-2.17%), Lactobacillus (Supplemented group: 0.36%, range 0%-1.8%), 
(Unsupplemented group: 0.06%, range 0%-0.31%), Bifidobacterium (Supplemented 
group: 0.35%, range 0%-3.5%), (Unsupplemented group: 0.03%, range 0%-0.16%), 
Clostridium (Clostridiceae) (Supplemented group: 0.24%, range 0%-0.76%), 
(Unsupplemented group: 0.07%, range 0%-0.21%), Lactococcus (Supplemented group: 
0.1%, range 0.03%-0.2%), (Unsupplemented group: 0.1%, range 0.02%-0.37%), 
Thalassospira (Supplemented group: 0.09%, range 0%-0.29%), (Unsupplemented group: 
0.1%, range 0%-0.24%), Catabacter (Supplemented group: 0.09%, range 0.04%-0.14%), 
(Unsupplemented group: 0.05%, range 0%-0.1%), and Escherichia-Shigella 
(Supplemented group: 0.09%, range 0%-0.5%), (Fig. 5.5 (a)), (Unsupplemented group: 
0.05%, range 0%-0.35%) (Fig. 5.5 (b)). 
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5.5 DISCUSSION 
As B. longum DPC 6315 has been identified as an EPS producer (Chapter 2) and 
potentially a bacteriocin producer (Chapter 2 and Chapter 3), any effects that the strain 
might have on the overall microbiota could be due to one or a combination of these 
potential probiotic traits. Quantification of the numbers of bacteria of the B. longum DPC 
6315 strain recorded in the faeces of individual mice confirmed gastrointestinal transit 
and survival of B. longum DPC 6315. Faecal recovery was approximately was ~4.4 × 10
4
 
CFU/g faeces in mice that received the strain in combination with the high fat diet. 
Fatty acid composition analysis revealed that mice that received B. longum DPC 
6315 and the high fat diet had significantly lower levels of linoleic acid and γ-linolenic 
acid in the liver compared to unsupplemented mice. The significantly lower levels of both 
linoleic acid and γ-linolenic acid (a metabolite of linoleic acid) in the liver suggest that 
linoleic acid has been metabolised to some degree in this tissue. This metabolism could 
be due to the presence of B. longum DPC 6315 which has been found possess the 
capability to metabolise linoleic acid to form another linoleic acid conjugate CLA 
(Barrett et al., 2007). Another possible explanation for this linoleic acid metabolism 
could be due to the presence of members of the genus Roseburia, which also have been 
reported to be able to convert linoleic acid to some of its precursors of CLA using the 
same biohydration pathway as that used by rumen bacteria (Devillard et al., 2007). 
Indeed, some Roseburia species have been identified as being among the most active 
producers of CLA and CLNA in the GIT (Devillard et al., 2007). Pyrosequencing 
revealed that in the supplemented mouse group there was a significant higher proportion 
of the genus Roseburia compared to the unsupplemented group. While both B. longum 
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DPC 6315 and some members of the genus Roseburia are capable of converting linoleic 
acid to c9, t11 CLA, no significant difference in c9, t11 CLA concentrations were 
recorded in the liver tissues taken from mice from the supplemented and unsupplemented 
groups in this study, and in the brain tissues taken from mice from both the groups no c9, 
t11 CLA was detected. A possible reason for both of these observations could be that the 
diet fed to the mice was high in α-linolenic acid instead of linoleic acid from which c9, 
t11 CLA is produced. Possibly, levels of linoleic acid in the high fat diet fed in this study 
were too low to see any significant differences in c9, t11 CLA content in the liver and 
brain tissues examined for fatty acid composition. It appears in this study that in the 
supplemented group, linolenic acid has been metabolised to form EPA which was then 
converted to DPA with significantly higher levels of both fatty acids found in the livers 
of mice in this group. It appears possible that the metabolic activities of B. longum DPC 
6315 in this study are more focused on producing metabolites of α-linolenic acid such as 
EPA (Wall et al., 2010), and then in turn DPA (Burdge et al., 2002) (as observed in the 
significantly higher levels of both fatty acids in the liver) instead of c9, t11 CLA (a 
metabolite of linoleic acid).  
The presence of significantly lower stearic acid levels in the brain of mice fed B. 
longum DPC 6315 compared to the unsupplemented mouse group suggests that linoleic 
acid is not being metabolised by B. longum DPC 6315 in this tissue, as stearic acid is a 
metabolite of linoleic acid (Devillard et al., 2007). No c9, t11 CLA was recorded in the 
brain tissues of mice from both the supplemented and the unsupplemented group. This 
suggests in this study, that in the presence of a diet rich in α-linolenic acid, B. longum 
DPC 6315 does not produce c9, t11 CLA in this tissue in vivo. In contrast the presence of 
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significantly higher levels of stearic acid in the liver of mice supplemented with B. 
longum DPC 6315 suggest that linoleic acid is being metabolised to some degree in this 
tissue, although no significant difference in c9, t11 CLA was recorded between the 
supplemented and unsupplemented groups in this study. As discussed above, a possible 
reason for this was the diet fed to the mice was high in α-linolenic acid instead of linoleic 
acid. So as discussed above, it appears in this study that in the supplemented group, 
linolenic acid has been metabolised by B. longum DPC 6315 to form EPA, and in turn 
DPA as observed by the significantly higher levels of both fatty acids found in the liver 
of mice in this group.  
Eicosanoids derived from arachidonic acid are regarded as being pro-
inflammatory in nature (Bagga et al., 2003; Calder, 2008), whereas eicosanoids derived 
from EPA are reported to be less inflammatory or even anti-inflammatory in nature 
(Bagga et al., 2003; Calder, 2008; Robinson & Stone, 2006). EPA can be further 
metabolised to DHA, which is one of the main polyunsaturated fatty acids found in the 
brain (Wall et al., 2010). It has a vital role in fetal brain development and is critical in the 
newborn for proper development and intelligence (Salem et al., 1996). It has been 
demonstrated in some studies that DHA provides support to learning and memory events 
in animal models of Alzheimer’s disease (Hashimoto et al., 2002) and brain injury (Wu et 
al., 2004). Similar findings were recorded in the study by Wall et al. (2010), where B. 
breve NCIMB 702258 and the precursor for EPA and DHA, α-linolenic acid was fed to 
mice, the control group received α-linolenic acid only. Significantly (P<0.05) higher 
levels of EPA in the liver and DHA in the brain compared to the control group were 
reported.  
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DPA has been reported in some ex vivo studies on rabbit and human blood 
platelets (Akiba et al., 2000; Phang et al., 2009) to inhibit platelet aggregation which is 
an early event in the development of thrombosis. DPA may also possess positive effects 
on the control of wound healing in vitro (Kanayasu-Toyoda et al., 1996). Endothelial cell 
migration and proliferation are important processes in the control of wound-healing 
response of blood vessels. Direct pretreatment of endothelial cells with DPA (0.01-1 
mg/ml) resulted in a dose-dependent increase in migration. Maximum stimulation of 
endothelial cell migration was achieved at a concentration one-tenth (0.5 mg/ml) of that 
required for maximal stimulation by EPA pretreatment (5 mg/ml) indicating that DPA is 
a potent stimulator of endothelial cell migration (Kanayasu-Toyoda et al., 1996).   
In agreement with previous work (Ley et al., 2005; Ley et al., 2006; Turnbaugh et 
al., 2006; Wall et al., 2012), taxonomy-based analysis showed that, at the phylum level, 
the mouse caecal microbiota was dominated by Firmicutes and Bacteroidetes (together 
harboring on average 90% of sequences). Whereas it is acknowledged that 
pyrosequencing of the 16S rRNA genes, as performed in this study, did not provide 
quantitative population data, it did yield an overview of the effects of administration of B. 
longum DPC 6315 on the entire mouse microbial population. Firmicutes were the most 
dominant phyla in both mouse groups, and were found at a significantly higher relative 
abundance in the mice fed α-linolenic acid supplemented with B. longum DPC 6315 
compared to those fed α-linolenic acid only. The study performed by Turnbaugh et al. 
(2006) demonstrated that microbiota transplanted from obese mice had a significantly  
(P<0.05) higher relative abundance of Firmicutes compared with lean mice microbiota. 
Other studies performed in both mice and humans (Ley et al., 2005; Ley et al., 2006) 
 231 
have shown a significantly greater relative abundance of Firmicutes in obese subjects 
compared to lean controls. These studies also showed a significant relative reduction in 
Bacteroidetes in obese animals compared to lean ones. In this study Bacteroidetes were 
detected at a significantly higher abundance in the mice fed the high fat diet only. There 
were no significant differences in bodyweight or fat composition between the two groups 
of mice so this would suggest that B. longum DPC 6315 has no effect on the energy 
harvesting capabilities of the overall mouse microbiota.   
At the family level Lachnospiraceae were the most abundant in each mouse group 
with a higher relative abundance in the supplemented group. This is in contrast to results 
reported by Wall et al. (2012) which found that feeding both B. breve DPC 6330 and B. 
breve NCIMB 702258 caused a significantly (P<0.05) lower proportion of 
Lachnospiraceae than did no supplementation. Rikenellaceae, Porphyromonadaceae and 
Bacteriodaceae were more abundant in the unsupplemented mouse group, while 
Bifidobacteriaceae and Lactobacillaceae were more abundant in the group supplemented 
with B. longum DPC 6315. Alistipes was the most abundant genus detected in both mouse 
groups being significantly higher in the unsupplemented group. This genus is closely 
related to the genus Bacteroides and contains species such as Alistipes finegoldii which 
has been found to cause bacteremia in colon cancer patients who had undergone surgical 
resection (Fenner et al., 2007). As stated earlier the relative abundance of the genus 
Roseburia was significantly higher in the group supplemented with B. longum DPC 6315. 
This genus has been reported to contain species that produce butyrate as a fermentation 
end product. Butyrate has been shown to be a major source of energy for colonic 
epithelial cells (Cummings, 1981; Cummings et al., 1987; Roediger et al., 1982). It has 
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been found to provide the body with 7-10% of its energy needs (Roy et al., 2006). 
Butyrate has also been shown to have anti-carcinogenic effects by preventing mutagens at 
their active site, molecular or DNA level (Smith, 1995). It is possible that the 
supplementation of B. longum DPC 6315 is leading to a higher relative abundance of this 
genus which contains butyrate producers.  
An interesting observation was that no significant difference in the relative 
abundance of the genus Bifidobacterium was recorded between the two mouse groups, 
even though the supplemented group received ~1 × 10
9 
CFU/day of B. longum DPC 
6315. This was also seen in the study Wall et al. (2012) in which no significant difference 
in the relative abundance of the genus Bifidobacterium was observed between a mouse 
group fed ~1 × 10
9 
CFU/day B. breve NCIMB 702258, a group fed ~1 × 10
9 
CFU/day B. 
breve DPC 6330 and an unsupplemented group (fed no Bifidobacterium strain). A 
possible explanation for this is that the presence of the Bifidobacterium strain being fed to 
the mice is inhibiting the growth of the Bifidobacterium species that are already present 
in the mouse caecum. B. longum DPC 6315 could possibly be producing a lantibiotic in 
vivo, as in Chapter 2, B. longum DPC 6315 was found to contain the lantibiotic 
prepeptide gene lanA, and in Chapter 3 to possess a lantibiotic operon with ~99% 
sequence identity to one found in B. longum DJ010A (Lee et al., 2011) which had been 
found to inhibit some bifidobacterial strains such as those from the species longum, 
adolescentis, breve, bifidum and animalis. In this study if B. longum DPC 6315 were 
producing a lantibiotic in vivo it could have inhibitory effects on other bifidobacterial 
strains present in the mouse caecum. The Bifidobacterium strain being fed at very high 
numbers (~10
9 
CFU) daily to the mice (such as B. longum DPC 6315) could therefore be 
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out-competing the other Bifidobacterium species already present in the mouse caecum. 
This would possibly lead to lower numbers of the Bifidobacterium species naturally 
present in the mouse caecum being recorded in the supplemented group of mice, with 
most of the recorded Bifidobacterium species in the supplemented group being those fed 
on a daily basis to the mice, and those in the unsupplemented group being those 
Bifidobacterium species that are already present in the mouse caecum. 
In conclusion, supplementation with B. longum DPC 6315 led to significant 
differences in fatty acid composition in both the murine liver and brain tissues compared 
to supplementation with α-linolenic acid only. B. longum DPC 6315 supplementation also 
led to significant differences in the overall caecal microbiota at both the phylum and 
genus level.  
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Table 5.1 Fatty acid profile in the liver of mice fed α-linolenic acid enriched diet 
supplemented with B. longum DPC 6315 or an unsupplemented diet for 6 weeks
1
. 
Fatty acid Mice fed B. longum DPC 6315 Unsupplemented mice 
 g/100g FAME g/100g FAME 
Palmitic acid, 16:0 26.1 ± 0.3 25.7 ± 0.5 
Palmitoleic acid, 16:1c9 3.0 ± 0.2 2.7 ± 0.2 
Stearic acid, 18:0 8.1 ± 0.2 
a
 7.4 ± 0.3 
b
  
Oleic acid, 18:1c9 30.1 ± 0.7 31.7 ± 0.8 
Linoleic acid, 18:2n-6 14.0 ± 0.3 
a
 15.4 ± 0.4 
b
 
c9, t11 CLA 
 
0.04 ± 0.2 0.03 ± 0.1 
Linolenic acid, 18:3n-3 5.2 ± 0.2 5.1 ± 0.2 
γ-Linolenic acid, 18:3n-6 0.1 ± 0.01
 a
 0.2 ± 0.01 
b
 
Dihomo-γ-linolenic acid, 20:3n-6 0.5 ± 0.02 0.4 ± 0.03 
Arachidonic acid, 20:4n-6 2.7 ± 0.1 2.8 ± 0.2 
EPA, 20:5n-3 1.2 ± 0.1 
a
 0.9 ± 0.1 
b
 
DPA, 22:5n-3 0.3 ± 0.1 
a
 0.2 ± 0.02 
b
 
DHA, 22:6n-3 2.3 ± 0.2 2.2 ± 0.2 
 
1
All values are means ±SEMs; n=10 mice per group. Values in the same row with different 
superscript letters are significantly different, P<0.05 (Unpaired T-test). Fatty acid methyl 
ester (FAME). 
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Table 5.2 Fatty acid profile in the brain of mice fed α-linolenic acid enriched diet 
supplemented with B. longum DPC 6315 or an unsupplemented diet for 6 weeks
1
. 
Fatty acid Mice fed B. longum DPC 6315 Unsupplemented mice 
 g/100g FAME g/100g FAME 
Palmitic acid, 16:0 30.9 ± 0.5 30.4 ± 0.7 
Palmitoleic acid, 16:1c9 0.8 ± 0.02 0.7 ± 0.02 
Stearic acid, 18:0 22.3 ± 0.4 
a
 23.2 ± 0.2 
b
 
Oleic acid, 18:1c9 19.6 ± 0.3 20.01 ± 0.1 
Linoleic acid, 18:2n-6 0.9 ± 0.02 0.9 ± 0.02 
c9, t11 CLA 
 
ND ND 
γ-Linolenic acid, 18:3n-6 0.3 ± 0.01 0.3 ± 0.02 
Dihomo-γ-linolenic acid, 20:3n-6 0.4 ± 0.01               0.4 ± 0.2 
Arachidonic acid, 20:4n-6 5.9 ± 0.1 5.9 ± 0.01 
EPA, 20:5n-3 0.1 ± 0.04 0.1 ± 0.2 
DPA, 22:5n-3 0.2 ± 0.01 0.2 ± 0.003 
DHA, 22:6n-3 7.0 ± 0.4 7.2 ± 0.01 
 
1
All values are means ±SEMs; n=10 mice per group. Values in the same row with different 
superscript letters are significantly different, P<0.05 (Unpaired T-test). ND = Not detected. 
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   Table 5.3 Alpha diversity measures for each mouse sample. 
 
Legend: Samples 1-10 fed B. longum DPC 6315 and high fat diet. Samples 11-19 fed α-linolenic  
                acid enriched diet only. 
 
  Sample 
    
Chao1 Shannon 
 
Simpson    
 PD whole 
tree 
Observed 
species 
Total number of 
Reads 
 1 1636.3 6.95 0.97 47.4 1120 20665 
          2 2500.3 7.28 0.98 57.68 1392 20624 
 3 1984.2 7.54 0.98 51.69 1248 18048 
          4 2343.3 6.81 0.96 54.86 1342 22225 
          5 1842.2 7.18 0.98 49.56 1207 24258 
 6 3281.8 7.82 0.98 70.19 1745 24822 
 7 2737 7.45 0.98 65.85 1636 28640 
 8 1808.1 7.07 0.97 48.73 1224 22809 
 9 5230.9 7.79 0.98 101.05 2645 29732 
    10 2270.9 7.3 0.98 57.65 1389 23463 
11 1998.3 6.49 0.96 51.16 1080 20196 
12 1672.6 6.5 0.96 42.68 1009 20692 
13 1677.5 6.73 0.97 45.62 1040 23479 
14 2802.7 6.89 0.96 62.72 1479 21943 
15 1614.4 7.09 0.98 46.7 1108 23374 
16 2316.8 7.06 0.98 54.94 1336 16192 
17 1848.4 7.47 0.98 50.76 1189 21058 
18 1557.7 6.76 0.97 45.7 1067 20491 
       19 2184.2 7.02 0.97 55.1 1264 22572 
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Figure 5.1 Rarefaction plot for assessment of OTU coverage. Each curve represents an  
                   individual mouse sample. 
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Figure 5.2 (a) PCoA of unweighted UniFrac distances of 16S rRNA sequences. 
 
Legend: Red points = Samples 1-10 fed α-linolenic acid enriched diet and B. longum  
               DPC 6315. 
               Blue points = Samples 11-19 fed α-linolenic acid enriched diet only. 
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Figure 5.2 (b) A cladogram generated using unweighted pair group method with UPGMA  
                        clustering of the 19 mouse microbiota datasets. 
Legend: bc.1-10 = Samples 1-10 fed α-linolenic acid enriched diet and B. longum DPC  
 6315. 
                     bc.12-15, 17-19, 21 and 22 = Samples fed α-linolenic acid enriched diet only. 
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Figure 5.3 (a) The aggregate relative proportion of phyla of the caecal microbiota of the 
mouse group fed α-linolenic acid enriched diet supplemented with B. longum DPC 6315. 
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Figure 5.3 (b) The aggregate relative proportion of phyla of the caecal microbiota of the  
                         mouse group fed α-linolenic acid enriched diet only. 
 
 
 
   
 
 
 
 252 
 
Figure 5.3 (c) Inter-individual variation in the proportion of the major phyla between the 
mouse samples fed α-linolenic acid enriched diet supplemented with B. longum DPC 
6315. Samples are ordered from left according to Firmicutes proportion. 
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Figure 5.3 (d) Inter-individual variation in the proportion of the major phyla in the  
                        mouse samples fed α-linolenic acid enriched diet only. 
                        Samples are ordered from left according to Firmicutes proportion. 
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Figure 5.4 (a) The aggregate relative proportion of family-level caecal microbiota of the 
mouse group fed α-linolenic acid enriched diet supplemented with B. longum DPC 6315. 
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Figure 5.4 (b) The aggregate relative proportion of family-level caecal microbiota of the  
                         mouse group fed α-linolenic acid enriched diet only. 
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Figure 5.4 (c) Inter-individual variation in the proportion of the major family-
level caecal microbiota of the mouse group fed α-linolenic acid enriched diet 
supplemented with B. longum DPC 6315.  
Samples are ordered from left according to Firmicutes proportion. 
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Figure 5.4 (d) Inter-individual variation in the proportion of the major family-level caecal  
                        microbiota of the mouse group fed α-linolenic acid enriched diet only.   
                                             Samples are ordered from left according to Firmicutes proportion. 
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Figure 5.5 (a) The aggregate relative proportion of genera of the caecal microbiota of the 
mouse group fed α-linolenic acid enriched diet supplemented with B. longum DPC 6315. 
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Figure 5.5 (b) The aggregate relative proportion of genera of the caecal microbiota of the  
                         mouse group fed α-linolenic acid enriched diet only. 
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Figure 5.5 (c) Inter-individual variation in the proportion of genera of the caecal 
microbiota of the mouse group fed α-linolenic acid enriched diet supplemented 
with B. longum DPC 6315.  
Samples are ordered from left according to Firmicutes proportion. 
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Figure 5.5 (d) Inter-individual variation in the proportion of genera of the caecal  
                        microbiota of the mouse group fed α-linolenic acid enriched diet only. 
                        Samples are ordered from left according to Firmicutes proportion. 
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6.1 GENERAL DISCUSSION 
Bifidobacteria are commonly used as probiotics for human consumption, and are 
normal inhabitants of the GIT of humans (Simon & Gorbach, 1984). They have a long 
history of safe use in fermented milks (Ishibashi & Yamazaki, 2001), and are commonly 
added to the human diet as probiotic supplements. Bifidobacteria have been reported to 
exert numerous positive effects on human health such as prevention of infection by 
pathogenic bacteria (Wang et al., 2004) immunostimulation (Furrie et al., 2005), anti-
carcinogenic capabilities (Le Leu et al., 2010), protection against infectious diarrhoea, 
(Saavedra et al., 1994), lowering of serum cholesterol (Xiao et al., 2003) and alleviation 
of lactose maldigestion (He et al., 2008). 
Bifidobacteria have been found to produce metabolites that have the capacity to 
exert a positive influence on host health. These metabolites include CLA (Coakley et al., 
2006), EPS (Salazar et al., 2008) and bacteriocins (Lee et al., 2011). The human 
intestinal strain B. longum DPC 6315 was examined in detail using both phenotypic and 
genomic approaches in this study. The strain produced both CLA and EPS and contained 
all the genes necessary for lantibiotic production. Other activities of bifidobacteria that 
can be viewed as having positive influences on host health are SCFA production 
(Lankaputhra & Shah, 1998) and the ability to utilize prebiotics that can help to increase 
beneficial gut microbiota (Cani et al., 2007).  
As bifidobacteria are naturally found in the human GIT, their presence and 
metabolic activities are generally considered integral to the maintenance of human health 
and subsequently well-being. They are found in the human GIT throughout life after 
appearing shortly after birth (van der Werf & Venema, 2001). There also appears to be a 
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general inverse relationship between bifidobacteria numbers and undesirable bacteria 
such as clostridia and Escherichia coli in the GIT as observed from clinical feeding 
studies (Alvaro et al., 2007; Chen et al., 1999), which would suggest that bifidobacterial 
metabolic activities have a role in preventing the growth in the GIT of these undesirable 
microorganisms. The utilization of non-digestible substrates by Bifidobacterium, such as 
complex carbohydrates including cellulose and starch provides the human host with a 
valuable energy source which would otherwise be lost from the body (Vaughan et al., 
2005). Bifidobacteria, as an indigenous bacterium in many human hosts have developed a 
symbiotic relationship with the host as both the bacterium and the carrier benefit from the 
association. Bifidobacteria are provided with substrates and anaerobic conditions in the 
GIT to support growth, and the host benefits from the beneficial metabolic activities of 
the Bifidobacterium species that inhabit the GIT.   
This thesis focused on the identification and characterization of certain potential 
probiotic traits of bifidobacteria isolated from the human GIT. One of these strains B. 
longum DPC 6315 was studied employing both genomic and phenotypic methods to 
examine in more detail its identified potential probiotic traits. In addition, the effect of B. 
longum DPC 6315 on the functional properties of yoghurt and on fatty acid metabolism 
and intestinal microbiota in a murine model was investigated. Great potential exists for 
the use of Bifidobacterium strains in future probiotic or functional foods, especially 
involving Bifidobacterium strains normally found in the GIT such as Bifidobacterium 
longum.  
As many of the positive effects on human health associated with bifidobacteria are 
due to the production of metabolites such as CLA, EPS and lantibiotics, bifidobacteria of 
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human intestinal origin were screened, using a combined phenotypic and molecular 
approach in Chapter 2. 38 B. longum strains isolated from human infant and adult faecal 
samples were differentiated into subspecies using ARDRA analysis. Of the 38 B. longum 
strains tested, 34 were designated B. longum subsp. longum and four B. longum subsp. 
infantis. Phylogenetic analysis revealed that each of these 38 B. longum strains was 
distinct from one another and that the B. longum strains appeared to share 40% or higher 
genetic similarity. Certain DNA macro-restriction fragments were found in a high 
proportion of the 38 B. longum strains such as those at ~110 kb, ~120 kb, ~194kb, ~23.1 
and at ~9.42 kb. These patterns would appear to be highly conserved regions of the 
genomes of the B. longum strains examined in this study. 
The screening analysis revealed that 15 B. longum subsp. longum and one B. 
longum subsp. infantis strain produced an EPS phenotype and that 24 B. longum subsp. 
longum and two B. longum subsp. infantis strains had a corresponding genotype with the 
wblE gene (Audy et al., 2010). As such 12 strains appeared to have the genes but did not 
produce EPS – in these cases the genes may not be expressed, may be deleted or mutated. 
Ten of the 38 strains converted free linoleic acid to CLA and although lantibiotic 
production was not confirmed in the laboratory by the methods employed in this study, 
genetic analysis revealed that 6 strains were positive for the lanA gene. This is the first 
known study to report the production of both EPS and CLA in one bifidobacterial strain. 
In total, 3 B. longum strains produced both EPS and CLA, while the strain B. longum 
DPC 6315 produced EPS, CLA and whilst it did not produce lantibiotic in vitro, it 
contained the lanA gene necessary for lantibiotic production. For this reason, this strain 
was the main focus of Chapters 3, 4 and 5 of this thesis. 
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      In Chapter 3, the genomic analysis of the human isolate B. longum DPC 6315 was 
performed. The genes for EPS, lantibiotic and genes believed to be involved in CLA 
production were identified in the draft genome of B. longum DPC 6315. The EPS 
produced by this bifidobacterial strain was found to be a unique EPS, with high levels of 
mannose which could possibly give the strain positive immunodulatory effects in vivo. 
The high levels of mannose in EPS produced by bifidobacteria have only been previously 
reported for three other Bifidobacterium species, i.e. B. longum DSM 21062, CHCC8773 
and CHCC8818 (Kildsgaard et al., 2011). This strain was reported to possess anti-
inflammatory effects in a trinitrobenzene sulfonate (TNBS)-induced colitis model when 
fed to mice at 1 × 10
9
 live bacteria daily for 5 consecutive days compared to the two other 
B. longum strains tested which were CHCC8773 and CHCC8818 (Kildsgaard et al., 
2011), causing a reduction in  TNBS-induced injury by 44% (P=0.007). It has also been 
previously reported that complex polymers containing mannose (mannans) possess 
significant biological activity when administered to mammals, which includes the 
activation of the immune system following the binding of mannose to recognition 
molecules such as the mannose receptor (CD206) expressed on macrophages and 
dendritic cells (Carroll & Prodeus, 1998; Diebold et al., 2002; Stahl & Ezekowitz, 1998). 
It is also possible that the EPS produced by B. longum DPC 6315 could have positive 
immunodulatory effects in vivo. An interesting future study would be to examine 
immunodulatory effects of the EPS produced by B. longum DPC 6315 in a murine model. 
    The lantibiotic gene operon identified in the genome of B. longum DPC 6315 was 
previously identified in B. longum DJO10A (Lee et al., 2008).  Using well diffusion 
assays and spot plate overlays, no activity of the B. longum DPC 6315 supernatants were 
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found against other B. longum strains (Chapter 2), or against various Gram-positive and 
Gram-negative pathogenic bacteria. This could be due to one of the genes essential for 
lantibiotic production not being expressed in B. longum DPC 6315 or that the level of the 
lantibiotic produced by the strain was too low to exhibit antimicrobial activity against 
indicator strains in vitro.  It is possible that this lantibiotic would have an effect in the 
GIT in vivo, as there is more competition for nutrients and binding sites from other gut 
bacteria, and the production of a lantibiotic in vivo would confer an advantage on B. 
longum DPC 6315 over other bacterial strains present.  
The focus of Chapter 4 was to examine the effect of exopolysaccharide producing 
B. longum DPC 6315 when used as an adjunct culture during yoghurt manufacture on the 
functional properties of yoghurt. The EPS producing bifidobacterial strain used to 
manufacture yoghurt in this study survived to the FAO/WHO minimum required levels of 
a probiotic culture (10
6
 CFU/g) in the product after 28 days of cold storage, although it 
did have a 1000 fold reduction in viability - most likely due to the low pH of the yoghurt. 
B. longum DPC 6315 produced relatively low amounts of EPS in the yoghurt produced in 
this study, and the EPS produced did not significantly increase the viscosity of this 
yoghurt compared to the control - although both yoghurts displayed a shiny, slightly ropy 
appearance. Overall, this study demonstrated that the production of EPS by B. longum 
DPC 6315 in yoghurt reduced the syneresis of the EPS containing yoghurt up to day 14 
of cold storage. The presence of this bifidobacterial strain in the yoghurt led to 
significantly higher levels of EPS compared to the control yoghurt, up to day 28 of cold 
storage. The levels of EPS significantly declined after day 7 of cold storage however, the 
strain was found to produce significantly higher concentrations of EPS when grown in 
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14% (w/v) RSM and 1% (w/v) yeast extract without the CH-1 yoghurt starter cultures. 
The wide range of EPS concentrations reported in yoghurt for different EPS producing 
strains could be due to the use of different strains, the level of inoculation, fermenting 
conditions, method of isolation, purification and quantification of EPS between studies 
(Amatayakul et al., 2006). With prolonged storage, a decrease in EPS-concentrations for 
the EPS-containing yoghurt was reported by Purwandari et al. (2007), where the EPS 
concentrations in all batches of yoghurt made with two different strains of Streptococcus 
thermophilus declined significantly (P<0.05), especially in the first week. The significant 
(P<0.05) reduction of the EPS concentration reported in these yoghurt batches during the 
first weeks of cold storage could be due to the activity of enzymes capable of degrading 
EPS (Degeest et al., 2002).  
It is possible that EPS degradation may be activated due to the cell’s requirements 
for energy maintenance, as the EPS may serve as an energy store in the presence of  
excess nutrients, which may be used later in the cell metabolism (Tolstoguzov, 2003). 
Many different studies have demonstrated the reduction in EPS concentrations after 
prolonged incubation of S. thermophilus (Cerning, 1990; Cerning et al., 1988; De, 1998; 
De Vuyst, 1999; Gancel & Novel, 1994; Macura & Townsley, 1984; Pham et al., 2000). 
It has been suggested that EPS degradation during fermentation is due to a change in the 
physical or chemical factors linked to glycohydrolase activity. In the study performed by 
Pham et al. (2000), a greater reduction in EPS concentration was found in the case of 
lactose-grown Lactobacillus rhamnosus R cells than in glucose-grown cells. The EPS 
producing culture had a positive effect in reducing syneresis in the yoghurt on day 0, 1, 7 
and 14 of cold storage with no significant difference in syneresis between the control and 
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EPS containing yoghurt on days 21 and 28. This is possibly due to the degradation of 
EPS in the EPS containing yoghurt with a reduction of EPS on day 14, 21 and 28 of cold 
storage, respectively. Syneresis is considered a major defect in the yoghurt industry and 
is directly related to the extent of physical disturbance to the network of protein micelles 
(Tamime & Robinson, 2007). It has previously been reported that ropy EPS has a greater 
ability to retain serum, resulting in lower syneresis in yoghurt (Folkenberg et al., 2005; 
Lucey et al., 1998). Some other studies have previously reported that the intensity of 
syneresis decreased in set-type yoghurts during prolonged storage (Guzel-Seydim et al., 
2005; Kearney et al., 2009; Purwandari et al., 2007; Robitaille et al., 2009). The EPS 
containing yoghurt in this study exhibited a significant reduction in syneresis up to day 
14 of storage compared to the control which indicates that at a certain concentration the 
EPS produced by B. longum DPC 6315 has the ability to bind free water and reduce 
syneresis in yoghurt.  
  The EPS produced by B. longum DPC 6315 after 28 days of cold storage was well 
distributed and mainly located around the edges of serum pores of the yoghurt, connected 
with the protein network as revealed by CLSM microscopy. A similar microstructure was 
also reported in the studies performed by Folkenberg et al. (2005) and Kearney et al. 
(2009), where an overlap of protein and EPS was observed and the yoghurt product was 
described as being very shiny, very ropy, with low serum separation and was resistant to 
mechanical treatment, which correlates positively with the results of this study. The 
extent of the interaction between the EPS produced by B. longum DPC 6315 and the 
yoghurt network is unknown, however the association between EPS and protein appears 
to be positive, as incompatibility between EPS and protein would lead to phase 
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separation, with EPS being expelled into the serum phase (Hassan et al., 2003). In future 
studies, it would be worthwhile to examine the effects of encapsulated B. longum DPC 
6315 cells in a fermented food. The encapsulation of the bacterial cells would ensure a 
higher survival rate, which may also lead to higher levels of EPS being produced with 
improved functional effects on the texture and syneresis of the food product.   
In Chapter 5, the effects of feeding B. longum DPC 6315 in a high fat diet enriched 
with α-linolenic acid on intestinal microbiota and fatty acid metabolism in a murine 
model was investigated. Dietary supplementation with B. longum DPC 6315 was found to 
have significant effects on fatty acid composition of the murine liver and brain. The 
group fed a high fat diet enriched with α-linolenic acid together with B. longum DPC 
6315 was found to have significantly lower levels of linoleic acid and γ-linolenic acid in 
the liver, and stearic acid levels in the brain compared with unsupplemented mice. In 
addition, mice that received B. longum DPC 6315 had significantly higher concentrations 
of stearic acid, EPA and DPA in the liver, compared to unsupplementated animals. The 
study previously performed by Wall et al. (2010), also reported similar findings, where B. 
breve NCIMB 702258 and the substrate for EPA and DHA, α-linolenic acid was fed to 
mice, with the control group receiving α-linolenic acid only. Significantly (P<0.05) 
higher levels of EPA in the liver and DHA in the brain were found following 
bifidobacteria supplementation compared with the control group. Eicosanoids from EPA 
are reported to be less inflammatory than those from arachidonic acid or even anti-
inflammatory in nature (Bagga et al., 2003; Calder, 2008; Robinson & Stone, 2006). EPA 
can be further metabolized to DHA, which has a vital role in fetal brain development and 
is critical in the newborn for optimum development and cognition (Salem et al., 1996). It 
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has been demonstrated in some studies that dietary DHA contributes to improved 
learning and memory events in animal models of Alzheimer’s disease (Hashimoto et al., 
2002) and brain injury (Wu et al., 2004). It is possible that the presence of B. longum 
DPC 6315 is causing the increases in both EPA and DHA in the liver and that this 
bacterial strain has the potential to positively influence the overall fatty acid composition 
of the host.   
In the mouse group supplemented with B. longum DPC 6315, Firmicutes were 
found at a significantly higher relative abundance in the caecum, while Bacteriodetes 
were found at a significantly higher proportion in the unsupplemented group. Some 
studies have found Firmicutes at significantly higher relative abundances in obese 
compared to lean subjects (Ley et al., 2005; Ley et al., 2006; Turnbaugh et al., 2006). 
There is no reason to suggest that this is the case with the feeding of B. longum DPC 
6315, as there were no observed differences in animal weight or fat composition between 
the groups. There were also significant differences at the genus level as Alistipes was 
detected at a significantly lower relative abundance in the B. longum DPC 6315 
supplemented group. The Alistipes genus is closely related to the genus Bacteroides and 
contains species such as Alistipes finegoldii which has been found to cause bacteremia in 
colon cancer patients who had undergone surgical resection (Fenner et al., 2007) - so a 
significantly lower relative abundance of this genus could be interpreted as a positive 
outcome, although future studies are warranted to confirm this. Roseburia was detected at 
a significantly higher relative abundance in the supplemented group and this genus has 
been reported to contain species that produce butyrate as a fermentation end-product, 
which has been shown to be a major source of energy for colonic epithelial cells 
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(Cummings, 1981; Cummings et al., 1987; Roediger et al., 1982). Butyrate provides the 
body with 7-10% of its energy needs (Roy et al., 2006), and has also been shown to have 
anti-carcinogenic effects by preventing mutagens at their active site, molecular or DNA 
level (Smith, 1995). It is possible that the supplementation of B. longum DPC 6315 is 
leading to a higher relative abundance of this genus which contains butyrate producers. 
Chapter 5 demonstrated that supplementation with B. longum DPC 6315 led to significant 
differences in fatty acid composition in murine liver and brain compared with 
supplementation with the high fat diet only. B. longum DPC 6315 supplementation also 
led to significant differences in the overall caecal microbiota at both the phylum and 
genus levels.  
Overall, the data in this thesis demonstrates that certain bifidobacterial strains can 
produce EPS and CLA. B. longum DPC 6315 also possesses the potential for bacteriocin 
production. The strain can also produce significant levels of EPS and significantly 
improve some of the techno-functional characteristics of yoghurt. It was also shown that 
B. longum DPC 6315 can modify the fatty acid composition in a murine model, 
producing significantly higher levels of the anti-inflammatory fatty acids, EPA and DHA 
in the liver. B. longum DPC 6315 also influenced the murine caecal microbiota, with a 
significantly higher relative abundance of Firmicutes and a significantly lower relative 
abundance of Bacteriodetes in the caecal microbiota of mice fed this strain compared to 
mice that did not receive B. longum DPC 6315. Supplementation with B. longum DPC 
6315 also led to a higher relative abundance of the genus Roseburia (containing some 
beneficial species) and a significantly lower relative abundance of Alistipes (containing 
some harmful species) in mice that received the bacterium compared to unsupplemented 
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mice. These various positive attributes of the strain make it a very attractive candidate for 
future probiotic use in humans. The next step in this progression would involve human 
intervention trials with a probiotic yoghurt where ingestion of the strain would be 
examined for its effect on the gut microbiota and human fatty acid metabolism and 
ultimately on human health. 
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